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ABSTRACT 
 
Cancer is a leading cause of illness and death in developed countries. Current leading 
anticancer drugs are limited by side-effects and the ability of malignant cells to become 
resistant. New drugs are being developed that display the capacity to target cancerous 
cells, without affecting healthy cells. This can be achieved by designing novel 
molecules that bind to specific targets that are exclusive to, or are highly conserved 
within, cancer cells. Some naturally occurring groove-binding polyamides (such as 
netropsin and distamycin A) are already capable of such specificity, as they comprise of 
a series of heterocyclic rings linked by single bonds that can rotate to match the 
conformation of the target DNA site. This project has focused on the synthesis DNA 
sequence selective compounds containing terpyridineplatinum(II) based moieties. New 
methods for the solution phase synthesis of polyamides, containing analogues of the 
heterocyclic rings N-methylpyrrole and 1-methylimidazole, have been developed with a 
focus on simplified purification and increased reproducibility. In this study, new 
methods for the incorporation of [Pt(terpy)Cl]Cl into polyamides by both solid and 
solution phase have been explored and contrasted. It was found that machine assisted 
protocols were ideal for the synthesis and purification of metallopolyamides, whilst 
solution phase methods were prohibitively difficult and require further development. 
Two novel platinum metallointercalators have been synthesised and tested for biological 
activity, including an extensive DNA binding study by circular dichroism and 1D and 
2D 1H NMR. Finally, a novel metallopolyamide derived from [Pt(terpy)Cl]Cl has been 
synthesised entirely by solid phase, as a proof of concept for the new method of 
incorporation described in this work.  
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CHAPTER ONE: INTRODUCTION 
 
The scientific world’s pursuit of the hereditary mechanism has unveiled fundamental 
truths regarding life, its conception and persistence. Since the structure of deoxyribose 
nucleic acid (DNA) was correctly proposed by Watson and Crick,1 subsequent studies 
have greatly influenced our understanding of human physiology and genetics. It can be 
argued that the field of medicine has the most to gain from this, as it has been shown 
that genetic material and abnormalities play a central role in the cause and proliferation 
of many deadly illnesses, such as cystic fibrosis,2 cancer,3 infection by human immuno-
deficiency (HIV)4,5 and hepatitis viruses.5 In some cases, tantalising clues as to how 
such illnesses could be eliminated have presented themselves, utilising the hereditary 
mechanisms and genetic material from which they originally spawned. The success of 
cis-diamminedichloroplatinum(II) (also known as cisplatin or cis-DDP, Figure 1.1), a 
DNA binding anticancer agent, is perhaps the most celebrated. Rosenberg first reported 
the cytotoxic activity of cis-DDP in 1969, which was discovered unintentionally during 
an experiment investigating the effects of electric fields on bacterial growth.6 Cis-DDP 
was found to display unprecedented levels of antineoplastic ability7 and became the 
cornerstone of effective treatment for many cancer types, including testicular, ovarian, 
gastrointestinal and those of the lung, bladder, head and neck.8 The ability of cis-DDP 
molecules to destroy cancer cells stems from their interaction with DNA, which triggers 
a cellular response that initiates the apoptosis of the cell. 
 
Figure 1.1: Cisplatin (cis-DDP). 
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1.1 The Structure of DNA 
DNA offers a plethora of potential binding sites for therapeutic agents due to its size 
and complexity.9 DNA can assume several structural conformations, depending on 
physiological conditions, the most predominant of which is referred to as B-DNA.10 
This conformation contains two antiparallel strands of nucleic acid. Both strands have a 
backbone of repeated deoxyribose phosphodiester units, attached via the carbohydrate 
component to the N9 atoms of the purine bases adenine (A) and guanine (G), or the N1 

























































3' end  
Figure 1.2: The primary structure of DNA. 
 
Complementary strands of DNA are stabilised by hydrogen bonding, between guanine 
and cytosine (G-C) and adenine and thymine (A-T), and held in the antiparallel double 
helix motif by stacking interactions between parallel bases (Figure 1.3).10 B-DNA can 
transform into an A-DNA helix, at lower humidity and elevated salt concentrations, 
which is characterised by a 20o tilting of the base-pairs and their net migration away 
from the central axis. This produces a more compacted structure with a hollow core. 
Both A-DNA and B-DNA display right-handed geometry. The Z-DNA conformation is 
adopted at high salt concentrations and is characterised by the adoption of left-handed 
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geometry. The Z-DNA helix is elongated and slender, and can be induced by the 
covalent binding of various metal complexes. 
 
Figure 1.3: HyperChem depictions of A-, B- and Z-DNA.  
 
The double helix is condensed in a highly ordered fashion within the nucleus. This is 
achieved by the wrapping of DNA around histone octamers to form “bead-like” units 
called nucleosomes, which themselves are organised into higher order structures, the 
ultimate goal of which is the formation of chromosomes. Chromosomes are capped with 
long tandem repeats of short (5-26 bp) sequences, known as telomeres, which modulate 
chromosome replication.11,12 The majority of telomeric DNA is double-stranded, with 
the remainder in the form of a G-rich 3′ single-stranded overhang.13 The G bases of the 
150-200 bp overhang are arranged into tetrads, which are stabilised by a cyclic 
Hoogsteen hydrogen-bonding arrangement.14 As normal healthy cells divide, telomeres 
shorten due to the inability of DNA polymerase to replicate the ends of linear 
molecules.15,16 Telomerase, a ribonucleoprotein, performs the function of maintaining 
and restoring telomere length.13 Correlation between telomerase activity and the growth 
of tumours has been demonstrated by many researchers.17,18 DNA can also adopt 
formations of a higher order, which may also provide alternative targets for DNA 
binding therapeutics. For example, self complementary sections of single stranded DNA 
can form hairpin structures and cruciforms (which consist of two opposed hairpins).19,20 
Hairpin structures in particular have been identified in genomic DNA and are 
considered to be potential sites for controlling gene expression.19 Many structures 
adopted by single-stranded DNA are associated with regions of the DNA code that are 
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Figure 1.4: The intrastrand cross 
link caused by the binding of 
cisplatin to DNA. 
involved in the regulation of transcription, such as promoter sites.19,20 Drugs that can 
target hairpin and cruciform structures in promoter regions may be able to stop 
transcription and control gene expression.19,21-25 
 
1.2 Cancer and cis-DDP 
DNA replication and transcription are vital processes 
for rapidly proliferating tumour cells. The cytotoxic 
effect of cis-DDP stems from its ability to inhibit 
these processes. cis-DDP binds irreversibly to the 
nitrogen (N7) of G and A,8,26 forming both intra- and 
inter-strand cross-links in the major groove of DNA, 
(Figure 1.427) causing a large bend towards the DNA 
major groove.28 Inhibition of DNA synthesis occurs 
mainly at G rich sites (such as the GC box regulatory 
region of prokaryotes), which is consistent with the 
belief that cis-DDP binds preferentially to these 
residues, and is thought to be due to the blocking of 
polymerase by the structural damage caused by 
platinum adducts.29 Without the ability to transcribe, 
the cell soon dies due to apoptosis. The mechanism of 
apoptosis caused by the cis-DDP-DNA adduct is poorly understood, and is thought to 
be triggered by a broad spectrum of cellular conditions.30,31 Interestingly, the trans-
isomer of DDP displays no significant activity, which is thought to be due to two key 
factors. It is characterised by kinetic instability and is consequently prone to 
deactivation by intracellular components, such as the sulfur-containing tripeptide 
glutathione (GSH), as well as displaying DNA binding regioselectivity and structural 
perturbations different to those of cis-DDP.32  
 
1.3 The Drawbacks of cis-DDP 
Guanine, the major genetic target for cis-DDP, is common in the nucleus. This leads to 
the formation of damaging platinum adducts in cells that do not display malignancy. 
Thus the ability of cis-DDP to inhibit DNA replication and kill cells is as indiscriminate 
as it is impressive. Cis-DDP is also prone to binding with cellular molecules other than 
DNA, which also causes adverse effects in healthy cells. These dose-limiting effects 
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include nephrotoxicity, nausea and vomiting, ototoxicity and peripheral neuropathy,33,34 
representing a major limitation to the drug’s use. Some cells possess an inherent 
resistance to cis-DDP, whilst others can acquire a resistance during treatment.35 In 
addition, some cells that have acquired resistance to cis-DDP also display cross-
resistance to other anticancer drugs that share the same, or similar, modes of action. 
These factors combine to minimise the drug’s therapeutic efficacy, and have prompted a 
concerted effort to synthesise new DNA binding compounds with higher activity and 
less side effects. 
 
1.4 Cis-DDP Analogues 
After the introduction of cis-DDP the search began for second-generation derivatives 
with more acceptable toxicity profiles, higher specificity for cancer cells, broader 
spectrums of activity, negligible levels of cross-resistance and higher solubility. Over 
3000 analogues have been synthesised, few of which have ever reached clinical trials. 
Drugs such as carboplatin and oxaliplatin have been developed, but cause 
indiscriminate, irreversible damage and side effects similar to their predecessor.29,36,37 
 
1.4.1 Carboplatin   
Carboplatin (Figure 1.5) is a derivative of cis-DDP, where the two chloride atoms have 
been replaced by a 1,1-cyclobutanedicarboxylate moiety, resulting in a lower rate of 






Figure 1.5: The structure of carboplatin.  
 
This lower rate of activation is responsible for a decrease in toxicity when compared to 
cis-DDP.37,38 After extensive clinical trials, carboplatin was made available for routine 
clinical use in 1988.26 Since then it has proven valuable as a substitute for its parent 
compound where the patient has poor tolerance to cis-DDP.39 The success of 
carboplatin gave credence to the belief that structural analogues of cis-DDP, which 
incorporated more stable leaving groups, could display lower levels of toxicity. 
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Unfortunately, carboplatin was found to display cross-resistance with its parent 
compound in many human cancers. 
 
1.4.2 Oxaliplatin 
Oxaliplatin (Figure 1.6) contains the 1R,2R-diaminocyclohexane (R,R-DACH) ligand, 
one in a family of compounds that were targeted for development due to their activity in 
cis-DDP resistant murine leukemia cell lines. Oxaliplatin was later observed to be active 
against several colon cancer cell lines, providing impetus for its clinical evaluation 
against this disease.34 On the basis of numerous successful trials, oxaliplatin was first 
approved for the treatment of colorectal cancer in Europe in 1999, followed by United 










Figure 1.6: The structure of oxaliplatin.  
 
Studies have demonstrated that oxaliplatin exhibits a 
different activity profile when compared to cis-DDP and 
carboplatin, and as a result, is active in some cross-
resistant cancers. The relative amount of adducts 
formed by oxaliplatin and cis-DDP are quite different. 
Oxaliplatin forms intrastrand cross-links more slowly 
due to its reduced rate of hydrolysis.41 The toxicity, 
however, remains equal to that of cis-DDP. The fact that 
oxaliplatin forms fewer DNA adducts compared with 
cis-DDP, at equally toxic doses, suggests that oxaliplatin 
lesions are more cytotoxic.42,43 Computer modelling 
studies of the DNA intrastrand cross-links of oxaliplatin 
have provided some insight into the structural basis of 
this phenomenon. The studies showed that whilst cis-
DDP and oxaliplatin induce a comparable 
conformational change in DNA, the protrusion of the DACH moiety into the major 
groove produces a bulkier adduct (Figure 1.744).  
Figure 1.7: The intrastrand 
crosslink caused by the binding 
of oxaliplatin to DNA. 
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1.5 Novel trans-diamminedichloroplatinum(II) (trans-DDP) Analogues 
 
1.5.1 Mononuclear trans-DDP Analogues 
Whilst Rosenberg demonstrated that the cis geometry of DDP was necessary for 
therapeutical activity, and that the trans isomer was inactive, there have been recent 

















































Figure 1.8: The structures of some monofunctional trans-Pt complexes that are known to be biologically 
active: 1, trans-[PtCl2(pyridene)2]; 2, trans-[PtCl2(thiazole)2]; 3, trans-[PtCl2(iminoether)2]; 4, trans-
[PtCl2(dimethylamine)(isopropylamine)]; 5, trans-[PtCl2(NH3)(quinoline)]; 6, trans-
[PtCl2(methylphenylsulfoxide)(quinoline)]; 7, trans-[PtCl2(dimethylesulfoxide)(quinoline)]. 
 
These compounds have displayed modes of action that vary greatly from their cis 
predecessors, allowing them to circumvent cis-DDP resistance in a variety of resistant 
human tumor cell lines (Table 1.1). Some display levels of cytotoxicity equal to their 
cis-isomers and cis-DDP, and far greater than that of trans-DDP. Most importantly, they 
display cytotoxicity relative to cis-DDP in the two lines most intrinsically resistant to 
cis-DDP, HX-62 and SKOV-3.45,46 
Table 1.1: The IC50 values (in μM) of trans-platinum complexes against L1210 murine leukaemia and 
cis-DDP resistant cell lines including L1210/DDP, HX-62 and SKOV-3.45,46 
Compound L1210 L1210/DDP HX-62 SKOV-3 
trans-[PtCl2(py)2] 1.20 1.10 4.5 5.9 
trans-[PtCl2(Tz)2] 1.60 7.40 4.1 6.2 
trans-[PtCl2(Me2SO)(quin)] 0.36 0.38 5.1 4.4 
trans-[PtCl2(MePhSO)(quin)] 3.50 2.40 6.1 4.5 
cis-DDP 0.33 9.22 12.6 4.4 
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Trans-[PtCl2(iminoether)2] exists as three isomers due to the E or Z configuration 
around the dual C=N bonds. The IC50 of one of the isomers, trans-EE, is 40 times lower 
than that of trans-DDP and similar to that of cis-DDP.47 These complexes displayed 
cytotoxicity comparable to that of cis-DDP over a variety of other human cancer cell 
lines,48 including an IC50 of 2.0 μM in the P388 cell line, 0.05 μM lower than cis-
DDP.49 Additionally, this family of complexes was able to circumvent cis-DDP 
resistance in A2780/Cp8 ovarian cancer cells.50,51 Analogues of the general structure 
trans-[PtCl2(amine)(isopropylamine)] exhibit IC50 values lower than cis-DDP (Table 
1.2) in cis-DDP resistant murine cell lines (PAM 212 and PAM 212-ras) and HL-60.52 
Table 1.2: IC50 values (in μM) of trans-platinum complexes against normal and H-ras oncogene 
transformed murine keratinocytes, and HL-60 leukemic cells that over-express the c-myc and N-ras 
oncogenes.52 
Compound PAM 212 PAM 212-ras HL-60 
[PtCl2(dimethylamine)(isopropylamine)] 56 6 17 
[PtCl2(propylamine)(isopropylamine)] 50 32 20 
[PtCl2(butylamine)(isopropylamine)] 71 21 18 
cis-DDP 114 156 25 
 
1.5.2 In vivo Antitumor Activity of Mononuclear trans-DDP Analogues 
Whilst the range of molecules that have been tested is limited, several trans-DDP 
analogues have demonstrated in vivo antitumor activity against P388 leukemia in mice 
(Table 1.3). 
Table 1.3: %T/C values of trans-platinum complexes against normal and cis-DDP resistant 
plasmacytoma cell lines (where %T/C = median survival time (× 100) of treated mice versus non-treated 
mice). %T/C > 125 is considered to be active and %T/C > 150 is considered to be highly active.49,52 







trans-[PtCl2(iminoether)2 8.0 1-7 171 133 
trans-[PtCl2(iminoether)2 12.0 1-7 196 - 
trans-[PtCl2(NH3)(Tz)] 12.5 1, 5, 9 148 - 
trans-[PtCl2(NH3)(quin)] 25.0 1, 5, 9 121 - 
cis-DDP 0.6 1-7 203 90 
trans-DDP 58.0 1 105 107 
 
Trans-EE-iminoether was found to be highly active (%T/C = 196), though this 
depended on the treatment schedule, and displayed significant effects against the cis-
DDP resistant cell line P388/DDP (%T/C = 133).49 This complex also showed antitumor 
activity against mice bearing Lewis lung carcinoma.49 Trans-[PtCl2(NH3)(Tz)] 
displayed moderate activity and trans-[PtCl2(NH3)(quin)] lacked significant antitumor 
activity in mice, which was probably due to water solubility issues.53 
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1.5.3 Molecular and Cellular Pharmacology of Mononuclear trans-DDP Analogues 
The encouraging results obtained for the cytotoxicity of trans-DDP complexes, in 
various cell lines, suggests that the mechanism of activity and pharmacology of these 
complexes is significantly different to their cis predecessors. An increase in activity can 
be attributed to many molecular and cellular interactions, amongst which cellular 
accumulation is thought to be highly influential. The complex trans-[PtCl2(Py)2] has 
displayed higher levels of accumulation than cis-DDP in L1210 cells.53 Similarly, 
increased uptake of trans-[PtCl2(NH3)(quin)] in comparison to cis-DDP has been found 
in CHO (Chinese Hamster Ovary) cells.54 The ability of trans-platinum-iminoether 
complexes to overcome cis-DDP resistance may also be due to increased cellular uptake 
and DNA platination, especially where the mode of resistance is associated with a 
reduced accumulation mechanism.51 Upon reaching their cellular target, trans-DDP and 
its analogues form very different DNA lesions when compared to cis-DDP, which may 
also contribute to the activity profiles of these congeners. Trans-DDP forms mainly 
interstrand DNA cross-links (~12% in linear DNA), preferentially between guanosine 
and complimentary cytosine residues, whilst a relatively large proportion of adducts 
remain monofunctional (~50%).55,56 It has been hypothosised that, unlike cis-DDP, 
trans-DDP forms few interstrand cross-links because of the slow closure of 
monofunctional adducts and deactivation by intracellular sulphur nucleophiles.26,57 The 
major lesions of trans-DDP do not significantly affect the conformation of DNA, whilst 
interstrand cross-links induce less severe conformational changes than those of cis-
DDP.8,58,59 Analogs of trans-DDP containing planar amine ligands, such as trans-
[PtCl2(NH3)(quin)] and trans-[PtCl2(NH3)(Tz)], form both interstrand cross-links and 
protein associated DNA breaks in cellular DNA.60 In naked DNA, trans-
PtCl2(NH3)(quin)] primarily forms monofunctional adducts with a similar rate to trans-
DDP.61 The closure rate of monofunctional adducts to form bifunctional adducts is also 
similar to that of trans-DDP.61 RNA polymerase mapping experiments suggest that the 
DNA adducts of trans-PtCl2(NH3)(quin)] are preferentially formed at guanine 
residues.62 The conformational modifications induced by these adducts are different to 
those caused by the adducts of trans-DDP. For example, the monofunctional interstrand 
adducts of trans-[PtCl2(NH3)(Tz)] cause conformational changes in DNA that are 
similar to those induced by the major intrastrand and interstrand cross-links of cis-
DDP.63 The prevalent DNA lesions formed by trans-platinum-iminoether complexes, 
even after long periods of incubation, are monofunctional adducts at guanine residues.64 
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The lesions of trans-[PtCl2(E-iminoether)2] prematurely terminate RNA synthesis at 
sites in a similar manner to the major DNA adducts of cis-DDP.65 This is significant, as 
monofunctional DNA adducts are not considered to be relevant to the cytostatic effects 
of cis-DDP and trans-DDP, whilst providing trans-[PtCl2(E-iminoether)2] with 
considerable antitumour activity.47,49  
 
1.5.4 Inhibition of DNA Synthesis by trans-DDP Complexes 
The potency of cis-DDP can be attributed to its ability to inhibit DNA synthesis. Of the 
analogues tested for this mechanism of action, several have been able to exert effects 
comparable to cis and trans-DDP. Both trans-[PtCl2(Py)2] and trans-platinum 
iminoether inhibit DNA synthesis at various stages.49,66  
 
1.5.5 Dinuclear and Trinuclear trans-DDP Derivatives 
Expanding upon the developments of novel mononuclear trans-DDP analogues are a 


































































Figure 1.9: Multinuclear complexes under investigation for the treatment of a variety of cancers resistant 
to cis-DDP and carboplatin: 1, BBR3005; 2, BBR3571; 3, BBR3464; 4, BBR3610; 5, BBR3611. 
 
These compounds contain two or more platinum centres linked by alkyl amines that 
contain either a charged, inert central platinum centre or some other functional group 
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that is capable of hydrogen bonding with DNA.67-75 They also have a single chloro 
leaving group on each terminal platinum, display charges ranging from 1+ to 4+ and 
have demonstrated both high levels of cytotoxicity and low resistance factors (Table 
1.4).8  
Table 1.4: IC50 values (in μg/mL) of multinuclear trans-DDP analogues against L1210 murine leukaemia 
and cis-DDP resistant cell lines L1210/DDP.8 
Compound L1210 L1210/DDP 
BBR3005 2.3 1.8 
BBR3571 0.042 0.0062 
BBR3464 0.116 0.093 
BBR3610 0.0012 0.0011 
BBR3611 0.005 0.00041 
cis-DDP 0.9 8.3 
 
1.5.6 In vitro Activity of Multinuclear trans-DDP Analogues 
Multinuclear platinum complexes are similar to their mononuclear predecessors in that 
they both induce cell death by apoptosis.76 BBR3005, BBR3464. BBR3571, BBR3610 
and BBR3611 have all demonstrated significant in vitro cytotoxic activity in ovarian 
carcinomas,77 neuroblastomas,77,78 osteocarcinomas,79 cervical cancers,79 SCLC (small 
cell lung cancer) and NSCLC (non-small cell lung cancer)79 cell lines, prostrate cancers 
and astrocytomas.78 BBR3464 has consistently displayed lower IC50 values than cis-
DDP in a variety of cell lines. When tested against a panel of seven human tumour cell 
lines (4 melanoma and 3 ovarian) BBR3464 had an IC50 of 0.6 μM, approximately fifty 
fold lower than that of cisplatin.80 It has also performed better than cisplatin in the 
National Cancer Institute drug screening panel of sixty cancer cell lines.80 Most 
importantly, multinuclear platinum complexes have been shown to overcome both 
intrinsic and acquired resistance to cisplatin. BBR3464 displayed a complete lack of 
cross-resistance in the cisplatin resistant sub-line of U2-OS osteocarcinoma.81 In this 
cell line resistance is assumed to be due to reduced cisplatin accumulation, reduced 
DNA platination, reduced expression of the mismatch repair (MMR) protein PMS2 and 
micro-satellite instability (MSI).81 BBR3464 appears to overcome this resistance on the 
basis of higher platinum accumulation and DNA binding.81  
 
1.5.7 In vivo Antitumor Activity of Multinuclear trans-DDP Analogues 
BBR3464 has displayed in vivo activity in several mice models during phase I and II 
trials, at concentrations equal to and below its maximum tolerated dose. It has also 
shown high levels of cytotoxicity against a series of human tumour xenographs (three 
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SCLC, one NSCLC, two ovarian and two gastric), including four tumours resistant to 
cis-DDP, achieving tumour weight inhibition of 80% in seven of the eight models.80 
During phase I trials anticancer activity was observed in at least two patients treated 
with BBR3464, one with pancreatic cancer and the other with colon cancer 
metastases.82 Phase II trials have yielded mixed results over three studies. In the first 
study BBR3464 recorded five partial responses from a total of forty six patients,83 
whilst the second study yielded only two objective responses from a total of thirty three 
patients.84 In the third study it was found to be ineffective in the treatment of gastric and 
gastro-oesophageal adenocarcinoma, with no complete responses from the forty five 
patients administered with the drug.85 
 
1.5.8 Molecular and Cellular Pharmacology of BBR3464 
The success of BBR3464 in cis-DDP resistant cell lines can be partially attributed to 
increased cellular uptake and DNA platination.86 Measurements of platinum levels 
within L1210 and L1210/DDP cells, after 2 hours of exposure to BBR3464, revealed 
drug accumulation much higher than that observed for cis-DDP.86 This improvement 
was also achieved in both sensitive and resistant osteosarcoma (U2-OS  and U2-
OS/Pt)81,87 and neuroblastoma (BE(2)-M17 and BE(2)-M17/Pt)78 cells. Many 
multinuclear platinum complexes have been shown to hydrolyse and bind to DNA much 
faster than cis-DDP,88-90 which is widely accepted as the rate limiting step for the 
formation of covalent adducts.91 The positive charge attributed to most di- and tri- 
nuclear trans-DDP analogues attracts them to the multiple negative charges that exist on 
the sugar/phosphate backbone of DNA. Studies have confirmed that positively charged 
platinum complexes associate in the DNA minor groove before forming covalent 
adducts.92-94 This pre-association occurs preferentially at A/T rich regions, presumably 
because of increased steric hindrance and decreased electrostatic attractions found at 
G/C rich sites.95  The result is an increase in covalent adducts within the vicinity of the 
pre-association.96 Qu et al. have shown that, when binding to the self complementary 
oligonucleotide d(ATGTACAT)2, the central tetra-amine component of BBR3464 settles 
in the minor groove before the complex binds covalently through the terminal platinum 
centres in the major groove.97 Whilst multinuclear platinum complexes are capable of 
forming both interstrand and intrastrand adducts, they have a significant preference 
toward long-range interstrand adducts and are capable of forming adducts between 
DNA and proteins.98-100 For example, BBR3464 molecules can form links spanning up 
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to six nucleotides, which are flexible and non-directional in nature.96,97,101-103 Most 
importantly, these interstrand adducts are not recognised by HMG1 domain proteins and 
are not effectively removed by nucleotide excision repair (NER).103 Conversely, whilst 
multinuclear platinum complexes have the ability to form intrastrand cross-links, they 
are not thought to be biologically relevant as they are efficiently removed from DNA by 
NER.104 Recent studies have suggested that the activity profile of BBR3464 may not be 
a direct result of the nature of the major adducts alone; DNA site-specific 
conformational changes and hydrogen bonding between the complex and the backbone 
of DNA may play a significant role. For example, whereas cis-DDP binding stabilises 
the B-DNA conformation,105,106 complexes containing monofunctional binding centres 
(such as BBR3464) are able to induce B-DNA to Z-DNA or A-DNA conformational 
change.107-111 This is thought to be due to the placement of the bridging linker in the 
minor groove, which produces hydrogen bonds between the complex NH2 and NH3 
protons and the oxygen atoms of the DNA backbone.112 Subsequent covalent binding of 
the terminal platinum centres locks the DNA conformational change, making the 
transition back to B-DNA impossible.111 While the biological repercussions of the 
conversion to Z-DNA or A-DNA are poorly understood, the ability of some 
multinuclear platinum complexes to induce these conformational changes may play an 
important role in their anticancer function.  
 
1.5.9 Limitations of BBR3464 
Multinuclear complexes have consistently displayed high levels of toxicity, with the 
maximum tolerated doses (MTD) being between 13 and 670 times lower than that of 
cis-DDP. Mice were administered BBR3464 as a preliminary study of the drugs toxicity 
during pre-clinical trials. The fractionated MTD was found to be between 0.3 and 0.45 
mg/kg, compared to 4.0 mg/kg for cisplatin. At this dose BBR3464 was showing 
myelotoxicity, gastrointestinal toxicity and neurotoxicity comparable with cisplatin, 
though pulmonary toxicity was considerably reduced and there was no ototoxicity. Two 
phase I clinical trials of BBR3464 have shown that the dose limiting toxicity (DLT) is 
neutropenia and diarrhoea. Other side effects included nausea and vomiting, 
thrombocytopenia and mild to moderate anaemia, whilst no neurological or renal 
toxicities were observed. The MTD for humans was found to be 0.12 mg/m2/day in a 
fractionated study, or 0.9 mg/m2/day as a single dose. 
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1.6 Sequence Selective Compounds 
Some efforts to develop new classes of superior anticancer agents have focused on 
attaching cytotoxic moieties to suitable carrier molecules, which are then capable of 
more efficiently attacking their biological target. As it is generally accepted that the 
biological target of many anticancer drugs is DNA, molecules that display high affinity 
and specificity for DNA are of great interest in the design of anticancer drugs utilising 
this strategy. Some naturally occurring groove-binding polyamides (such as netropsin 
and distamycin A) are capable of this, as they comprise of a series of heterocyclic rings 





























1 2  
Figure 1.10: The structures of netropsin (1) and distamcyin (2). 
 
Netropsin, which was first isolated from Streptomyces netropsis,113 has displayed 
antiviral and antitumour activity.113 It is characterised by a polymeric aggregation of 
dual cationic amide functionalities separated by 5-membered pyrrole rings. Distamycin, 
an analogue of netropsin which was isolated from Streptomyces distallicus,114 can be 
distinguished by its additional N-methylpyrrole constituent and mono-cationic 
functionality. The binding of these molecules to DNA has been analysed by X-ray 
crystallography, allowing their affinity for specific DNA sequences to be explored.115-117 
Recognition of specific DNA sequences by distamycin and netropsin appeared to be due 
to hydrogen bonding and steric effects between the ligand and specific hydrogen bond 
donors and acceptors on the floor of the minor groove, formed by the edges of each base 
pair (Figure 1.11). 






























Figure 1.11: Schematic of the G/C and T/A base pairs, indicating hydrogen bond donors and acceptors 
exposed to the minor groove. 
 
In the complex the planar organic netropsin molecule bound in the minor groove in the 
AATT region, with each carboxamide unit forming two hydrogen bonds with the N3 of 












The innate flexibility of netropsin allows a small torsional twist that facilitates this 
interaction, by promoting close contact between the donor/acceptor residues.118 
Distamycin was found to bind in a similar manner. In higher concentrations (at least 2:1 
polyamide/DNA ratio) distamycin molecules were observed binding to the 
oligonucleotide d(CGCAAATTTGCG)2 in a paired, antiparallel formation in the A/T 
tract with high orientational and enhanced sequence specificity (Figure 1.13).119 The 
effect of this interaction on the conformation of DNA was determined by X-ray studies, 

























Figure 1.12: Netropsin binding to DNA. 









































Figure 1.13: Schematic view of distamycin binding in the minor groove of DNA in a 2:1 ratio. 
 
1.6.1 Lexitropsins 
It was postulated that the the DNA binding preference of these molecules could be 
altered from A/T to G/C by substituting one or more pyrrole rings with an appropriate 
proton accepting heterocycle. Analogues of netropsin and distamycin containing 1-
methylimidazole, characterised by a proton accepting nitrogen group, where found to 
display recognition of G/C sites, more specifically the exocyclic amino group of guanine 
in the minor groove.122 This was, however, coupled with noticeably reduced binding 
affinity. This was attributed to the wider nature of the minor groove in G/C regions, in 
which a slim molecule may not produce close van der Waals contacts.122 The netropsin 
analogue 1-methylimidazole-2-carboxyamidenetropsin (2-ImN) was observed binding 
to the sequence 5'-TGACT-3' as an antiparallel dimer, even at low polyamide/DNA 
concentration ratios, indicating that binding was a highly co-operative event.122,123 
Stacking of the conjugated rings of the ligand, as well as the predicted hydrogen bonds 
to specific DNA base pair atoms, contribute to the overall stability of the dimer/DNA 
adduct (Figure 1.14). 

























































Figure 1.14: Schematic view of 2-ImN binding to the sequence 5'-TGACT-3'.  
 
The specific recognition of both G/C and A/T base pairs by the 2-ImN dimer 
demonstrated the synergy that can be achieved between the base pair selectivity of the 
pyrrole and imidazole constituents. This proof of concept paved the way for the 
development of more complex sequence specific DNA binding molecules. 
 
1.6.2 Hairpin Linked Polyamides 
In an attempt to formalise the reading frame of selectivity in this family of molecules, a 
method was developed to bind the two components of a potential dimer, using flexible 
linkers to form a permanent head-to-tail hairpin motif.124 This resulted in both increased 
affinity and specificity in molecules when compared to their unlinked parent 
polyamides.124,125 For example, the hairpin polyamide ImPyPy-γ-PyPyPy-Dp (where Im 
= 1-methylimidazole, Py = N-methylpyrrole, γ = γ-aminobutyric acid and Dp = 
dimethylaminoproylamide) has been used to recognise a base pair sequence with an 
approximate 300-fold greater affinity than the unlinked polyamides ImPyPy and 
PyPyPy.124 Further experimentation demonstrated that the position of the γ-
aminobutyric acid component had no significant effect on the affinity of the molecule 
for its matched sequence, though single base pair mismatch affinities were altered.126  
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1.6.3 Limitations of Polyamide Sequence Selectivity 
Whilst the development of polyamides containing longer pyrrole and imidazole chains 
allowed for higher DNA binding affinity and selectivity, the upper limit for recognition 
of DNA sequences was shown to be 9-10 base pairs.127 From X-ray analysis it was 
determined that after four or five consecutive heterocycles both the Im and Py 
components fail to maintain adequate contact with the DNA minor groove due to its 
curvature.128 Second generation designs incorporated β-alanine residues interspersed 
strategically throughout the structures, overcoming the degeneracy problem by 
increasing the flexibility of the molecule and providing more residues for stabilisation 
by hydrogen bonding.129 The β-alanine components themselves displayed some DNA 
affinity due to their ability to form hydrogen bonds,130 further cementing their place as a 
useful tool in the synthesis of these molecules. 
 
1.6.4 Base Pairing Rules 
Considerable efforts have been made to characterise the affinity of various heterocycles, 
including those already mentioned and their analogues, to specific base pairs. This 
research has given rise to a set of base pairing rules that relate to the anti-parallel 
association of Py, Im and 3-hydroxy-N-methylpyrrole (Hp) polyamides to their 
predicted target DNA sequences, orientated N to C terminus with respect to the 5′-3′ 
direction of the DNA duplex. This facilitates the selection of specific groups in the 
polyamide chain on the basis of the nucleotide sequence of interest. Heterocyclic rings 
can be selected from a pool consisting of Im, Py and Hp, which form four ring-pairings 
(Im/Py, Py/Im, Hp/Py, Py/Hp) that can distinguish between all four Watson-Crick base 
pairs (Table 1.5). A Py/Py ring-pairing is specific for both T:A and A:T sequences, but 
cannot distinguish between the two. 
 
Table 1.5: The heterocyclic ring pairings required for base pair selectivity, where shaded areas designate 
a favourable interaction and – designates an interaction that is not favoured. 
Pair C:G G:C T:A A:T 
Im/Py -  - - 
Py/Im  - - - 
Hp/Py - -  - 
Py/Hp - - -  
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Im/Py and Py/Im pairings distinguish between 
G:C and C:G base pairs based on the 
following premise. An imidazole on the 
cytosine side of the base pair is unable to form 
a hydrogen bond with the exocyclic amino 
group of guanine, situated in the minor 
groove. When situated closer to the guanine, 
however, exact recognition is achieved 
through a specific hydrogen bond between N3 
of the imidazole ring and N2 of guanine 
(Figure 1.15).131,132 The recognition of A:T 
and T:A base pairs is not as simple, as the H-
bond acceptors at N3 of adenine and O2 of thymine are almost identically located in the 
minor groove.133 The asymmetrical cleft in the floor of the minor groove between 
thymine O2 and adenine 2H134 facilitates recognition by the Hp ring, in preference to 
Py, of the thymine base. The position and orientation of the hydroxyl group of Hp 
allows it to fit in the cleft between A and T, and form two hydrogen bonds with the O2 
of thymine (Figure 1.16).135  
 
Figure 1.16: The molecular interaction between an antiparallel pairing of Hp/Py and the base pair T:A.  
 
1.6.5 Alternative Ring Systems 
Further studies have attempted to broaden the range of DNA base pair specific aromatic 
heterocycles, though there have been few significant advances. Experimentation with 
the benzimidazole ring has revealed its ability to impart curvature upon the hairpin 
Figure 1.15: The molecular interaction 
between an antiparallel pairing of Im/Py and 
the base pair G:C. 
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polyamides in which they are incorporated, complementing the shape of DNA in a 
fashion that promotes selectivity over a longer base-pair reading frame. This system 
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Figure 1.17: Five-membered heterocyclic amino acids. The parent Im, Py and Hp residues are boxed. 
Analogs include benzimidazole (Bi), thiophene (Tp), 3-methylthiophene (Tn), 4-methylthiazole (Th), 5-
methylthiazole (Nt), 3-hydroxythiophene (Ht), 1H-pyrrole (Nh), 1-methyl-1H-pyrazole (Pz) and furan 
(Fr). 
 
1.6.6 Sequence Specific DNA Alkylating Agents 
Hairpin polyamides alone are incapable of permanently 
damaging DNA in the manner required for significant 
biological activity against cancer. Conversely, while most 
known anticancer agents display inherent reactivity towards 
purine bases, this selectivity is hardly worth noting when 
compared to the results achieved by polyamides that have 
been specifically engineered to target a DNA base pair 
sequence.136 New developments in the search for cytotoxic 
polyamides have centred on achieving a synergistic affect 
between potent DNA alkylating agents with sequence 
selective moieties.137 For example, conjugates between 
Duocarmycin A (Figure 1.18) and Im/Py hairpin 
polyamides have been synthesised and display selective alkylation. Duocarmycin A is 
an antibiotic which displays strong antitumour activity and that binds preferentially to 
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A/T rich sequences. It selectively alkylates N3 of adenine at the 3' end of three or more 
consecutive A/T base pairs in DNA.138 Initial attempts to impart further sequence 
selectivity upon this molecule involved the addition of a distamycin component, which 
altered the site of alkylation significantly. The new molecule alkylated G residues in 
G/C rich sequences, facilitated by the formation of a heterodimer between duocarmycin 
A and distamycin.139,140 By substituting a pyrrole ring with an imidazole, the sequence 
specificity could be further modulated in a predictable fashion. Two further analogues 
were synthesised, incorporating a duocarmycin A segment coupled to different hairpin 
polyamides, and shown to selectively alkylate at the N3 of purine bases at their target 
sequence (Figure 1.19).141 This formed the basis of the development of a new class of 
DNA alkylating agents, characterised by the successful mating of sequence selectivity 



































Figure 1.19: The hairpin polyamide based DNA alkylating agents (where X = C or N). 
 
1.6.7 Cyclopropylpyrroloindole Incorporation 
Second generation sequence selective DNA alkylators incorporated a vinyl linker 
between the polyamide and the alkylating agent, whilst the duocarmycin A component 
was replaced with cyclopropylpyrroloindole (CPI). These alterations increased the 
alkylating efficiency to 69%, compared to the 8% of the parent compound.142 This 
enhancement was attributed to the CPI moiety stacking with the imidazole component, 
in the same way that duocarmycin A stacked with distamycin to form a heterodimer.  
CPI is an active component in the cytotoxic antibiotic (+)-CC-1065 (Figure 1.20). 
Research into the mechanism of its activity revealed that it bound in the minor groove 
of DNA to A/T-rich sequences before selectively alkylating at the N3 of adenine.143 
 


















Figure 1.20: The natural occurring antibiotic (+)-CC-1065. 
 
1.6.8 In vitro Activity of CPI-lexitropsins 
A series of lexitropsins have been coupled to the CPI moiety and evaluated as 
antitumour agents (Figure 1.21).144,145 Many of these compounds displayed impressive 
activity profiles against four different cancer cell lines (murine leukaemia, murine 
mammary carcinoma, human T-lymphoblast and human B-lymphoblast cells), exceeded 
that of the alkylating component alone. Structure-activity relationship studies revealed 
that cytotoxicity increased as the number of pyrrole rings incorporated increased in the 
series. Despite the positive results, (+)-CC-1065 derivatives are characterised by poor 
water solubility, a substantial hurdle if they are ever to be administered as a therapeutic 
agent.146 Modification of the drug design will be required to solve this problem, and is 





















R1 = H, R2 = CH3, n = 3
R1 = H, R2 = CH3, n = 2
R1 = H, R2 = CH3, n = 3
R1 = Bn, R2 = H, n = 1
R1 = Bn, R2 = H, n = 2
R1 = Bn, R2 = H, n =3  
 Figure 1.21: Novel CPI-lexitropsin analogues. 
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1.6.9 Polyamides with Alternative Alkylating Agents  
Further research has focused on modifying the CPI moiety in an attempt to increase the 
overall activity of these molecules. CPI pyrazole analogues (Figure 1.22) have been 
synthesised and shown to display cytotoxicity in L1210 cell 
lines, but are limited by poor water solubility, limited 
sequence selectivity and a low affinity for DNA.147 Future 
studies will attempt to couple polypyrrole pseudopeptides to 
these agents, with the aim of addressing these issues. The 
DNA alkylating group seco-CBI,148 an analogue of CPI, has 
been coupled to a polyamide and investigated for biological 
activity (Figure 1.23). Although it was able to alkylate a 
specific DNA sequence in both cell free and intracellular 
conditions, and showed an ability to inhibit cell growth by 
50%, it required a 50-fold higher concentration than the derivatives of CPI to achieving 
the same results. This reduction in activity has been attributed to the effect the relatively 


















































Figure 1.23: A sequence selective hairpin polyamide coupled to seco-CBI. 
 
A small library of hairpin polyamides was conjugated with the DNA alkylating agent 
chlorambucil (Chl) and screened for biological activity. The compound 1R-Chl (Figure 
1.24) was deemed to be the most promising, displaying both in vitro and in vivo 
cytostatic activity. This agent was found to alter the morphology of SW620 (human 












Figure 1.22: CPI- pyrazole 
analogues. 
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cycle. It displayed little cytotoxic activity, however, with more than 90% of cells 
metabolically active after treatment. During in vivo studies, SW620 cells were treated 
with 1R-Chl for a period of three days prior to injection in mice. None of the 1R-Chl 
treated mice developed tumours. To prove the validity of these results, mice were 
injected with SW620 cells and treated with 1R-Chl or PBS (phosphate buffer saline) 
after tumour formation (one week). The 1R-Chl treatment was shown to suppress 















































Figure 1.24: A sequence selective hairpin polyamide coupled to the DNA alkylating agent chlorambucil 
(Chl). 
 
Follow up experiments allowed the tumours to grow for longer periods prior to drug 
treatment. As predicted, the mice treated with 1R-Chl had no significant increase in 
tumour volume over the course of the assay. Other compounds in the series that 
contained different sequences of Im/Py units did not induce the same morphological 
alterations or cytostatic activity. Inverting the chirality of the amino acid component to 
form the 1S-Chl isomer also led to a complete loss of activity, demonstrating the 
sensitivity of the structure-activity relationship in this class of molecules.  
 
1.6.10 Platinum Incorporation in Sequence Selective Drugs 
Considering the cytotoxicity of many platinum complexes, it surprising that only a few 
platinum incorporating sequence selective polyamides have been synthesised. Both 
netropsin and distamycin have been co-ordinated with cis-DDP to form bis-netropsin 
and bis-distamycin. These larger molecules still form cooperative associations and show 
considerable affinity for the sequence, 5′-TTTTAAAA-3′, even when coordinated by 
platinum.150 Brabec et al. have attached cis-DDP to the end of distamycin in an effort to 
harness the binding affinity of this groove binder (Figure 1.25).151,152  
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Figure 1.25: The coordination products of cis-DDP and distamycin. 
The two isomers of the cis-DDP-distamycin conjugate [Pt-DIST(R) and Pt-DIST(S)] 
formed a higher percentage of interstrand cross-links with DNA when compared to the 
parent cis-DDP molecule. This was attributed to distamycin’s minor groove binding 
capability,153 but only served to localise the platinum in the minor groove rather than the 
major groove where active platinum compounds tend to bind. Furthermore, the innate 
specificity for GG and AG sequences displayed by cis-DDP was not significantly 
altered by the incorporation of the sequence selective polyamide moiety, as was 
observed in distamycin tethered alkylating agents.154 
 
1.6.11 DJ1953-2 and DJ1953-6 
The effect of co-ordinating the terminal end of a pyrrole-pyrrole-imidazole polyamide 
with platinum was recently explored by Jaramillo et al.155 The aim was to synthesise a 
molecule that would bind in the minor groove to a specific sequence, and then bind 
covalently to the DNA through its platinum moiety. The compounds synthesised were 



















n = 1 (DJ1953-2)
n = 3 (DJ1953-6)
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Figure 1.26: The general structure of compounds in the DJ1953 family of platinum(II) complexes. 
 
They were shown to bind to DNA in a coordinate covalent manner using electrospray 
ionisation mass spectrometry. Greater affinity to the target DNA sequence 
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d(CATTGTCAGAC)2 when compared to the double base pair mismatch sequence 
d(CATTGAGAGAC)2 was displayed by circular dichroism. The data from the CD 
spectra was used to calculate preliminary binding constants (Table 1.6).  
 
Table 1.6: Preliminary binding constants of the metallo-polyamides DJ1953-2 and DJ1953-6 to matched 
and mismatched DNA oligonucleotide sequences.155 
Complex d(CATTGTCAGAC)2 d(CATTGAGAGAC)2 
DJ1953-2 1.2 (± 0.1) × 106 3.0 (± 0.1) × 105 
DJ1953-6 2.4 (± 0.1) × 106 1.3 (± 0.1) × 106 
 
DJ1953-2 was shown to unwind the DNA helix by 13o, which is similar to the degree of 
unwinding induced by the 1,2-intrastrand adduct of cis-DDP,156 though neither metal 
complex induced a significant change in DNA melting temperature. Unlike simple 
groove binding agents, DJ1953-2 was able to inhibit RNA synthesis during in vitro 
transcription assays. Neither compound displayed impressive cytotoxicity in L1210 
murine leukaemia cell lines, though DJ1953-6 proved more active (34 μM) than its 
shorter counterpart DJ1953-2 (>50 μM). It was proposed that the linker length in 
DJ1953-6 was sufficient to allow the platinum terminals to bind covalently in the major 
groove, perhaps with a mode similar to BBR3464. These molecules demonstrated the 
ability to selectively associate with target DNA sequences with subsequent covalent 
binding through platinum centres. Further development of this concept was required 
however, to achieve greater biological activity and determine the effects of varying 
platinum centre motifs on binding and cytotoxicity.  
 
1.7 Project Aims 
The aim of this work was to evaluate 2,2′:6′,2″-terpyridineplatinum(II) as a potential 
DNA intercalating moiety in biologically active metallopolyamides. Such compounds 
would combine selective minor groove binding ability, afforded by a polyamide 
component, with DNA intercalating platinum(II) terminals.  
 
New and efficient methods were developed for the synthesis of a polyamide component 
suitable for platinum(II) coordination. This involved novel coupling procedures and 
purification methods that circumvent low yielding column chromatography steps. 
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Two mononuclear terpyridineplatinum(II) molecules, specifically chosen to be suitable 
for incorporation into sequence selective polyamides by both solution and solid phase 
techniques, were synthesised. One of these molecules had been previously described, 
whilst the other was novel and analysed for DNA binding strength and base pair affinity 
by both circular dichroism (CD) and 1D and 2D 1H NMR techniques. Crystals of the 
novel mononuclear species were also grown and analysed by x-ray crystallography 
revealing the stacking interactions of this new molecule. 
 
As a proof of concept the two mononuclear species were successfully conjugated to 
form a novel dinucleur species, using a standard peptide coupling routine. This 
molecule was also analysed for DNA binding strength and base pair affinity by circular 
dichroism (CD), 1D and 2D 1H NMR techniques. The cytotoxicity of the two novel 
intercalating species was also tested against the L1210 murine leukenia cell line.  
 
A novel strategy for the incorporation of the terpyridineplatinum(II) species was then 
developed whereby a terpyridineplatinum(II) based polyamide was synthesised entirely 




















































Figure 1.27: The intercalating species investigated in this study, including the intermediate mononuclear 
synthons 1, and 2, the dinuclear species 3 formed by the coupling of the two mononuclear species by 
standard peptide coupling techniques, and the novel intercalating sequence selective polyamide 4 
obtained purely by machine assisted protocols. 
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CHAPTER TWO: SOLUTION PHASE SYNTHESIS 
 
2.1 INTRODUCTION 
The successful synthesis of sequence selective polyamides, based on N-methylpyrrole 
and 1-methylimidazole, relies on the availability of several heterocyclic building blocks 
displaying various functionalities. The preparation of these precursors requires elaborate 
synthetic schemes, starting from the parent heterocycles. The introduction of a nitrogen 
containing group at the 4 position is particularly difficult, and is widely recognised as 
the Achilles Heel of such schemes, resulting in low overall yields.157,158 Recent efforts 
have focused on maximising the yield and efficiency of these reactions.159 This work 
utilised the trichloroacetyl functional group to direct further substitution of the parent 
heterocycles and as an alternative to the less reactive carboxylic or acid chloride 
derivative in the first coupling step. Subsequent coupling of the building blocks in this 
work was achieved using adaptations of standard peptide coupling procedures. Such 
methods have improved greatly over the past few years, as the advent of solid phase 
technology has encouraged the development of new and innovative strategies for 
stepwise elongation and segment condensation. The synthesis of oligopeptides in 
solution once involved the use of acid chloride-amine coupling regimes, which have 
now been replaced by the routine incorporation of additives and coupling agents (Figure 
2.1). Such methods have dramatically improved the facile synthesis of complex 
molecules in rapid time and increased overall yields. 
 









































Figure 2.1: Some commonly used coupling agents,160 including EDCI, DMAP, HOBt, TBTU and HBTU 
which were used in this work. 
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2.2 MATERIALS AND METHODS 
 
2.2.1 Reagents 
Potassium tetrachloroplatinate(II) (99%) was purchased from Precious Metals Online. 
1,5-Cyclooctadiene (99+%), 2,2′:6′,2″-terpyridine (98%), 1-Methylimidazole (99%), 
triethylamine (99.5%), sodium methoxide (95%), 10% palladium on charcoal, N,N-
diisopropylethylamine (99.5%) and DOWEX® 550A OH anion exchange resin was 
purchased from the Sigma-Aldrich chemical company. N-methylpyrrole (99%) was 
purchased from Alfa Aesar. Trichloroacetic acid (99%) was purchased from Chem-
Supply. Thionyl chloride (98%) was purchased from Riedel-de Haën. Nitric Acid (70%) 
was purchased from J. T. Baker. Di-tert-butyl dicarbonate (98%) acetic anhydride 
(99+%) and 1,6-diaminohexane (99%) were purchased from Fluka. Ninhydrin was 
purchased from Ajax. 2-(1H-Benzotriazole-1-YL)-1,1,3,3-
tetramethyluroniumhexaflourophosphate, (HBTU, 99%) was purchased from Protein 
Technologies, Inc. Trans-platinum(II)diamine dichloride (99.5%) was purchased from 
Precious Metals Online. Silver nitrate (99.8%), was purchased from BDH Chemicals. 
Trifluoroacetic acid, peptide synthesis grade, was purchased from Peptech. All other 
reagents and solvents were used as received unless otherwise stated. Dimethylsulfoxide 
(d6-, 99.9%), dimethylformamide (d7-, 99.9%) and deuterium oxide (d2-, 99.9%) were 
purchased from Cambridge Isotope Laboratories.        
 
2.2.2 General methods  
Reactions were monitored by thin layer chromatography (TLC) using 0.25 mm thick 
pre-coated UV sensitive silica gel plates purchased from Fluka. Compounds were 
visualised with short-wave ultraviolet light at 254 nm. Flash chromatography was 
carried out using Kieselgel 60 (230-400) mesh.  
 
2.2.3 Characterisation 
Routine 1H NMR spectra were obtained using a 300 MHz Varian Unity plus NMR 
spectrometer using commercially available solvents referenced to the residual solvent 
peak.161 195Pt NMR spectra were obtained using a Bruker 400 Avance 400 MHz 
spectrometer. The following abbreviations apply to spin multiplicity: s (singlet), bs 
(broad singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Mass spectra were 
obtained at the Mass Spectrometry Laboratory at the University of Wollongong, NSW, 
Chapter Two: Solution Phase Synthesis  30
Australia. Elemental analysis was performed at the Australian National University in 




2.3.1 Preparation of Trichloroacetyl Chloride 
Trichloroacetyl chloride was synthesised using the methods reported by von Bosshard et 
al.162 Trichloroacetic acid (50.00 g, 0.27 mol), SOCl2 (25 mL) and DMF (1 mL) were 
heated to 80 oC for 3 hours. The product was distilled (114-117 oC) yielding the 
colourless liquid (42.08 g, 85.7 % yield). 
 
2.3.2 Synthesis of the Monomeric Building Blocks 
 
2.3.2.1 2-Trichloroacetyl-1-methylimidazole (1) 
Compound 1 was synthesised using methods reported by Jaramillo et al.159 1-
methylimidazole (10.00 g, 0.12 mol) in DCM (80 mL) was added dropwise to 
trichloroacetylchloride (22.00 g, 0.12 mol) in DCM (80 mL) over a period of 2 h, 
producing a yellow solution with white suspension. The mixture was stirred for 6 h at 
room temperature then cooled to 0 oC in an ice bath and Et3N (17 mL, 0.12 mol) was 
added dropwise over 1 h. The reaction mixture was filtered to remove the triethylamine 
salt. The volume of the filtrate was reduced by evaporation under reduced pressure, 
from which the pure product (16.29 g, 59.7% yield) was obtained by flash 
chromatography (1:4 hexane/DCM). 1H NMR (300 MHz, d6-DMSO): δ 7.37 (s, 1H), 
7.17 (s, 1H), 3.90 (s, 3H). 
 
2.3.2.2 2-Trichloroacetyl-N-methylpyrrole (2) 
Compound 2 was synthesised using methods reported by Nishiwaki et al.163 N-
methylpyrrole (10.00 g, 0.12 mol) in DCM (40 mL) was added dropwise to 
trichloroacetyl chloride (22.00 g, 0.12 mol) in DCM (40 mL) over 3 h and left to stir 
overnight. The solvent was reduced by evaporation under reduced pressure and the 
residue was purified by flash chromatography (1:4 hexane/DCM) to provide the pure 
product (17.00 g, 62.5% yield). 1H NMR (300 MHz, d6-DMSO): δ 7.43 (m, 2H), 6.28 
(q, 1H), 4.08 (s, 3H). 
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2.3.2.3 4-Nitro-2-trichloroacetyl-N-methylpyrrole (3) 
Compound 3 was synthesised using methods adapted from those reported by Hotzel et 
al.164A mixture of HNO3 (70 %, 12 mL) and Ac2O (60 mL) was added dropwise to a 
chilled solution (-40 oC) of 2 (17.00 g, 0.13 mol) in Ac2O (40 mL) over a period of 30 
min. The reaction mixture was allowed to return to room temperature and left to stir for 
2 h. The mixture was then cooled to -20 oC, isopropanol added (125 ml) and left at -20 
oC overnight to induce precipitation. The solid was then collected by filtration, washed 
with cold isopropanol and dried under vacuum (10.10 g, 49.5% yield). 1H NMR (300 
MHz, d6-DMSO): δ 8.55 (d, 1H, J = 1.2 Hz), 7.81 (d, 1H, J = 1.8 Hz). 
 
2.3.2.4 Methyl-N-methyl-4-nitropyrrole-2-carboxylate (4) 
Compound 4 was synthesised using methods reported by Jaramillo et al.159 To a 
solution of 3 (4.00 g, 13 mmol) in anhydrous MeOH (150 mL) was added sodium 
methoxide (0.86 g, 16 mmol) and the mixture stirred for 1 h. The reaction was cooled 
and quenched with HCl (1 M). The solvent was removed under reduced pressure, H2O 
added and extracted with DCM (3 × 50 mL). The organic layers were combined, dried 
over anhydrous MgSO4 and the solvent removed under reduced pressure to provide the 
pure product (2.40 g, 98.8% yield). 1H NMR (300 MHz, d6-DMSO): δ 8.24 (s, 1H), 
7.24 (s, 1H), 3.91 (s, 3H), 3.79 (s, 3H). Anal. Calc’d for C7H8N2O4: C, 45.66; H, 4.38; 
N, 15.21; found: C, 45.74; H, 4.42; N, 15.21. 
 




Compound 5 was synthesised using methods adapted from those reported by Xiao et 
al.165 Compound 4 (1.00 g, 10.8 mmol) in MeOH (60 ml) and 10% Pd/C (10% w/w, 
0.10 g) were stirred under H2(g) (1 atm) overnight. The catalyst was removed by 
filtration through a celite pad.* The solvent was removed by evaporation under reduced 
pressure after the addition of DMF (5 ml). Compound 1 (1.23 g, 11 mmol) was 
immediately added and the mixture was stirred for 24 h. The solvent was removed 
under reduced pressure. The residue was dissolved in DCM (5 mL) and shaken with 1 
                                                 
*Caution; 10% Pd/C is highy flammable and must be kept moist during filtration to prevent ignition. 
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M HCl (20 mL), then allowed to stand for 30 min. The crystalline solid was collected by 
filtration and washed with DCM (5 × 10 mL). The solid was suspended in distilled 
water and neutralised with 1 M NaOH to yield the pure product (1.39 g, 98.2 % yield) 
which was collected by filtration and washed thoroughly with distilled water. 1H NMR 
(300 MHz, d6-DMSO): δ 10.55 (s, 1H), 7.53 (d, 1H, J = 2.1 Hz), 7.39 (d, 1H, J = 1.0 
Hz), 7.03 (d, 1H, J = 1.0 Hz), 7.02 (d, 1H, J = 1.8 Hz), 3.97 (s, 3H), 3.83 (s, 3H), 3.72 
(s, 3H). Anal. Calc’d for C12H14N4O3: C, 54.96; H, 5.38; N, 21.36; found: C, 54.69; H, 
5.35; N, 21.22. 
 
2.3.3.2 4-(1-methylimidazole-2-carboxyamido)-N-methypyrrole-2-carboxylic acid 
(6) 
To a solution of 5 (0.70 g, 2.67 mmol) in THF/MeOH (1:1, 6 mL) was added LiOH (1 
M, 6 mL) and the solution stirred at 60 oC for 5 h. The organic solvents were removed 
under reduced pressure and the solution acidified with HCl (1 M, pH = 3). The crude 
product was collected by lyophilisation and used without further purification. 1H NMR 
(300 MHz, d6-DMSO): δ 12.20 (bs, 1H), 10.48 (s, 1H), 7.45 (d, 1H, J = 1.8 Hz), 7.38 (s, 




Compound 4 (0.49 g, 2.67 mmol) was dissolved in methanol (50 mL) and stirred 
overnight under a slightly positive hydrogen atmosphere after the addition of 10% Pd/C. 
Formation of the amine was monitored by TLC with ninhydrin. The catalyst was 
removed by filtration through a pad of celite,* DMF was added (3 mL) and methanol 
was removed under vacuum. A solution of crude 6 in DMF (3 mL) was added, followed 
by HBTU (0.96 g, 2.54 mmol), and DIEA (1.4 mL, 8 mmol). The solution was stirred 
for 1 h, after which the solvent was concentrated under reduced pressure. The crude 
product was precipitated by the addition of distilled water. The product was 
recrystallised from DCM, then triturated with MeOH to provide the pure product (0.64 
g, 62% yield). 1H NMR (300 MHz, d6-DMSO): δ 7.38, (d, 1H, J = 2.1 Hz), 7.33 (d, 1H, 
J = 2.1 Hz), 7.26 (d, 1H, J = 1.0 Hz), 7.06 (d, 1H, J = 1.0 Hz), 6.95 (d, 1H, J = 2.1 Hz), 
                                                 
* Caution; 10% Pd/C is highly flammable and must be kept moist during filtration to prevent ignition. 
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6.94 (d, 1H, J = 2.4 Hz), 4.06 (s, 3H), 3.93 (s, 3H), 3.90 (s, 3H), 3.80 (s, 3H). Anal. 
Calc’d for C18H23N6O5.5: C, 53.59; H, 5.75; N, 20.82; found: C, 53.6; H, 5.64; N, 20.57. 
 
2.3.3.4 Methyl-4-[methyl 4-(1-methylimidazole-2-carboxyamido)-N-methylpyrrole-
2-carboxyamido]-N-methypyrrole-2-carboxylic acid (8) 
To compound 7 (0.70 g, 1.82 mmol) in THF/MeOH (1:1, 6 mL) was added LiOH (1 M, 
6 mL) and the solution stirred at 60 oC for 5 h. The solvent was evaporated, the solution 
cooled and acidified with HCl (1 M, pH = 3). The crude product was collected by 
lyophilisation and used without further purification. 1H NMR (300 MHz, d6-DMSO): δ 
12.17 (bs, 1H), 10.49 (s, 1H), 9.93 (s, 1H), 7.42 (d, 1H, J = 2.1 Hz) 7.39 (d, 1H, J = 2.1 
Hz), 7.27 (d, 1H, J = 1.0 Hz), 7.17 (d, 1H, J = 1.0 Hz), 7.03 (d, 1H, J = 2.1 Hz), 6.83 (d, 
1H, J = 2.4 Hz), 3.98 (s, 3H), 3.83 (s, 3H), 3.81 (s, 3H). 
 
2.3.4 Synthesis and Coupling of the Diaminohexane Linker 
 
2.3.4.1 tert-Boc-diaminohexane (9) 
The compound tert-Boc-diaminohexane (9) was prepared using an adaptation of the 
methods described by Krapcho et al.166,167 A solution of di-tert-butyl dicarbonate (2.18 
g, 0.01 mol) in DCM (12 mL) was added over a period of 2 h to a solution of the 
diamine (9.30 g, 0.08 mol) in DCM (36 mL), which was cooled in an ice bath. The 
mixture was left to stir for 24 h and the solvent was removed under reduced pressure. 
Water (60 mL) was added to the residue and the insoluble bis-substituted product was 
collected by filtration. The filtrate was extracted with DCM (3 × 50 mL), the organic 
fractions combined and backwashed with H2O. The organic layer was collected, dried 
over MgSO4 and evaporated to yield the pure product as a clear oil (2.33 g, 54% yield). 
1H NMR (300 MHz, D2O): δ 2.94 (t, 2H, J = 7.0 Hz), 2.52 (t, J = 7.0 Hz), 1.38 (m, 4H), 




To a mixture of compound 8 (0.08 g, 0.21 mmol), compound 9 (0.06 g, 0.27 mmol), 
HBTU (0.12 g, 0.31 mmol), in DMF (5 mL), was added DIEA (0.24 mL, 1.30 mmol) 
and the solution stirred for 1 h. The solvent was removed under reduced pressure and 
the residue was purified by flash chromatography (10% MeOH/DCM), to provide the 
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product as a light brown solid (0.09 g, 79% yield), which was dried under vacuum. 1H 
NMR (300 MHz, d6-DMSO): δ 10.48 (s, 1H), 9.91 (s, 1H), 7.99 (t, 1H, J = 6.0 Hz), 
7.39 (d, 1H, J = 1,2 Hz), 7.28 (d, 1H, J = 1.5 Hz), 7.17 (d, 1H, J = 1.5 Hz), 7.14 (d, 1H, 
J = 1.8 Hz), 7.04 (d, 1H, J = 1.2 Hz), 6.84 (d, 1H, J = 1.5 Hz), 6.79 (bs, 1H), 3.98 (s, 
3H), 3.83 (s, 3H), 3.78 (s, 3H), 3.12 (m, 2H), 1.49 (m, 2H), 1.35 (s, 17H). 
 
2.3.5 The Synthesis of Chloroterpyridineplatinum(II) Chloride 
 
2.3.5.3 Dichloro(1,5-cyclooctadiene)platinum(II) [Pt(COD)Cl2] 
[Pt(COD)Cl2] was synthesised using methods adapted from McDermott et al.168 
Potassium tetrachloroplatinate (1.00 g, 2.4 mmol) was dissolved in 16 mL of water and 
filtered. To the deep red filtrate was added glacial acetic acid (24 mL) and 1,5-
cyclooctadiene (0.88 g, 8.0 mmol). The reaction mixture was stirred rapidly and heated 
to about 90 oC on a steam bath. Over 30 min the deep red solution slowly became pale 
yellow as crystals were deposited. The volume of the solution was reduced to approx. 
12 mL by evaporation under reduced pressure. The light yellow needles were collected 
and washed with 50 mL portions of water, ethanol and ether. After being dried at 100 oC 
for 60 min the product was weighed (0.95 g, 98% yield), and decomposed between 250 
and 280 oC (lit. dec. 220-278 oC). The product was used without further purification or 
characterisation. 
 
2.3.5.4 Chloroterpyridineplatinum(II) chloride [Pt(terpy)Cl]Cl.2H2O (11) 
[Pt(terpy)Cl]Cl.2H2O was synthesised using methods adapted from Annibale et al.169 
To a suspension of [Pt(COD)Cl2] (0.15 g, 0.40 mmol) in water (55 mL), 2,2′:6′,2″-
terpyridyl (0.094 g, 0.40 mmol) was added with stirring and the mixture warmed at 40-
50 oC. After 15 min all the solid dissolved and a red-orange clear solution was observed, 
which was cooled to room temperature and filtered to remove any unreacted 
[Pt(COD)Cl2]. The solvent was removed under reduced pressure leaving a red-orange 
solid (0.16 g, 80 % yield) which was collected and washed thoroughly with diethyl ether 
and air dried. 1H NMR (300 MHz, D2O): δ 7.97 (m, 3H), 7.72 (M, 5H), 7.63 (d, 2H, J = 
5.8 Hz), 7.27 (dt, 2H, J1 = 9 Hz, J2 = 1.8 Hz). 195 Pt NMR (400 MHz, D2O): δ -2721.14 
(s). Anal. Calc’d for C15H15Cl3N3O2PtCl2: C, 33.66; H, 2.82; N, 7.85; found: C, 33.96; 
H, 2.86; N, 7.88. 
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To a solution of compound 10 (0.07 g, 0.13 mmol) in EtOAc (2 mL) was added 4 M 
HCl/EtOAc (0.25 mL) and the solution stirred for 1.5 h. The solvent was removed under 
reduced pressure and the residue stirred with DOWEX® 550A OH anion exchange resin 
(0.04 g, 0.13 mmol). The solution was decanted and evaporated, CHCl3 (5 mL) added 
and the solid (0.05 g, 90% yield) collected and dried under vacuum. 1H NMR (300 
MHz, d6-DMSO): δ 10.49 (s, 1H), 9.91 (s, 1H), 8.01 (t, 1H, J = 6.0 Hz), 7.94 (s, 1H), 
7.59 (bs, 2H), 7.41 (s, 1H), 7.27 (s, 1H), 7.15 (s, 1H), 7.05 (s, 1H), 6.89 (s, 1H), 3.98 (s, 
3H), 3.83 (s, 3H), 3.78 (s, 3H), 2.76 (m, 2H), 1.49 (m, 2H), 1.29 (m, 8H). ESI-MS m/z 




2.4.1 Ligand Synthesis 
Elaborate methods for the stepwise elongation of sequence selective polyamides have 
been developed using both solution, and more recently, solid phase techniques. The 
conversion of protected amino or nitro acids to their corresponding acyl chloride, 
followed by reaction with amino esters, was an important technique in the early stages 
of the development of peptide synthesis. Unfortunately, the conditions traditionally 
employed for acyl chloride formation (thionyl chloride, phosphorous pentachloride, at 
high temperatures etc.) are too vigorous to be appropriate for use in conjunction with 
sensitive substrates or relatively fragile automated systems. Such methods are now 
being circumvented in favour of higher yielding routines. Figure 2.2 is a graphical 
representation of the reaction scheme used in this work to synthesis the polyamide 
ligand. In this work the best results were achieved through the use of agents that 
promote the formation of an active ester when added to the carboxylic acid, providing a 
favourable target for nucleophillic attack. Early attempts to use ester aminolysis as a 
routine technique for peptide bond formation yielded disappointing results. Introducing 
more efficient leaving groups, such as the esters of phenols and other acidic 
functionalities, has proven to be a fruitful adaptation of this concept, facilitating the 
formation of the desired peptide bond to the degree that they are now used routinely for 
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the rapid coupling of amino acids on solid phase. The reason for this is that, unlike ester 
saponification, the rate limiting step in the aminolysis of phenyl esters involves the 
collapse of a tetrahedral intermediate, not its formation. Therefore the addition of a 
more efficient leaving group improves the rate at which the tetrahedral intermediate 
collapses, driving the reaction equilibrium towards formation of the desired product. 
The only exception to this is the first coupling reaction (f) which proceeds quite rapidly 
based on the reactivity of the trichloroacetyl group alone, greatly simplifying 


























































































Figure 2.2: Ligand reaction scheme: (a) trichloroacetyl chloride, Et3N, DCM, 0 oC, 8 h; (b) 
trichloroacetyl chloride, DCM, 15 h; (c) HNO3, acetic anhydride; (d) MeOH, NaOMe, 1M HCl; (e) 10% 
Pd/C, H2(g), MeOH, 1 h; (f) 4b, HBTU, DIEA, DMF, N2(g), 1 h; (g) 1 M LiOH, THF/MeOH (1:1); (h) 4b, 
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Figure 2.3: Formation of 2-trichloroacetyl-1-methylimidazole (1) and 2-trichloroacetyl-N-methylpyrrole 
(2) from commercially available starting materials. 
 
This reaction is a modified Friedel-Crafts acylation, whereby the acyl group (in this case 
trichloroacetyl chloride) is introduced to the aromatic precursors (N-methylpyrrole or 1-
methylimidazole, Figure 2.3). The acyl group is highly reactive so the reaction does not 
require the addition of a Lewis Acid, and is easily prepared by reacting trichloroacetic 
acid with thionyl chloride. Electrophillic attack by the strongly polarised acyl group is 
followed by the displacement of a proton, which is transferred to the anion derived from 
the electrophile (in this case the liberated chloride ion). The formation of HCl restores 
aromaticity to the ring, and is followed by the addition of triethylamine to quench the 
reaction. In imidazole synthesis, during addition of the acetyl group, an N-acetylated bi-
product forms, which is removed by the addition of triethylamine. After removal of the 
solvent by evaporation under reduced pressure, the residues were purified by flash 
chromatography (1:4 hexane/DCM). Column overloading and smearing was a frequent 
and unavoidable problem experienced during this stage of the preparation. The batch 
sizes were large out of necessity and the crude residue difficult to load due to its viscous 
(and often partially crystalline) nature. For this reason chromatography steps were often 
repeated after the bulk of impurities had been removed, yielding the pure product. The 
products were collected as yellow oils which yielded large yellow needles upon cooling. 
Previous synthetic schemes requiring a terminal imidazole substituent have involved the 
conversion of the trichloroacetyl group to a methyl ester, followed by hydrolysis to 
provide the carboxylic acid for coupling. This work has shown that the reactivity of the 
trichloroacetyl group was sufficient to permit coupling to free amines, without the use 
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Figure 2.4: The formation of 4-nitro-2-trichloroacetyl-N-methylpyrrole (3). 
 
2-Trichloroacetyl-N-methylpyrrole was reacted with 70% HNO3 in acetic anhydride to 
give the mono-substituted nitro product (Figure 2.4). The trichloroacetyl group strongly 
directs substitution to the 4 position, with aromaticity being restored after the 
displacement of a proton to the solvent. Alternatively, freshly prepared 2-
trichloroacetyl-N-methylpyrrole was reacted with fuming nitric acid, in the presence of 
concentrated sulfuric acid, also giving the mono-substituted nitro product. Concentrated 
sulfuric acid increases production of the nitronium ion (NO3+), a potent electrophile, 
facilitating substitution. Unlike the published method, this reaction was quenched with 
ice, inducing precipitation of the product in high yield. Due to the extended preparation 
time and added safety considerations pertaining to the use of fuming nitric acid, this 
method was not routinely utilised. 
 










Figure 2.5: Formation of the nitrated ester (4a). 
 
4-Nitro-2-trichloroacetyl-N-methylpyrrole was rapidly converted to a methyl ester in 
methanol, without the aid of an acid catalyst, due to the strong reactivity of the 
trichloroacetyl group (Figure 2.5). Sodium methoxide was added to the reaction mixture 
to neutralise the subsequent HCl formed during the conversion. Acidification of the 
solution and extraction with DCM gave the nitro ester in high yields. 
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2.4.1.4 Catalytic Hydrogenation of 4-Nitro-2-trichloroacetyl-N-methylpyrrole and 






















Figure 2.6: Formation of the amino ester (4b) and coupling with compound 1 to give the dimer (5). 
 
An attempt was made to perform both the hydrogenation of compound 4 and ensuing 
coupling in ethyl acetate, following published methods for the reaction of a similar 
molecule.165 It was hoped that the use of this solvent system would reduce handling 
times after amination, avoiding complications due to the inherent instability of the free 
amine. Complete conversion to the amine was monitored by TLC (10% MeOH/DCM 
v/v) using the stain ninhydrin, and was ultimately achieved after 24 h. The coupling 
reaction (Figure 2.6) proceeded slowly, with significant traces of the starting monomers 
still evident after 24 h, at which point the reaction was terminated and the product 
retrieved in low yield by flash chromatography. In order to reduce the reaction time the 
hydrogenation solvent was replaced with methanol, allowing the complete conversion 
of compound 4a to the free amine (4b) within 1 h. After filtering through celite, to 
remove the Pd/C catalyst, DMF was added to retain the unstable amine in solution 
whilst the methanol was removed by evaporation under reduced pressure. The coupling 
reaction was performed in DMF over a period of 20 h, without the presence of a catalyst 
or base. Evaporation of the DMF under reduced pressure yielded the crude product in 
high yield. Initial purification attempts followed the previously published methods, 
involving flash chromatography with 10% MeOH/DCM eluent. Whilst this method was 
successful in providing a pure product it also led to a significant loss in yield, possibly 
due to the products limited solubility in this solvent system. During experiments to 
improve the efficiency of this purification step, it was discovered entirely by accident 
that the pure product could be crystallised from the crude material by acidification in 
dilute HCl. From this discovery a new method was developed, whereby the reaction 
solvent was evaporated under high vacuum, and the residue dissolved in DCM. This 
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solution was shaken with 1 M HCl and left to stand for 30 min. The protonated form of 
the product 5 crystallised from the mixture as pale green needles, which were collected 
by filtration and washed with DCM to remove unreacted 1. The needles were 
resuspended in distilled water and neutralised with 1 M NaOH to yield a salmon 
coloured precipitate. The solid was collected by filtration and washed thoroughly with 
water to remove any traces of NaCl and unreacted free amine. A yield of 98% was 
achieved, which is a considerable increase when compared to the 64% yield expected 
for the standard coupling scheme. Success of the coupling using the DMF solvent 
system (as opposed to ethyl acetate) can be attributed to its polar aprotic characteristics, 
and highlights the unpredictable reactivities of these monomers. 
A brief equilibrium study of the protonated 4-(1-methyl-imidazole-2-carboxyamido)-N-
methylpyrrole-2-carboxylate species (ImPyPy.HCl) was performed to help elucidate the 
nature and mechanism of this unexpected development. The sample for this study as 
prepared by the suspension of 0.227 g of ImPyPy.HCl in 10 mL of distilled water 
(0.076 M). The pH of the solution was measured with a pH probe. From the measured 
pH the concentration of the H3O+ ion was calculated, from which the concentration of 
other relevant ions were determined (See Appendix B). The equilibrium study was 
performed under the assumption that the compound is monoprotic, based on the 
characteristic appearance of its titration curve (below).  
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A summary of the relevant values obtained in this experiment is provided in Table 2.1. 
 
Table 2.1: The Ka, pKa and ionisation percentage (x) of ImPyPy.HCl.  
Compound Ka pKa x 
ImPyPy.HCl 1.6×10-2 1.78 37% 
 
The predicted structure of the protonated compound is illustrated in Figure 2.7, and is 
consistent with the protonation models of similar molecules which have been analysed 
by x-ray crystallography, such as 1,1-(butane-1,4-diyl)bis(imidazolium)bis 
(perchlorate).170 The experimentally determined equivalence point of the titration 
(approximately 1.17 mL of 0.65 M NaOH) was consistent with the predicted 
equivalence point (also 1.17 mL), which was based on the monoprotic model illustrated 
in Figure 2.7 (See Appendix B). This provides strong evidence that the model is an 
accurate depiction of the species formed. 
 
 
Figure 2.7: The crystal (1) and molecular (2) structures of 1,1-(butane-1,4-
diyl)bis(imidazolium)bis(perchlorate) and the proposed structure of the protonated species ImPyPy.HCl 
(3). The formation of hydrogen bonds between the protonated nitrogen species and the oxygen species of 
the perchlorate counter ion promote the formation of a three dimensional lattice that provides crystals 
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Figure 2.8: Hydrolysis of compound 5. 
 
The carboxylic acid (6) was formed by the base-promoted hydrolysis of compound 5 
(Figure 2.8). This reaction was initially performed using 1 M NaOH at room 
temperature. The reaction was monitored by TLC over a period of 24 h, after which the 
disappearance of starting material was observed. The base NaOH was replaced with 1 
M LiOH in an effort to reduce reaction times, and the mixture heated at 60 oC. Under 
these conditions only 5 h were necessary to achieve complete hydrolysis of the starting 
material, depending on the reaction scale. Initial attempts to precipitate the product by 
acidification and collection by vacuum filtration were unsuccessful. The solid was 
found to be insoluble in all solvents, making it impossible to separate the product from 
NaCl or LiCl salts by extraction techniques. Filtration of the solid also proved to be 
difficult due to the small particle size of the precipitate, requiring filtration through a 
0.45 μM membrane. Due to the nature of the filter, the product could not be washed 
using organic solvents (such as ether) that would otherwise aid in the purification and 
drying of the solid. A new method for recovery of the product was developed whereby 
the organic solvent was removed under vacuum and the residue acidified with 1 M HCl 
(3 mL). The product was then lyophilised for 24 h. Attempts to remove the solvent 
under vacuum were plagued by bumping, due to the consistency of the mixture as it 
approached dryness. Lyophilisation yielded the product as a crude solid, contaminated 
by LiCl, which has no adverse effect on the proceeding coupling reaction and was easily 
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Figure 2.9: Formation of the amino ester and coupling with compound 6 to give the trimer (7). 
 
Complete conversion of compound 4 to the free amine (Figure 2.9) was achieved 
following the routine outlined in Section 2.4.1.4. The coupling was initially performed 
in DMF over a period of 2 h, with the addition of 1.5 molar equivalents of the coupling 
agents HOBT and TBTU, and 5 molar equivalents of Et3N. Formation of the activated 
ester of 6 occurred almost immediately (within 5 min) after the addition of base, in the 
presence of the coupling agents. The reaction mixture was left to stir at ambient 
temperature for a further 2 h under nitrogen. DMF was removed by evaporation under 
reduced pressure and the residue was purified by flash chromatography (2% 
MeOH/DCM). After removal of the solvent, the pure product was collected as a light 
brown solid in low yield. After successfully circumventing purification by column 
chromatography in Section 2.4.1.4, an attempt was made to develop a similar, more 
efficient, purification scheme for this step of the reaction pathway. To facilitate this, the 
coupling procedure was altered to utilise different coupling agents, as HOBT and TBTU 
were found to complicate the chromatography process by frequently co-eluting with the 
product. This would also simplify attempts to purify the product by basic extraction, 
precipitation or crystallisation techniques. A new method was devised, whereby HOBT 
and TBTU were exchanged for the water soluble coupling agents EDCI and DMAP. 
This would facilitate purification by extraction. The coupling was performed in DMF 
over a period of 2 h with the addition of 1.5 equivalents of EDCI and DMAP, 5 
equivalents of Et3N and 1.5 equivalents of the free amine. Formation of the product was 
monitored by TLC to confirm the effectiveness of the new activation system. The 
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reaction solvent was removed by evaporation under reduced pressure and the residue 
was dissolved in DCM for extraction with H2O. It was predicted that the coupling 
agents, unactivated carboxylic acid (6), free amine (4b) and base would partition in the 
aqueous phase, allowing the pure product to be obtained from the organic phase. This of 
course assumed that the extra 0.5 equivalents of the free amine would promote the 
complete consumption of the activated carboxylic acid, which would otherwise partition 
within the organic phase, requiring elimination by a second purification step. Addition 
of H2O to the extraction mixture, however, caused the immediate precipitation of 
several species, including the activated carboxylic acid and the trimer product. The 
crude solid was collected by filtration and air dried, then redissolved in a minimum of 
DCM and purified by column chromatography (10% MeOH/DCM). The solvent was 
removed under vacuum to yield the product in low yield. As it was not apparent 
whether the low yield was due to an inappropriate coupling agent system (TLC is by no 
means a quantitative method) or adherence of the product to the head of the column, the 
development of a second method was required.  
 
The next coupling was performed in DMF over a period of 2 h, with the addition of 0.95 
equivalents of the coupling agent O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-
hexafluoro-phosphate (HBTU), and 3 equivalents of diisoproylethylamine (DIEA) to 
form the activated ester. Activation of the carboxylic acid for peptide synthesis by this 
method was originally established within our research group for the purposes of solid 
phase synthesis, and found to be very effective. It was predicted that this method could 
easily be applied to solution phase synthesis, eliminating the need for two coupling 
agents. The reaction mixture was left to stir at ambient temperature for a further 2 h 
under nitrogen. DMF was removed by evaporation under reduced pressure, and H2O 
was added to yield the crude product as a white precipitate. The solid was collected by 
filtration to eliminate any unreacted free amine, air dried, then dissolved in DCM 
leaving unreacted 6 in suspension. After filtration to remove the solid 6, the filtrate was 
evaporated to dryness and triturated with MeOH, to remove the unreacted activated 
ester of 6. Yield and purity of 7 was comparable to published methods, though the 
elimination of the chromatography step marks another significant improvement in the 
overall synthetic scheme. 
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Figure 2.10: Hydrolysis of compound 7. 
 
The carboxylic acid 8 was formed by the base-promoted hydrolysis of 7 (Figure 2.10), 
as outlined in Section 3.2.5. Reaction times were identical to those experienced during 
the hydrolysis of 6. Acidification of the final product yielded a fluffy lime coloured 
solid, which was collected by filtration, washed with H2O and air dried briefly before 
lyophilisation over 12 hours. 
 














Figure 2.11: Protection of the 1,6-diaminohexane linker. 
 
The mono-protection of 1,6-diaminohexane (Figure 2.11) for use as a spacer between 
the polyamide and platinum binding components was achieved by the adaptation of two 
methods.166,167 A solution of di-tert-butyl dicarbonate in DCM was added dropwise over 
a period of 2 h to a solution of the diamine in DCM, which was cooled with an ice bath. 
Addition of the protecting agent over several hours, at low temperatures, aided in the 
selective mono protection of the diamine. The use of DCM as the reaction solvent is the 
main departure from the published synthetic method, which utilised dioxane at room 
temperature, due to the superior solubility of the starting materials at low temperatures 
in DCM. This was important as low reaction temperatures were found to decrease 
production of the unfavoured bis-protected product. After concentration under reduced 
pressure, water was added to the residue to precipitate any insoluble bis-substituted 
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product, which was isolated by filtration. The filtrate was extracted with DCM and the 
organic fractions combined and backwashed with H2O to eliminate any residual 1,6-
diaminohexane. The organic layer was collected, dried over MgSO4 and evaporated 
under reduced pressure to yield the product as viscous clear oil.  
 
The product was found to be sensitive to moisture, making strict anhydrous storage 
protocols necessary in order to increase its short shelf life. The product was best stored 
as a solution in DCM under an anhydrous nitrogen atmosphere, though it often proved 
safer to freshly prepare the product before each coupling reaction.  
 
Coupling of the mono-protected linker to the polyamide moiety was achieved using the 
standard coupling methods previously described (Figure 2.12). A solution of compound 
8 in DMF was treated with coupling agents (initially HOBT and TBTU, though these 
were later replaced by HBTU) and 3-5 molar equivalents of base (again, Et3N was 
replaced by DIEA later in the project due to positive results in solid phase experiments). 
The solution was stirred for 5 min, to which was then added 2 molar equivalents of the 
linker (9). After coupling for 2 h, the solvent was removed under reduced pressure and 
the residue purified by flash chromatography (2% MeOH/DCM). The excess linker was 
easily separated from the product 
by this method; and whilst HOBT 
and TBTU would often co-elute 
with the product to some degree 
(requiring a second 
chromatography step), no such 
problems were encountered with 
HBTU. Attempts to improve the 
efficiency of the purification step 
by precipitation and extraction 
methods failed to increase the 
yield or purity of the product, 
and were ultimately abandoned 


































Figure 2.12: Coupling of the linker and polyamide 
component. 
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2.4.2 Metal Complex Synthesis 
As it has been described previously, various analogues of the trans-platinum(II) motif 
have displayed high levels of cytotoxic activity in a broad range of cancer cell lines. 
Trans-DDP has been previously studied as a potential platinum centre for 
metallopolyamides in the works of Jaramillo et al.155 (utilising solution phase 
techniques) and Taleb et al.171 (utilising solid phase techniques). The family of 
complexes synthesised in those studies displayed only low levels of biological activity, 
which may be partially due to their poor solubility in water. In this study the platinum 
complex [Pt(terpy)Cl]Cl was chosen for coordination to the polyamide ligand, as it has 
the ability to intercalate DNA once the chloride ligand is replaced by a less labile group. 
It therefore provides an alternative mode of DNA binding. The aim of utilising a 
platinum complex that displays a different DNA binding mode was to contrast the affect 
that this has on biological activity and efficacy of the molecule. The 2+ charge of the 
product was also expected to have a favourable effect on solubility and DNA binding 
affinity.  
 















Figure 2.13: Synthesis of [Pt(terpy)Cl]Cl (11) from K2[PtCl4] via a [Pt(COD)Cl2] intermediate. 
 
The complex [Pt(terpy)Cl]Cl was synthesised from commercially available starting 
material, following previously established protocols in a two step process (Figure 2.13). 
This complex is known to exist as two possible crystalline dimorphs, red and yellow.172 
The platinum complex K2[PtCl4] was first coordinated with 1,5-cyclooctadiene, which 
was then displaced by the coordination of the tridentate ligand 2,2′:6′,2″ terpyridyl. 
Removal of the solvent provided a red-orange solid which was identified as the less 
Chapter Two: Solution Phase Synthesis  48
stable red dimorph. The more stable yellow dimorph was obtained by recrystallisation 
from a mixture of H2O/EtOH (1:1, v/v) in accordance with previously published 
methods.172 The pure product was then dried under vacuum for 24 h at 60 oC. The 















Figure 2.14: An expansion of the 300 MHz NMR spectrum of [Pt(terpy)Cl]Cl in D2O, showing the 
aromatic proton assignments. Assignments follow those previously published. 
 
The chemical shift of the single resonance in the 195Pt spectrum is consistant with the 
formation of a PtN3Cl coordination sphere (where N3 = three nitrogen ligands). As 
previously reported, the 1H NMR spectrum of the product was both solvent and 
concentration dependant; self stacking of the molecules in solution causes the entire 
spectrum to shift upfield as the metal complex concentration increases.172  
 
2.4.3 Metal Complex Coordination 
 
2.4.3.1 Deprotection and Ionic Exchange of Compound (10) 
In order to provide a free amine for the coordination of the metal complex, 
terpyridineplatinum(II) chloride, the Boc protecting group was removed at low pH and 
the subsequent salt neutralised (Figure 2.15). Two neutralisation methods were 
attempted, the first being an adaptation of previously published procedures. In the first 
method the ligand was treated with 4 M HCl in ethyl acetate, causing the rapid 
deprotection of the amine.  













































Figure 2.15: Deprotection and anion exchange of the polyamide ligand in preparation for coordination. 
 
After 1.5 h the solution was concentrated under high vacuum, yielding an orange 
crystalline residue. The residue was dissolved in water and stirred with DOWEX® 550A 
OH anion exchange resin to convert the salt to the free amine. The solution was 
decanted from the resin and concentrated under reduced pressure. Chloroform was 
added to induce precipitation of the product, which was collected by filtration and dried 
under vacuum. The yields for this reaction were disappointingly low, requiring a closer 
examination of the anion exchange procedure. The reaction was repeated, and 
monitored by TLC with the aid of ninhydrin stain to visualise the formation of the free 
amine. Whilst the neutralisation of the HCl salt was confirmed, the resin appeared to 
change colour and the yield was again low. It was hypothesised that the organic 
molecule was becoming trapped in the resin matrix, a phenomena that was not observed 
in the previous studies of Jaramillo et al.,155 on which these methods are based. This 
may be due to inconsistency in the pore size of the resin across batches, as care was 
taken to purchase from the same supplier. Whilst the slight variation in properties 
between batches is generally not a problem, it was sufficient in this case to cause a 
dramatic reduction in the yield of the reaction. It was concluded that the use of anion 
exchange resin in the neutralisation of this compound was not a consistently repeatable 
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technique, so an alternative method was devised. In this method the neutralisation 
procedure involved the addition of NaHCO3, though there was concern that the addition 
of dissociated salt ions to the reaction mixture would have a negative affect on the 
platinum(II) coordination attempts. Attempts to separate the free amine from the sodium 
salts by extraction and chromatography were unsuccessful, with both the polyamide and 
the salt partitioning in the aqueous phase, or otherwise adhering to the head of the 
various columns attempted.  
 













































Figure 2.16: Proposed reaction scheme for the coordination of the platinum centre to the polyamide 
ligand ImPyPy(CH2)6NH2 (11). 
 
The attempted coordination of the platinum centre (11) to the polyamide ligand (12) 
began with the removal of chloride from the platinum co-ordination sphere, followed by 
the nucleophilic attack of the deprotected ligand (Figure 2.16). First attempts were made 
in H2O over long reaction times (48 and 96 hours) and at high temperatures (60 and 100 
oC), with both the ligand and the metal complex in equimolar amounts. Separate 
reactions were performed for the ligand neutralised by DOWEX® 550A OH anion 
exchange resin and NaHCO3. Attempts to obtain the product from the reaction mixtures 
using adaptations of previously published protocols were unsuccessful, and the 
terpyridineplatinum(II) chloride was recovered by crystallisation from a 1:10 (v/v) 1M 
HCl(aqueous)/methanol mixture, suggesting that no reaction had occurred. 
 
An alternative method was attempted whereby the platinum species were first stirred in 
H2O solution, with the addition of AgNO3, for 24 h at room temperature. This is an 
adaptation of a method described by Jaramillo et al.155 which involved the nitration of 
trans-DDP in DMF. The use of the DMF solvent system considerably improved the 
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elimination of AgCl (which is highly DMF insoluble) in that study. Unfortunately it was 
found that [Pt(terpy)Cl]Cl was not soluble in DMF, requiring an aqueous reaction 
mixture. Slightly less than the required equivalents of AgNO3 were used, to minimise 
the risk of AgNO3 contamination in the final product. Following the precipitation and 
removal of AgCl, the vacant site on the platinum centre was taken by a H2O molecule or 
nitrate anion, which could have then been favourably displaced by the nitrogen donating 
ligand. Several methods were attempted for the filtration of AgCl, employing various 
media such as celite, nylon membranes and filter cartridges. It was found in this study 
that successful activation of the platinum species by AgNO3 is coupled with a reduction 
in water solubility. The resultant solid (which is pastel orange in colour) was lost in 
large amounts when celite or filter cartridges were employed, altering the molar 
equivalents of metal complex present in the reaction mixture. This was overcome by 
filtering the mixture using a Buchner funnel and 45 μm membrane filter, then washing 
the collected solid with excess water until all traces of the orange solid had disappeared. 
The activated platinum complex was then stirred with the polyamide ligand in 
equimolar amounts for 48 h at room temperature. No product was obtained, although 
the [Pt(terpy)Cl]Cl species was successfully recovered from the reaction mixture using 
the previously described recrystallisation method. A third set of reaction conditions 
were utilised whereby the metal complex was first activated with AgNO3 as previously 
described, then heated at reflux for 48 h with the ligand. This method also failed to 
produce the target product, and the [Pt(terpy)Cl]Cl was again recovered without having 
reacted. 
  
The two methods by which the amine was neutralised appeared to have no affect on the 
success of any of the reactions, other than perhaps being equally detrimental to the 
outcome. This necessitated a review of the entire proposed synthetic scheme, focusing 
on the reproducibility and achievability of pure products in the ligand synthesis 
(Sections 2.4.1.7 and 2.4.1.8) and the varying degrees of product purity achieved during 
the neutralisation procedures (Section 2.4.3.1).  
 
2.4.4 Alternative Platinum Incoroporation Scheme 
A new method of metal complex incorporation was explored whereby the synthesis of 
compound 10 (Section 2.4.1.8) and subsequent deprotection, neutralisation and 
coordination reactions (Sections 2.4.3.1 and 2.4.3.2) were bypassed, and the 
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monoprotected linker was coordinated to the complex prior to its incorporation into the 
























































Figure 2.17: Proposed scheme for the alternate method of metal complex incorporation, (a) AgNO3, with 
the absence of light, 48 h; (b) 1M HCl, 48 h followed by DOWEX® anion exchange resin; (c) HBTU, 
DIEA, DMF, N2(g), 1 h. 
 
Looking back at the procedures it was clear that the steps up to and including hydrolysis 
of compound 8 (Section 2.4.1.7) were reproducible and capable of yielding adequate 
amounts of the required products in a pure state. Conversely, the synthesis and 
purification of compound 10 (Section 2.4.1.8) was difficult to reproduce in both the 
large quantities and purity required for further attempts to coordinate the platinum 
complexes, especially considering the subsequent difficulties encountered in the 
deprotection, neutralisation and coordination of this product (Section 2.4.3.1). The new 
strategy was a good test of the reactivity of the amino linker to the platinum center, and 
would then allow the new platinum complex to be incorporated into the polyamide by 
standard coupling procedures. This would also pave the way for a new method of 
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Figure 2.18: Proposed reaction scheme for the coordination of the mono-protected diamino linker to 
trans-DDP and [Pt(terpy)Cl]Cl. 
 
As a “proof of concept”, the first attempts to coordinate the mono protected diamino 
linker (9) were made with the trans-DDP metal centre, as it had displayed some 
reactivity towards free amines in previous studies (Figure 2.18). Initial reaction 
conditions were adapted from previously published methods, with the trans-DDP 
reacted with the ligand in H2O over long reaction times (48, 72 and 96 h), at high 
temperatures (60 and 100 oC) and with trans-DDP in a 5:1 excess to prevent 
disubstitution. These reactions were unsuccessful, confirming previous observations that 
the reactivity of the free amine alone was not enough to promote coordination to the 
platinum centres.  
 
An alternative method was implemented, whereby the platinum species was first 
activated with 0.95 molar equivalents of AgNO3, before reaction with the ligand for 48 
hours at room temperature, using DMF as the solvent. This reaction proved successful, 
and upon removal of the solvent under reduced pressure both the product and excess 
trans-DDP were precipitated by the addition of acetone. The pure white product was 
then recrystallised from the crude pale yellow solid with methanol, in 70% yield. The 
195Pt NMR spectrum shows a single resonance at -2420 ppm indicating a change in the 
coordination sphere of the platinum metal which is consistant with the chemical shift 
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observed in PtN3Cl complexes (where N = two trans-ammine ligands and one primary 
amine ligand). More specifically, this is consistent with the substitution of one of the 
ligands of trans-DDP with the Boc protected diamino linker. This new synthon was 
retained for use in other projects (see Appendix E). 
 
The platinum centre [Pt(terpy)Cl]Cl was then reacted with the ligand under similar 
conditions, albeit in an aqueous solvent system. As disubstitution did not pose a 
problem, the equivalents of the ligand were increased (10:1 ligand to metal complex) in 
the hopes of driving the equilibrium of the reaction further towards formation of the 
product. The reaction was attempted at ambient temperature, 60 oC and 100 oC for 48 
hours without any success. 
 
The results of these reactions showed that the free amine of both the mono-protected 
diamino linker (10) and the deprotected diamino ligand (11) was not a strong enough 
nucleophile to displace the chloride in the fourth position of the coordination sphere of 
[Pt(terpy)Cl]Cl. They also showed that [Pt(terpy)Cl]Cl displayed reduced solubility 
after activation by various silver salts to displace the same chloride ligand.  
 
2.5 CONCLUSIONS 
The synthesis of the polyamide component was an overall success. Traditional methods 
for the purification of such molecules involve column chromatography, which was 
found to be costly in that much of the product at each stage of the reaction scheme was 
lost during this process due to poor solubility in the prescribed solvent systems. This led 
to the development of precipitation techniques that used this lack of solubility as an 
advantage. Whilst no attempt was made to synthesise more elaborate polyamides in this 
study, these methods should still be viable as the number of heterocyclic rings increases 
past the three described here, as solubility generally decreases according to the 
increasing size of the polyamide. Any advances in increasing the solubility of these 
compounds are predicted to improve the usefulness of column chromatography as a 
purification method. Additionally, the purification of compound 5 via the formation of a 
crystalline protonated salt may provide an avenue for the procurement of crystals 
suitable for analysis by x-ray crystallography. This may require protonation by 
perchloric acid, instead of the HCl used in this study, to provide a counterion that is 
capable of hydrogen bonding and thus promote the formation of three dimensional 
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structures. If successful, this method could be extended to other polyamide compounds 
which contain an imidazole component capable of protonation. Whilst the 1H NMR 
spectra of compound 11 and the other organic intermediates were consistent with 
previously published data, the proton resonances could not be unambiguously assigned 
due to compartmentalisation of connectivity in the 2D NOESY spectra. Further 
experimentation utilising a variety of 2D experiments and conditions may provide more 
definitive characterisation of the individual organic species. 
 
The addition of the six carbon chain diamino linker to the polyamide posed some 
problems during the purification stage, as no precipitation method could be developed 
that improved upon the results of column chromatography, which itself was inefficient 
and costly due to the low yields obtained. Whilst the removal of the Boc protecting 
group in preparation for coordination to the platinum centre was successful, the results 
of published neutralisation methods were not repeatable.155 The subsequent failure of 
the platinum coordination reactions required a review of the entire reaction scheme, and 
the attempt of a novel method for the incorporation of [Pt(terpy)Cl]Cl.  
 
A new method, involving the coordination of 9 prior to incorporation by standard 
peptide coupling techniques was attempted, that if successful, would provide a complex 
suitable for incorporation into polyamides using standard solid phase synthesis 
techniques. As an initial test, the metal complex trans-DDP was successfully 
coordinated to compound 9. Attempts to obtain the (2,2′:6′,2″-terpyridine)platinum(II) 
analogue of this new complex were unsuccessful. 
 
The difficulties in the synthesis of the [Pt(terpy)Cl]Cl conjugated polyamide can be 
explained by the kinetic phenomena known as the trans-effect. The trans-labilising 
effects of chloride ligands on platinum(II) are well documented, with the chloride 
ligands in trans-DDP directing substitution strongly in the position trans to themselves. 
This effect promotes the rapid substitution of one chloride ligand for the free amine of 9 
in the reaction described previously (Section 2.4.4.1). The ligands in [Pt(terpy)Cl]Cl, 
however, do not direct substitution as strongly as the chloride ligands of trans-DDP. 
The activation energy for these reactions is therefore much higher than the equivalent 
reaction involving trans-DDP. Attempts were made to reduce the activation energy of 
the substitution reaction, by first activating the platinum species before the introduction 
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of the amino linker. In trans-DDP the activating agent silver nitrate was used to 
successfully displace a chloride ligand with a labile NO3 group, which further promotes 
coordination of the ligand at that position. The activated platinum group was then 
separated from the AgCl by-product using a simple filtration step. [Pt(terpy)Cl]Cl was 
also activated, though it displayed a reduction in water solubility, but did not react with 
the amine species under any of the conditions performed in this work. Alternative 
methods for the incorporation of these metal complexes are explored in Chapter 3, 
involving the use of more reactive sulphur containing linkers.  
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DNA intercalating agents are of interest in the search for superior anticancer agents due 
to their novel binding mode. Molecules that bind to DNA by intercalation are generally 
characterised by planar aromatic ligands that insert between stacked base pairs in the 
minor or major groove, or both. Partial intercalation can also occur where the structure 
and conformation of the molecules prevent their full insertion between the base 
pairs.173,174 Formation of the drug/DNA adduct is reversible, though it is stabilised by a 
combination of electrostatic, entropic, hydrogen bonding, van-der Waals and 
hydrophobic interactions.175-177 As a consequence of intercalation, DNA displays 
lengthening, stiffening and unwinding of the DNA helix178 as well as a loss of regular 
helical structure in its backbone. This is the result of a change in the sugar-phosphate 
torsional angles as the base pairs are forced apart to accommodate the aromatic 
compound.179 The degree to which the DNA helix can be lengthened by intercalation 
has been studied by electric dichroism, and suggests a range of extensions, from 2.0 to 
3.7 Å, depending on the intercalating species.180 In addition to this the usual offset angle 
of one base to the next is decreased from 36o to 26o as a result of intercalation. 181-184 
Intercalation induced structural changes to DNA have also been investigated by near-
infrared Raman spectroscopy, which indicated a transition from B-DNA to an A-like 
form (see Chapter One) as the concentration of the intercalating species increased.185 
This alteration of tertiary structure of DNA leads to a change in DNA topology that 
causes a blockade of functions at a biochemical level. This can lead to a cessation of 
cell proliferation. The presence of an intercalator inserted between two base pairs 
excludes the neighbouring intercalation sites from being occupied. This phenomena is 
commonly referred to as the Nearest Neighbour Exclusion Principle,186 and results in 
periodic intervals of 10.2 Å between two drugs binding, spanning three individual 3.4 Å 
binding sites.179,186,187 This principle is supported by the results of X-ray diffraction 
studies which have demonstrated the upper limit of binding to be one drug molecule for 
every four nucleotides.188,189 
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3.1.1 Organic Intercalators 
The binding process of intercalation was first observed in a study probing the 
interaction of various acridines with DNA.190 Further examination of the x-ray 
scattering of Proflavine191 and DNA192 were to follow. In general, all organic 
intercalators have molecular structures based on one of six different parent motifs; 
anthracenes, acridines, anthraquinones, phenanthridines, phenanthrolines and 
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Figure 3.1: The six parent motifs for organic intercalators; anthracenes (1), acridenes (2), anthraquinones 
(3), phenanthridines (4), phenanthrolines (5) and ellipticines (6). 
 
3.1.2 Organic Intercalators as Anticancer Therapeutics 
Derivatives of daunorubicin and doxorubicin are intercalating agents that are used in 
cancer chemotherapy as they are both able to inhibit topoisomerase I and II, a nuclear 
enzyme that regulates DNA topology through single or double strand breaks 
respectively.193-196 Daunorubicin (Figure 3.2) is a natural product derived from the 
bacterium Streptomyces coeruleorubidus, and is used in the treatment of non-
lymphocytic leukaemia (myelogenous, monocytic and erythroid) in adults and acute 
lymphocytic leukaemia in children and adults.197 A liposomal preparation of the drug is 
also used as a first line treatment for Kaposi’s sarcoma, closely associated with 
advanced HIV infections. Doxorubicin is a natural product obtained from the bacterium 
Streptomyces peucetius var. caesius and is used in the treatment of many cancer types, 
including acute lymphoblastic and myeloblastic leukaemia, neuroblastoma, soft tissue 
and bone sarcoma, breast, ovarian, transitional cell bladder, thyroid, broncogenic and 
gastric carcinoma, malignant lymphoma and Hodgkin’s disease.197 





























Figure 3.2: The general structure of daunorubicin and doxorubicin, also marketed as Daunomycin and 
Adriamycin. 
 
Daunorubicin intercalates at CpG sequences. The anthroquinone ring system becomes 
inserted into the major groove whilst the carbohydrate component acts as a minor 
groove binding agent. This interaction is stabilised by π-π stacking, as well as hydrogen 
bonding between the hydroxy residue at C9 of the intercalater and guanine (G2), as well 
as between the acetyl keto group at C13 and O2 of cytosine.198 The use of these drugs in 
the clinic is limited by serious side effects as well as acquired resistance.196 The primary 
DLT is myocardial toxicity, which may cause death through congestive heart 
failure.199,200 Also, because of the inherent mutagenic properties of these compounds, 
prolonged treatment can lead to the formation of resistant tumours201 and/or secondary 
cancers.202 Two other organic intercalators have been approved for clinical use, 
Mitoxantrone and Amsacrine (Figure 3.3). Mitoxantrone is used in the initial treatment 
of acute non-lymphocytic leukaemia in adults,203-205 though it is primarily prescribed for 
the treatment of multiple sclerosis (MS). Amsacrine has been used in the treatment of 
acute adult leukaemia and malignant lymphomas, but displays poor activity profiles in 



















Figure 3.3: The chemical structures of Mitoxantrone (1) and Amsacrine (2), currently used in the clinical 
treatment of cancer and multiple sclerosis. 
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Further development of this family of compounds has focused on the synthesis of new 
organic intercalators206-208 that will localise preferentially within cancer cells209 and on a 
greater understanding of the interactions involved between DNA and the drug 
molecules.208,210-213 A series of isoxazolidinyl intercalators have been synthesised that 
display high cytotoxicity in MOLT-3, THP-1, U937 and Vero cell lines.206 The binding 
of these molecules was investigated by UV-vis spectrophotometry, revealing that the 
isoxazolidinyl compounds intercalate DNA with binding constants of the order 6 × 103 
M-1. Analogues of doxorubicin have been synthesised that are designed to overcome 
resistance to current treatments,207 two of which (WP744 and WP769) displayed activity 
2 to 36 times higher than the parent molecule in advanced neuroblastoma cell lines.  
 
3.1.3 Square-Planar Metallointercalators 
The intercalation of square-planar metal complexes was first demonstrated with the 
compound [Pt(terpy)S(CH2)2OH]+ ([Pt(terpy)(HET)]+)  by UV-vis, viscosity, circular 
dichroism (CD), fluorescence displacement and unwinding experiments.214 It was 
shown to bind reversibly to calf thymus DNA (ct-DNA), increasing the helical length, 
whilst an increase in the DNA melting temperature of 5-6 oC indicated a significant 
increase in DNA stability.214,215 The complex [Pt(terpy)](HET)]+ was calculated to bind 
ct-DNA with a constant in the order of 2 × 105 M-1, which is comparable to that of 
ethidium bromide (3.9 × 105 M-1) under equavalent experimental conditions (0.1 M 
sodium chloride, pH 7.5).214 A series of new cationic terpyridineplatinum(II) complexes 
coordinated with sulfur donor ligands with various functional components were later 
prepared, as a means of evaluating the effects of charge, polarity and steric hindrance on 
the process of DNA intercalation. The conjugation of two or more such species was also 
performed using well established organic synthetic techniques. Other ligands consisting 
of π-electron rich planar ring systems (Figure 3.4) have also been shown to intercalate 
DNA when coordinated to a metal centre, including 2,2′-bipyridene when coordinated 
to form a square-planar platinum complex.216 Molecules of this type show a strong 
DNA sequence selectivity for 5′-GpC sites217 because of their higher dipole moment, 
with most platinum(II) intercalators binding with constants in the range of 104 to 107 M-
1.217-220 Variance in binding strength appears to be due to differences in the charge and 
extent of the aromatic system of individual molecules, with the general trend being phen 
> terpy > bipy.217  




































Figure 3.4: Some examples of square planar metallointercalators showing platinum(II) complexes 
coordinated to terpyridine (1, 2), bipyridine (3) and phenanthroline (4, 5 and 6), where the symbol * 
indicates a chiral centre (R or S). 
 
Square planar metallointercalators have displayed the ability to bind DNA with a 
number of orientations, including through the major or minor groove, or by partial 
intercalation. For example, the crystal structure of [Pt(terpy)(HET)]+ bound to the 
dinucleotide (CpG) showed the platinum intercalator interacting with the major 
groove.221 In contrast it has been shown that platinum intercalators containing 
phenanthroline and phenanthrenequinone diamine bound to the oligonucleotide 
d(GTCGAC)2 from the DNA minor groove in 2D NMR studies.222 Additionally it has 
been shown that bulky ancillary ligands may prevent full insertion of the intercalating 
ligand into the DNA helix. The inclusion of the chiral ligand 1,3-diamino-1,2,2-
trimethylcyclopentane (R,S- and S,R-tmcp) was shown to prevent the full insertion of a 
neighbouring methylated phenanthroline ligand into the DNA helix.223 The 
metallointercalators instead bound by partial intercalation in a “side-on” fashion.223  
 
3.1.4 The Biological Activity of Square-Planar Metallointercalators 
Square planar platinum(II) complexes have been synthesised with the ligands 1,10-
phenanthroline (phen); 2,2′-bipyridine (bipy); 3,4,7,8-tetramethyl-1,10-phenanthroline 
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(Me4phen) and 2,2′:6′,2″-terpyridine (terpy), and their cytotoxicity against murine 
leukaemia determined (Table 3.1).224  
Table 3.1: The cytotoxicity of selected square-planar platinum complexes illustrated in Figure 3.4 against 
several different cell lines.224-227 
Intercalator Cell Line IC50 (μM) Standard IC50 standard (μM) 
2 HL60 1.0 cis-DDP 4.2 
3 L1210 33 Not Reported Not Reported 
4 (S,S-dach) L1210 0.13 cis-DDP 0.5 
4 (R,R-dach) L1210 1.5 cis-DDP 0.5 
5 L1210 11.2 cis-DDP 0.5 
6 Molt-4 9.8 Not Reported Not Reported 
 
Studies revealing the structure/activity relationships of these molecules and derivatives 
are ongoing, and have yielded significant results. 
 
3.1.5 Bis-intercalating Metallointercalators 
The pursuit of improved cytotoxicity has led to the development of bis-intercalating 
species, for both organic and metal based intercalators, which consist of two sets of 
intercalating moieties joined by a linking chain or spacer. The rationale behind this is 
that bis-intercalating species should bind a greater number of DNA base pairs 
simultaneously, with higher affinity due to their greater charge. By binding a larger 
number of base pairs simultaneously bis-intercalators may display higher DNA 
specificity than mononuclear species. Coupled with an increase in the number of DNA 
drug associations afforded by increased DNA affinity, such molecules may display 
higher toxicity profiles. Additionally the bifunctional drug/DNA adducts may be more 
difficult to repair, or induce larger/novel conformational changes in DNA, again 
bypassing or hindering DNA repair mechanisms. As a result, a series of bis-platinum 
intercalating complexes have been synthesised, utilising substituted terpyridine ligands 
as their major intercalating component, linked by a variety of rigid, variable length 
hydrophobic and hydrophilic chains (Figure 3.5).228-231  




























































Figure 3.5: Some examples of square-planar platinum(II) bis-intercalators with flexible and inflexible 
linking chains. 
 
Lowe et al.228 demonstrated that the biological activity of bis-[2,2′:6′,2″-
terpyridineplatinum(II)] complexes was strongly dependant on the nature of the linker. 
Compounds with a flexible linker at the 4-position displayed poor cytotoxicity, whilst 
analogues with short, rigid, linkers were very effective antitumour agents (Table 3.2).  
Table 3.2: The cytotoxicity of selected square-planar platinum(II) bis-intercalating complexes illustrated 
in Figure 3.5 against several different cell lines.225,228,230 
Intercalator Cell Line IC50 (μM) Standard IC50 standard (μM) 
1 NCH37 5.7 Not Reported Not Reported 
1 HNO97 4.8 Not Reported Not Reported 
4  CH1 0.55 cis-DDP 0.4 
4  CH1dox 0.42 cis-DDP 0.5 
5 (n = 6) KB-3-1 24 cis-DDP 5.5 
5 (n = 6) CNE3 16 cis-DDP 11 
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The high charge density attributed to these molecules caused by the double positive 
charge on each platinum atom provides them with increased DNA binding and 
platination profiles. Close examination of the interactions between these molecules and 
DNA revealed they could bind via a non-classical DNA intercalating binding 
mechanism. The coordinate covalent bonds of the linking chains in these complexes 
displayed an unexpected degree of lability, producing a reactive electrophilic platinum 
species in solution that is able to form irreversible coordinate covalent bonds with 
DNA.232 For example, a study with [{Pt(terpy)}2-μ-4,4′-vinylenedipyridene]2+ and the 
oligonucleotide d(CGTACG)2 revealed the decomposition of the bis-intercalator yields 
a 2,2′:6′,2″-terpyridineplatinum(II) complex which forms a coordinate covalent adduct 
through the N7 position of guanosine.232 
 
3.1.6 The Biological Activity of Bis-intercalating Metallointercalators  
The biological activity of the bis-[2,2′:6′,2″-terpyridineplatinum(II)] complexes 
developed by Lowe and co-workers were examined in a panel of six human ovarian 
cancer cell lines; two that are sensitive to cis-DDP (CH1, A2780), two with resistance to 
cis-DDP (CH1cis, A2780cis), one with resistance to doxorubicin (CH1dox) and the 
highly resistant cell line SKOV-3.228 The cytotoxicity was found to be dependant on 
three variables; chain length, charge density and the nature of the counter ions. 
Molecules with shorter linkers displayed higher activity than those with longer chains. 
The more highly charged complexes were also more cytotoxic than their lower charged 
counterparts, or those with a lower charge density. Finally the complexes appeared to be 
more active as tetrafluorborate salts than their water soluble nitrate salt alternatives.228 
All of the complexes displayed little or no cross-resistance in matched cell lines. In 
another study the bis-intercalators were tested against three glioblastomas (NCH37, 
NCH82 and NCH89) and two head and neck squamous cell carcinoma cell lines 
(HNO97 and HNO199), and were found to have IC50 values between 2.5 and 6.2 μm.230 
These compounds have been shown to inhibit thioredoxin reductase (TrxR) activity, 
which is a key component in the metabolism of human tumours, in gliobastoma cell 
cultures.230 It was proposed that TrxR is the major target for these complexes, but that 
they also continue to inhibit DNA replication giving them a net increase in activity 
when compared to cis-DDP.230 It was also proposed that transport of these platinum bis-
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intercalating species by human serum albumin (HSA), which plays a central role in drug 
pharmacokinetics in humans,233 may also play a role in their higher activity.234  
3.1.7 Synergistic Intercalators 
Attempts have been made to combine the effects of DNA intercalating compounds with 
other functionalities. This includes organic intercalators235-252 and cis-DDP like 
metallointercalators,253-259 organic intercalators linked to DNA-alkylating agents such as 
mustards,260-264 and metallointercalators linked to carborane cages for use in radiation 










































Figure 3.6:  Some examples of synergistic intercalators, which combine organic intercalators with 
platinum(II) DNA covalent binding and organic DNA alkylating moieties. 
 
In all cases the synergistic affect of the various binding functionalities was predicted to 
increase DNA binding affinity, improve DNA uptake and adduct formation as well as 
the possibility of sequence or regio-selectivity. Platinum centres have been incorporated 
in a variety of compounds that include various organic DNA intercalators, with the 
majority of studies focusing on acridine and anilinoacridine.236,244,249,251 The first in this 
family of complexes involved the linking of acridine to platinum through 
ethylenediamine and a variable length alkane chain (Figure 3.6).246-248  
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The results of DNA binding experiments indicated that intercalation of the organic 
ligand and coordinate covalent binding of the platinum centre occur simultaneously, 
with a distance between the dual binding sites of one to three base pairs.247,248 This 
cooperative binding induces a significant alteration in the conformation of DNA, 
leading to an enhancement in the unwinding of the DNA helix. Additionally, whilst 
platinum binding usually causes a shortening of the helix due to bending of the DNA, 
the incorporation of the intercalator negates this effect, slightly increasing the length of 
the helix.245 In another study a bis-(naphalimide)-platinum(II) complex (labelled 5 in 
Figure 3.6) was shown to unwind supercoiled DNA by 48o, compared to the individual 
parent binding moieties, which unwind DNA by 12o and 24o respectively.250 Similarly, 
an anilinoacridine-platinum complex induced DNA unwinding twice that of the native 
platinum complex.244 This proved that the effects of two dissimilar binding moieties 
binding to DNA simultaneously could produce a more prominent change in the 
conformation of DNA. In addition to this, whilst platinum complexes containing two 
chloride ligands in the cis conformation generally form intrastrand GpG and ApG 
adducts preferentially, the addition of an intercalating group in the molecule was found 
to alter the sequence specificity of the platinum moiety. The increased frequency in the 
development of low intensity blockage sites in DNA transcription assays suggests that 
these compounds form less distinct adducts.236 Whilst the majority of sequences 
targeted by synergistic complexes are similar to cis-DDP, GpG246 and GpC,238 some 
complexes show an affinity for GpA, GpT246,261 and ApT249 sequences. This indicates 
that the DNA sequence binding affinity of the whole compound is dictated by the 
groove and sequence recognition of the intercalating group,249 and that the platinum 
group will target nucleophilic sites within the vicinity of intercalation. The length of the 
linker between the two functionalities therefore plays an important role in the nature of 
the adduct formed by these complexes. The shorter the linker the more of an influence 
the intercalating group has on the specificity of the platinum binding group.243 In 
transcription assays synergistic intercalators have successfully inhibited DNA 
transcription in a time and concentration dependant manner. This is consistent with the 
proposed modes of action, in that blockage bands are observed both shortly after the 
addition of the metal complex due to intercalation and later on, with bands increasing in 
intensity due to covalent binding of the platinum centre.235,236,238-240,249-251 The coupling 
of an intercalator to platinum also appears to increase the rate of DNA-platinum adduct 
formation.237-240,243,249 Synergistic intercalators containing a platinum ethylenediamine 
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moiety have been shown to react with DNA up to four-fold faster than the parent 
dichloroethylenediamine platinum(II) complex [Pt(en)Cl2] alone.240 Synergistic 
intercalators also appear to be far more damaging to DNA than other binding agents.238 
A greater number of more intense blockages are observed in DNA transcription assays 
when compared to the parent intercalater and platinum groups on their own.238,242 In the 
human cancer cell line P388, platinum conjugated phenanthridium complexes display a 
six-fold enhancement in DNA damage compared to equimolar amounts of cis-DDP. The 
ability to induce DNA damage depends once again on the length of the linking chain. It 
has been shown that, unlike covalent binding bi- and tri-nuclear platinum complexes 
that increase in activity as the linker size increases,112,269 the trend is for synergistic 
intercalators to display greater activity as the linker length decreases.242 The actual 
cytotoxicity of these complexes varies greatly, though most are significantly more 
active than their native individual constituents.237,245 Several anilinoacridine-
platinum(II) complexes have displayed a three- to five-fold increase in activity 
compared to their parent intercalator in P388/W cells, but display only differential 
cytotoxicity in the cis-DDP resistant cell line P388/P.244 Acridinecarboxamide-
platinum(II) complexes are equally active in vitro in both P388/W and P388/W cancer 
cell lines.245 In assays with P388/AMSA cell line, which is resistant to amsacrine, these 
complexes were ten-fold more active than cis-DDP and [Pt(en)Cl2].245 Significant 
cytotoxicity of synergistic intercalators has also been demonstrated in various cancer 
cells lines such as: HeLa,240 A2780 and A2780cisR,250 CH1,250 L1210 and 
L1210/DDP,252 and PAM 202-ras.250 A series of platinum based intercalators linked to 
a variety of carboranes have been synthesised in an attempt to enhance existing 
radiation oncology.265-268 This family of complexes includes mononuclear platinum 
complexes coordinated with an intercalating terpyridine ligand and linked to 1,2- 1,7- 
and 1,12-carborane through variable length thioalkyl chains. These complexes are 
designed to be inactive without the presence of thermal radiation, which would 
otherwise inhibit the uptake of sufficient levels of 10B nuclei within cells. They do, 
however, display activity in ovarian cancer cell lines ,268 depending on the length of the 
linker and the stereochemistry of the carborane cage, which is directly related to the 
aqueous solubility of the compounds. This was made apparent in a cytotoxicity study 
against the human ovarian carcinoma cell line 2008, which decreased in the order of 
1,2- > 1,7- > 1,12-carborane, which corresponds with the order of decreasing solubility 
in water. Incidentally, all of the compounds display relatively poor solubility in water 
Chapter Three: Synthesis of the Metallointercalator Synthons  68
and other polar solvents, which can be increased by 
the addition of a pendant glycerol group to the 
carborane chain.267 Again, it has been shown that the 
complexes with shorter thioalkyl linkers are more 
cytotoxic than their longer counterparts,268 though in 
this case it is directly due to the decrease in water 
solubility that occurs as the hydrophobic component 
is extended, and not due to any bifunctional 
interaction between the complex and DNA. The 
successful intercalation of the platinum-terpyridine 
moiety has been observed by UV-vis 
experimentation.265 Recent development in this 
work has involved the synthesis of multinuclear 
intercalating species linked to one or more 
carborane cages (Figure 3.7). This has had an interesting affect on the cytotoxicity of 
the new molecules, which tends to increase as the thioalkyl linker length increases to the 
extent that the compound [{Pt(terpy)}2μ-{closo-1,2-carborane}]2+ is as cytotoxic as cis-
DDP in the L1210 cell line, and eight times more cytotoxic than cis-DDP in the resistant 
L1210/DDP cell line.266 
 
3.1.8 Chapter Three Objectives  
In Chapter Two the methods for the attempted synthesis of a synergistic 
terpyridineplatinum(II) based metallointercalator conjugated with a sequence selective 
moiety were discussed (Figure 3.8). It was predicted that this combination of 
functionalities would provide a more cytotoxic compound when compared to its 
covalent binding trans-DDP based parent molecule (DJ1953-6), due to its higher charge 
and DNA binding affinity.  
Figure 3.7: General structure of 
terpyridineplatinum(II) based 































































Figure 3.8: The molecular structure of the synergistic sequence selective metallointercalator that this 
work attempted to produce, interacting with a second molecule to form an informal dimer capable of bis-
intercalation. Attempts to synthesise this molecule were unsuccessful. 
 
 
The methods of the previous chapter were unsuccessful in producing the compound, so 
an alternative method for the incorporation of the intercalating platinum(II) group was 
proposed. Instead of coordinating through the free amine of a linker as previously 
described, this method would utilise thioalkyl linkers, which have already been 
successfully coordinated with [Pt(terpy)Cl]Cl (Figure 3.9).270 It was predicted that the 
affinity of platinum for sulphur would drive this reaction, though at the cost of reduced 
charge. As it has been discussed, the charge of these molecules plays an important role 
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Figure 3.9: [Pt(terpy)(HET)]+ (1), [Pt(terpy)(ET)]+ (2), [Pt(terpy)(FMT)]+ (3), [Pt(terpy)(CMT)]+ (4), and 
[Pt(terpy)(AET)]+ (5), a family of terpyridineplatinum(II) based metallointercalators that have been 
previously synthesised. 
 
The thioalkyl linkers chosen for this work, 2-mercaptoethylamine and 3-
mercaptopropionic acid (Figure 3.10), also include an amino or carboxylic acid terminal 
for rapid incorporation into the polyamide component via standard coupling procedures. 
This would allow the incorporation of the metallointercalator into a variety of new 
molecules by both solution and solid phase, several of which are explored in this thesis. 
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Figure 3.10: 2-Mercaptoethylamine (1) and 3-mercaptopropionic acid (2). 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Reagents 
Silver nitrate (99.8%) was purchased from BDH Chemicals. 2-Mercaptoethylamine 
hydrochloride (99%), 3-mercaptopropionic acid, 99+% (Aldrich), N,N-
diisopropylethylamine (99.5%), DOWEX® 1 × 8-200 chloride exchange resin and 
tetrabutylammonium chloride, 99% were purchased from the Sigma-Aldrich chemical 
company. 2-(1H-Benzotriazole-1-YL)-1,1,3,3-tetramethyluroniumhexaflourophosphate, 
(HBTU, 99%) was purchased from Protein Technologies, Inc. All other reagents and 
solvents were used as received unless otherwise stated. Acetonitrile (d3-, 99.9%), 
dimethylsulfoxide (d6-, 99.9%), dimethylformamide (d7-, 99.9%) and deuterium oxide 
(d2-, 99.9%) were purchased from Cambridge Isotope Laboratories.        
 
3.2.2 Characterisation 
Routine 1H NMR spectra were recorded on a 300 MHz Varian Unity plus. 2D NOESY 
and ROESY271 spectra were recorded on a Bruker Avance 400 MHz NMR spectrometer. 
The probe was matched, tuned, and the 90o pulse measured before all experiments. 2D 
ROESY spectra were acquired with 2048 data points in F2, 512 increments and 16 
scans, with a 10 ppm spectral width. Commercially available deuterated solvents were 
used and referenced to the residual solvent peak.161 The following abbreviations apply 
to spin multiplicity: s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet). Mass spectra were obtained at the Mass Spectrometry Laboratory at the 
University of Wollongong, NSW, Australia. Elemental analysis was performed at the 
Australian National University in Canberra, ACT, Australia. X-ray crystallography was 
performed at Chiralabs Ltd., Oxfordshire, United Kingdom, by Dr Delphine Le Pevelen. 
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3.3 EXPERIMENTAL 
 
3.3.1 Synthesis of the Mononuclear Species 
 
3.3.1.1 [Pt(terpy)SCH2)2NH2]Cl.2.5H2O (13, [Pt(terpy)(AET)]Cl)  
Compound 13 was synthesised by an adaptation of the method reported by Jennette et 
al.179 [Pt(terpy)Cl]Cl.2H2O (0.37 g, 0.69 mmol) and AgNO3 (0.24 g, 1.38 mmol) were 
combined in H2O (10 mL) and the resulting suspension was stirred in the absence of 
light for 72 hrs. The solution was filtered through a 0.45 μm nylon membrane and the 
mixture of orange and white solids were washed with H2O (approx. 200 mL) until all 
the [Pt(terpy)NO3]NO3 had redissolved, leaving only white AgCl. The filtrate was 
transfered to a 250 mL 3-neck flask which was fitted with a stopper, pH electrode and 
rubber septum, and N2(g) was bubbled through the solution for 5 mins (pH ~ 3). A 
solution of 2-mercaptoethylamine hydrochloride (0.20 g, 1.77 mmol) in H2O (5 mL) 
was added to the solution of [Pt(terpy)NO3]NO3 causing the colour change to change 
instantly to purple (pH ~ 2.5). The solution was adjusted to pH 6 using a concentrated 
NaOH solution, causing the purple colouration to intensify. The solution was then 
filtered (0.45 μm nylon membrane), reduced to ~ 5 mL under vacuum and then dropped 
slowly into acetone (300 mL) resulting in the formation of a fine purple precipitate. The 
solids were collected (0.45 μm), washed with acetone (150 mL), diethyl ether (100 mL) 
and air dried before being redissolved in a minimum amount of H2O. The metal 
complex was precipitated by the addition of saturated KPF6 solution (3 mL), the purple 
solid was collected, washed with diethyl ether (100 mL) and air dried. The complex was 
then suspended in H2O (50 mL) before stirring with DOWEX® 1 × 8-200 chloride 
exchange resin (0.5 g) overnight. The solution was filtered to remove the resin, 
evaporated to ~ 5 mL and dropped slowly into acetone (250 mL) causing the formation 
of a fine purple precipitate. The solid was collected, washed with acetone (50 mL) and 
diethyl ether (50 mL) and air dried. (0.35 g, 86%); 1H NMR (300 MHz, D2O) δ: 8.84 (d, 
2H, J = 6.19 Hz), 8.18 (m, 3H), 8.01 (m, 4H), 7.61 (m, 2H), 3.01 (t, 2H, J = 8 Hz), 2.52 
(t, 2H, J = 8 Hz); 195Pt NMR (400 MHz, D2O) δ: -3165.11 (s); Anal. Calc’d for 
C17H22ClN4O2.5PtS: C 34.90; H 3.79; N 9.58; found: C, 34.54; H, 3.42; N, 9.91. 
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3.3.1.2 [Pt(terpy)S(CH2)2COOH]Cl (14, [Pt(terpy)(MPA)Cl]) 
[Pt(terpy)Cl]Cl.2H2O (0.54 g, 1.0 mmol.) was dissolved in H2O (10 mL). A stream of 
N2(g) was bubbled through the solution for the duration of the reaction. Three 
equivalents of tetrabutylammonium hydroxide was added (0.8 M in MeOH, 3.75 mL, 
3.0 mmol).  3-Mercaptopropionic acid (0.27 g, 2.5 mmol) was dissolved in H2O (5 mL) 
and added to the basic solution of [Pt(terpy)Cl]Cl.2H2O causing an instant colour 
change to purple. The solution was filtered (0.45 µm nylon membrane), reduced to ~ 5 
mL under vaccuum and dropped slowly into acetone (100 mL), resulting in the 
formation of a fine purple precipitate. The solid was collected by filtration through a 
0.45 µm nylon filter, washed with acetone (50 mL), diethyl ether (50 mL) and air dried 
before being redissolved in a minimum amount of H2O. The metal complex was 
precipitated by the addition of saturated KPF6 solution (3 mL), the purple solid was 
collected, washed with diethyl ether (100 mL) and air dried. The complex was then 
dissolved in ACN (50 mL) before precipitation by the addition of a saturated 
tetrabutylammonium chloride/ACN solution. The solid was collected, washed with 
acetone (50 mL) and diethyl ether (50 mL) and air dried (0.46 g, 81%). 1H NMR (300 
MHz, D2O) δ: 8.6 (d, 2H, J = 6.2 Hz), 8.11 (m, 3H), 7.93 (m, 4H), 7.51 (m, 2H), 2.42 
(s, 4H); 195Pt NMR (85 MHz, D2O) δ: -3211.71 (s); ESI-MS m/z calcd for 
C18H16N3O2PtS [M + H]+ 533.48, found 533.2. Anal. Calc’d for C18H16N3O2F6PS: C, 
31.86; H, 2.38; N, 6.19; found: C, 31.95; H, 2.53; N, 6.31. 
 
3.3.2 Synthesis of the Di-nuclear Species 
 
3.3.2.1 [Pt(terpy)]2S2C5H9ONCl2 (15, [{Pt(terpy)}2(DMECA)]Cl2) 
Compound 14 (0.1 g, 0.18 mmol) was dissolved in a minimum amount of distilled water 
and converted to the DMF soluble PF6 salt by the addition of a saturated PF6 solution. 
The solid was collected by filtration, washed with distilled water (3 × 5 mL) and air 
dried overnight. Compound 14 was then dissolved in DMF (3 mL), with HBTU (0.074 
g, 0.20 mmol) and DIEA (0.1 mL, 0.60 mmol) and left to stir for 5 min. Separately, 
compound 13 (0.097 g, 0.18 mmol) was converted to the perchlorate salt by first 
dissolving it in H2O followed by the addition of saturated NaClO4. The solid was 
collected and dried under vacuum with great caution,* then dissolved in DMF (3 mL) 
                                                 
* Perchlorate (ClO4) salts can be explosive when dry and subjected to heat or friction.  
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and added to the activated carboxylic acid solution. The reaction mixture was stirred at 
room temperature for 4 h under a slightly positive nitrogen atmosphere. The crude 
compound was precipitated by the addition of a saturated tetrabutylammonium bromide 
solution (~ 50 mL). The solid was collected by filtration, washed thoroughly with 
ethanol and ether, then dissolved in a minimum amount of H2O and converted to the 
PF6 salt by the addition of a saturated PF6 solution. The solid was collected by filtration 
and washed with H2O and air dried. The solid was redissolved in a minimum amount of 
ACN and precipitated by the addition of a saturated tetrabutylammonium chloride 
solution. The dark solid was collected by filtration and washed with copius amounts of 
ACN (4 × 20 mL) and ether (4 × 20 mL) to remove any residual tetrabutylammonium 
chloride. Yield (0.13 g, 67%).1H NMR (300 MHz, D2O) δ: 9.14 (d, 2H, J = 5.0 Hz), 
8.97 (d, 2H, J = 5.0 Hz), 8.4-8.1 (m, 8H), 8.0-7.85 (m, 6H), 7.78 (t, 2H, J = 5.45 Hz), 
7.67 (t, 2H, J = 5.45 Hz), 3.20 (t, 2H, J = 5.25 Hz) , 2.55 (t, 2H, J = 4.83 Hz) , 2.50 (t, 
2H, J = 4.83 Hz) , 2.25 (t, 2H, J = 4.69 Hz); 195Pt NMR (400 MHz, D2O) δ: -3187.13 
(s), -3221.25 (s); ESI-MS m/z calcd for C35H31N7OPt2S2 [M + H]+ 510.5, found 509.8. 
 
3.3.3 Crystal Preparation 
Crystals of [Pt(terpy)(MPA)Cl suitable for x-ray study were obtained by vapour 
diffusion of diethyl ether into a concentrated metal complex solution in water. The 
complex crystallised as dark red prisms, which is consistent with published observations 
regarding similar compounds.  
 
3.4 RESULTS AND DISCUSSION 
 
3.4.1 Synthesis of the Mononuclear Species 
Due to the great difficulty experienced in coordinating amine linkers of the required 
length and functionality to [Pt(terpy)Cl]Cl, a search was made for alternative linkers 
that display greater reactivity to this species. Platinum terpyridine compounds have been 
under investigation for some time, with the initial studies of [Pt(terpy)Cl]+ to ct-DNA 
revealing both intercalation and covalent interactions. In response to this the complex 
was reacted with a variety of sulfur donor ligands, with the aim of blocking the covalent 
interaction through substitution of the labile chloride ligand. This successfully 
prevented any covalent binding of the complex to DNA over the time course of the 
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binding experiments, because the rate of substitution of the Pt-S bond is several orders 
of magnitude slower than that of the Pt-Cl bond. Thus the intercalation properties of the 
moiety could be accurately explored in isolation. Various sulfur containing linkers are 
commercially available, though in this work the choices were limited by the 
requirements of the coupling chemistry to be attempted. By solution phase chemistry a 
free amine terminal was required for the final coupling of the metal group to the 
polyamide. For synthesis by purely solid phase techniques, however, a carboxylic acid 
terminal was required. With this in mind, two sulfur containing linkers were deemed 
appropriate for coordination with the platinum groups, 2-mercaptoethylamine and 3-
mercaptopropionic acid.  
 















Figure 3.11: The coordination of 2-mercaptoethylamine to [Pt(terpy)Cl]Cl. 
 
The coordination of 2-mercaptoethylamine to [Pt(terpy)Cl]Cl had been previously 
described, providing an ideal starting point for the synthesis of these building blocks. 
Initial attempts to coordinate 2-mercaptoethylamine did not use AgNO3 to activate the 
platinum centre as prescribed. These reactions yielded a mixture of products that could 
not be separated. Further attempts did utilise AgNO3 in exact accordance with published 
methods, whereby [Pt(terpy)Cl]Cl was converted to the nitrate salt by the addition of 
two equivalents of AgNO3 and stirring in water overnight. As with all reactions 
employing activation by AgNO3, the silver chloride by-product must be completely 
removed from the activated nitrate species in order to prevent a redox reaction that 
would cause the reaction to fail. The sulfur donor ligand, 2-mercaptoethylamine 
hydrochloride was dissolved in a small amount of water and added to the reaction 
mixture, through which a constant stream of nitrogen was bubbled. The pH of the 
reaction mixture was monitored using a pH probe and adjusted to avoid basic 
conditions, under which the compounds were reported to be unstable. Deprotonation of 
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the sulfur residue was achieved between pH 5 and 6, promoting the formation of the 
desired Pt-S bond between the linker and the platinum centre. As mentioned in the 
methods obtained from the literature, the best results were achieved when the product 
was isolated as quickly as possible after the addition of the 2-mercaptoethylamine. The 
fine purple solid, compound 13, was collected by vacuum filtration and purified by a 
series of salt conversions from Cl to PF6 and back to Cl again using a saturated PF6 
solution and DOWEX® 1 × 8-200 ion exchange resin.  
 
















Figure 3.12: The coordination of 3-mercaptopropionic acid to [Pt(terpy)Cl]Cl. 
  
[Pt(terpy)Cl]Cl was dissolved in a small amount of H2O through which a continuous 
stream of nitrogen was bubbled. Three equivalents of the base tetrabutylammonium 
hydroxide were added to this solution. Addition of the sulfur donor ligand (3-
mercaptoproponionic acid, d = 1.22 g/mol) to this solution caused an immediate colour 
change from orange to a dark purple. It should be noted that changing the order of the 
addition of reagents has a significant effect on the success of the reaction. The product 
was isolated as quickly as possible after the addition of the 3-mercaptopropanoic acid, 
by concentration under vacuum and precipitation by the addition of acetone. The fine 
purple solid was collected by vacuum filtration, then immediately redissolved in H2O 
and precipitated by the addition of a saturated PF6 solution. The crude product was then 
purified by a series of salt conversions from PF6 to Cl and back again, using a saturated 
PF6 solution and tetrabutylammonium chloride in acetone. Initial attempts to synthesis 
14 utilised silver nitrate to activate the [Pt(terpy)Cl]Cl species prior to coordination, but 
this provided no significant increase in the yield obtained and it was later discovered by 
x-ray crystallography (discussed in Section 3.4.3) that the washing procedures 
introduced AgCl to the reaction mixture, in at least one of the reactions performed.  
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3.4.1.3 1H NMR Characterisation of the Mononuclear Species 
The proton labelling scheme for both molecules is provided in Figure 3.13. The 
assignment of the [Pt(terpy)(AET)]+ resonances followed those previously published, 
whilst the assignments for [Pt(terpy)(MPA)]+ were determined by 2D NOESY 1H 































Figure 3.13: The proton labelling scheme for [Pt(terpy)(AET)]+ (13) and [Pt(terpy)(MPA)]+ (14). 
Equivalent protons are not labelled. 
 
The doublet furthest downfield in the spectrum of [Pt(terpy)(AET)]+ and 
[Pt(terpy)(MPA)]+ displays platinum coupling and is assigned as H6. The chemical shift 
of this resonance is consistent with other thiolate complexes synthesised, and appears 
0.8-1.7 ppm further upfield in the equivalent spectrum of[Pt(terpy)Cl]Cl. Proton H6 is 
coupled to H5 (JH5-H6 = 6.2 Hz). The triplet at ~ 7.55 ppm integrating for two protons 
corresponds to the H5 proton. The complex multiplet at ~ 8.15 ppm houses the H4 and 
H4′ resonances, whilst the complex multiplet at ~ 8.05 ppm houses the H3 and H3′ 
aromatic protons on the intercalating ligand, integrating to 3 and 4 protons respectively. 















Figure 3.14: An expansion of the 300 MHz 1H NMR spectrum of a, [Pt(terpy)(MPA)]Cl (14) and b, 
[Pt(terpy)(AET)]Cl (13). showing the aromatic proton assignments in D2O.  
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The resonances of the coordinated ligands are assigned with the aid of platinum 
coupling to the H7 protons (Figure 3.15). Interestingly, the H7 and H8 protons of 
[Pt(terpy)(MPA)]Cl appear at the same chemical shift in D2O, as a singlet integrating 
for 4 protons. This was unexpected as two resolved triplet resonances are observed in 
the amino analogue [Pt(terpy)(AET)]Cl. These peaks are slightly better resolved in 











Figure 3.15: An expansion of the 300 MHz NMR spectrum of a, [Pt(terpy)(MPA)]Cl (14) and b, 
[Pt(terpy)(AET)]Cl (13). showing the aliphatic proton assignments in D2O.  
 
The proton labelled H9 in both complexes is only visible in 1H spectra obtained using 
organic solvents with non-exchangeable protons. The H9 amine peak of 
[Pt(terpy)(AET)]PF6 was assigned as the resonance at 6.29 ppm due to exchange with 
D2O. The H9 carboxylic acid proton of [Pt(terpy)(MPA)]PF6 was assigned as the 
resonance at 12.04 ppm, also due to exchange with D2O. 
 
The proton assignments for both [Pt(terpy)(AET)]+ (13) and [Pt(terpy)(MPA)]+ (14) 
have been summarised in Table 3.3.  
Table 3.3: The proton assignments for both [Pt(terpy)(AET)]+ (13) and [Pt(terpy)(MPA)]+ (14) as Cl and 
ClO4 or PF6 salts, at 0.01 M concentration. 




H4′ H5 H6 H7 H8 H9 
13 Cl 8.17 8.35 7.77 9.02 2.69 3.17 - 
13 ClO4 8.32 8.32 7.82 9.29 2.74 3.18 6.29 
14 Cl 8.10 8.27 7.68 8.79 2.58 2.58 - 
14 PF6 8.42 8.59 7.90 9.29 2.63 2.78 12.04 
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Chemical shifts in all cases were both solvent and concentration dependent, probably 
due to an intermolecular stacking interaction, which is consistent with previously 
published observations. For example, during this work the spectral resonances for 
[Pt(terpy)(MPA)]+ were observed moving upfield as a function of increasing 
concentration. Interestingly, the H6 resonances appeared to display the greatest shift 
under these conditions, moving twice as far as the other aromatic resonances. In 
previous studies involving [Pt(terpy)(AET)]+ this phenomena was found to be solvent 
dependant, with organic solvents appearing to suppress the interaction. A short series of 
1H NMR experiments were performed to determine the effects of solvent on the 
chemical shifts of the [Pt(terpy)(MPA)]+ resonances. It was found that, unlike other 
complexes in its family, organic solvent does not appear to suppress the interaction; the 
same magnitude shift was observed in both D2O and CD3CN (Table 3.4). 
 
Table 3.4: A summary of results demonstrating the concentration dependence of chemical shifts in the 1H 
spectrum of [Pt(terpy)(MPA)]+ in D2O and CD3CN. The H3 assignment was centred on the largest peak 
of the multplet. Values are given in ppm. ∆ values indicate the change in chemical shift from the previous 




Ion Solvent H3(∆) H5(∆) H6(∆) 
0.01 Cl D2O 7.94 7.52 8.65 
0.02 Cl D2O 7.90(-0.04) 7.49(-0.03) 8.58(-0.07) 
0.03 Cl D2O 7.88(-0.02) 7.47(-0.02) 8.54(-0.04) 
0.01 PF6 CD3CN 8.32 7.83 9.45 
0.02 PF6 CD3CN 8.28(-0.04) 7.79(-0.04) 9.35(-0.10) 
0.03 PF6 CD3CN 8.26(-0.02) 7.77(-0.02) 9.31(-0.05) 
 
The 195Pt spectra of the two compounds is also indicative of the replacement of a 
chloride ligand for sulphur in the platinum coordination sphere. The spectrum of 
[Pt(terpy)(AET)]Cl displays a single peak at -2988.25 ppm; a significant upfield shift of 
267.11 ppm compared to [Pt(terpy)Cl]Cl. Similarly [Pt(terpy)(MPA)]Cl displays a 
single peak at -3211.71 ppm; an upfield shift of 490.57 ppm when compared to 
[Pt(terpy)Cl]Cl.  
 
3.4.1.4 Crystal Structure of [Pt(terpy)(MPA)Cl] 
The tendency of platinum terpyridine complexes to aggregate in solution has been 
studied previously, and is usually governed by strong π-π interactions. Of those studies, 
the x-ray crystal structure of [Pt(terpy)(HET)]NO3179 was of special interest as the 
mercaptoethanol tail was predicted to influence the packing arrangement due to its 
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hydrogen bonding capability, in a similar manner to the carboxylic acid component of 
the novel [Pt(terpy)(MPA)Cl] complex. Such interactions would be expected to have a 
significant effect on the DNA binding properties of the molecules. The crystal structure 
of the mononuclear [Pt(terpy)(MPA)]Cl species, which had been synthesised with the 
aid of AgNO3 to activate [Pt(terpy)Cl]Cl, was obtained using single crystal x-ray 
diffraction. The structure of the complex is well resolved, revealing an asymmetric unit 
consisting of two equivalent [Pt(terpy)(MPA)]+ complexes, one silver chloride molecule 
and five water molecules which are disordered (the sum of which is designated 
[Pt(terpy)(MPA)]2AgCl.5H2O, Figure 3.16). 
 
 
Figure 3.16: The crystal structure of the species [Pt(terpy)(MPA)]2AgCl.5H2O. The disordered water 
molecules have been omitted for the purposes of clarity. 
 
The crystallographic data and associated collection parameters for this complex are 
summarised in Table 3.5. 
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Table 3.5: Crystallographic data and associated collection parameters for the species 
[Pt(terpy)(MPA)]2AgCl.5H2O. 
 [Pt(terpy)(MPA)]2AgCl.5H2O 
Molecular Formula C36H32AgClN6O9Pt2S2 
Molecular Weight 1325.77 
Crystal System Triclinic 
Space Group P1 (No. 1) 
a 10.1504 (10) Å 
b 11.0400 (10) Å 
c 20.0658 (2) Å 
V 2194.9 (4) Å3 
α 80.0575 (4) 
β 89.4286 (4) 
γ 82.3498 (4) 
Dc 2.01 
Z 2 
Crystal Size (mm) 0.40 × 0.10 × 0.02 
Absorption Coefficient 7.073 mm-1 
F(000) 1262 
Crystal Colour Red 
Crystal Habit Plate 
λ(Mo-Kα) 0.71073 
T(Guassian)min, max 0.35, 0.87 
θ Range for Data Collection 5o – 27o 
2θmax 55o 





Completeness to θ 26.953 (99.2%) 
Final R indices [I>3σ(I)] R1(F) = 0.0386, wR2(F2)= 0.0476 
Goodness-of-fit on F2 1.0365 
 
The H atoms were all located in a difference map, but those attached to carbon atoms 
were repositioned geometrically. The H atoms were initially refined with soft restraints 
on the bond lengths and angles to regularise their geometry (C-H in the range 0.93-0.98 
Å, N-H in the range 0.86-0.89 Å and O-H = 0.82 Å) after which the positions were 
refined with riding constraints. The chloride counter ions, which are required to balance 
the 1+ charge of the metal complex, were not well described in the crystal structure. It 
was first hypothesised that some of the carboxylic acid groups may be ionising to 
provide the balance in charge, but closer observation of the differential bond lengths 
suggests that only neutral carboxylic acid groups are present. Furthermore, the presence 
of a small electron density indicated the presence of a hydrogen atom on each of those 
groups. Possible explanations for this anomaly include the counter ion existing in a 
channel of disordered density in the centre of the crystal packing columns, random 
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ionisation of the carboxylic acid groups or an unexpected charge state of the metal 
complex.  
 
The coordination geometry of the species [Pt(terpy)(MPA)]2AgCl.5H2O is essentially 
square planar with distortion caused by the steric constraints imparted by the tridentate 
terpyridine ligand. The ORTEP diagram of the species is provided below in Figure 3.17. 
 
Figure 3.17: The ORTEP diagram of the species [Pt(terpy)(MPA)]2AgCl.5H2O displaying the atom 
numbering scheme. Hydrogens are not numbered. Free oxygen atoms (numbered O101, O103, O104, 
O105 and O107) belong to water molecules. Cl91 is a chloride ion. 
 
For each [Pt(terpy)(MPA)]+ unit in the structure, the Pt-N distance to the middle 
nitrogen atom of the terpyridine ligand (N13 and N63; 1.969(4) Å) is slightly shorter 
than the distances of each platinum to the other nitrogen atoms in the coordinated ligand 
(N2 and N19; 2.029(4) Å and 2.026(5) Å respectively, as well as N52 and N69; 
2.047(4) Å and 2.032(4) Å respectively). This characteristic is highly conserved 
amongst terpyridineplatinum(II) complexes. The mercaptoethanol analogue 
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[Pt(terpy)(HET)]NO3 (Figure 3.18), displays almost identical bond lengths in this 
regard, where the equivalent bond is 1.968(5) Å (slightly shorter than the other Pt-N 
bonds; 2.023(5) Å and 2.030(5) Å respectively).179 Other complexes in this family such 
as [Pt(terpy)(NS)]ClO4, [Pt(terpy)(NN′S)]ClO4 and the di-nuclear species 



























1 2 3 4
NO3 ClO4 ClO4 2ClO4
 
Figure 3.18: Terpyridineplatinum(II) based complexes that display similar coordination parameters; 1, 
[Pt(terpy)(HET)]NO3; 2, [Pt(terpy)(NS)]ClO4; 3, [Pt(terpy)(NN′S)] ClO4; 4, [{Pt(terpy)}2(SNS)] ClO4. 
 
The N-Pt-N angles; 81.02(19) Å, 80.50(19) Å, 80.11(18) Å and 80.69(18) Å, are 
significantly smaller than the theoretical value of 90o expected for square planar 
complexes. This is also characteristic of four-coordinate terpyridineplatinum(II) 
complexes.179,231,272,273 
 
The length of the bonds between platinum and sulfur; 2.2963(11) Å and 2.3064(11) Å, 
are comparable to the Pt-S distance of the metal complexes depicted in Figure 
3.18.179,272 For example, the complex [Pt(terpy)(HET)]NO3 has a Pt-S distance of 
2.303(2) Å.179 The N-Pt-S angles; 102.74(13) Å, 95.86(12) Å, 106.82(12) Å and 
92.49(12), further reflect the strain caused by chelation of the terpyridine ligand and is 
comparable with complexes of similar structure.  
 
The mercapto ligands of the [Pt(terpy)(MPA)]2AgCl.5H2O species have less 
conformational freedom due to the interaction with the Ag atom of AgCl (with Ag-S 
distances of 2.4552(13) Å and 2.4685(13) Å), unlike the crystal structure of 
[Pt(terpy)(HET)]NO3 which displayed disorder of the mercaptoethanol carbon atoms.179 
 
A summary of the bond lengths and angles pertaining to the coordination geometry and 
mercaptopropionic acid ligands are provided in Table 3.6 and Table 3.7 respectively. 
The final positional, thermal and occupancy parameters (with their standard deviations 
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derived from the inverse matrix of the final least squares refinement cycle) as well as 
interatomic distances and angles (with their standard deviations) are provided in 
Appendix F.  
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Table 3.7: Interatomic distances (Å) and bond angles (deg.) of the [Pt(terpy)(MPA)]2AgCl.5H2O 
mercaptopropionic acid ligands. 




























The stacking interaction of [Pt(terpy)(MPA)]2AgCl.5H2O is different to that of similar 
mononuclear complexes due to the interaction of the AgCl molecule. For the complex 
[Pt(terpy)(HET)]NO3 two stacking interactions are observed (Figure 3.19179).  
 
Figure 3.19: The stacking interactions of [Pt(terpy)(HET)]NO3 (1 and 2) and the crystal packing 
arrangement (3) that they induce. 
 
In the first interaction the nitrogen and sulfur atoms of the mercaptoethanol ligand, 
which are expected to have a partial negative charge, are positioned across from the 
positive platinum and polarisable terpyridine carbon atoms and extend perpendicular to 
1                                2                                    3 
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the plane of the aromatic rings. The two molecules stack in a head-to-tail motif with an 
interplanar distance of 3.43 Å. The alternate stacking arrangement displays greater 
overlap of the aromatic rings, but retains the head-to-tail motif and similar 
intermolecular distance of 3.42 Å. The stacking interaction of 
[Pt(terpy)(MPA)]2AgCl.5H2O involves a head-to-head motif which is stabilised by the 
presence of the AgCl (Figure 3.20). This is similar to the conformation adopted by di-
nuclear species such as [{Pt(terpy)}2(SNS)]ClO4, though the distance between the two 
platinum centres is much further in [Pt(terpy)(MPA)]2AgCl.5H2O.  
 
Figure 3.20: The stacking interaction of [Pt(terpy)(MPA)]2AgCl.5H2O involving a head-to-head motif 
which is stabilised by the presence of the AgCl (left) and two [Pt(terpy)(MPA)]2AgCl.5H2O units 
interacting within the packing structure demonstrating the distance between the aromatic ligand planes 
(right). The distance between the two silver atoms is 3.0984(8) Å. 
 
The intramolecular distance between the two platinum centres in 
[{Pt(terpy)}2(SNS)]ClO4 is 2.92 Å,272 compared to the intermolecular distance of 4.69 
Å observed for [Pt(terpy)(MPA)]2AgCl.5H2O, which also arises from the interaction of 
the AgCl molecule. The propanoic acid moiety extends perpendicular to the plane of the 
aromatic rings, similar to the mercaptoethanol ligand of [Pt(terpy)(HET)]NO3.179 
 
The unique stacking arrangement of [Pt(terpy)(MPA)]Cl in the presence of AgCl has a 
remarkable effect on the crystal packing arrangement, which involves columns of 
[Pt(terpy)(MPA)]Cl stabilised by silver ions (Figure 3.21). Distinct layers are observed 
containing the platinum centres, terpyridine ligands, sulfur atoms and AgCl molecules, 
with the propanoic acid moiety projecting between the layers. Between the columns are 
channels of disordered density, possible due to water molecules and/or counterions. In 
comparison, the complex [Pt(terpy)(HET)]NO3 forms sheets within the crystal lattice 
stabilised by the previously described stacking interactions, with the cations laterally 
4.69 Å
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displaced from one unit cell to the next.179 This prevents the generation of a columnar 
stack perpendicular to the terpyridine plane. 
 
 
Figure 3.21: The crystal packing arrangement of [Pt(terpy)(MPA)]2AgCl.5H2O in the presence of AgCl, 
involving columns of [Pt(terpy)(MPA)]Cl stabilised by silver ions. 
 





























Figure 3.22: The coupling of [Pt(terpy)(AET)]ClO4 and [Pt(terpy)(MPA)]PF6. 
 
As a “proof of concept” the two mononuclear species were coupled together using 
standard organic based coupling techniques (Figure 3.22), which could also be 
implemented in machine assisted schemes. Successful coupling of the two species 
proved two things; that the carboxylic acid terminal of [Pt(terpy)(MPA)]+ can be 
activated using standard protocols and reagents (HBTU and DIEA, 5 min), and that 
[Pt(terpy)(AET)]+ can successfully react with an activated ester in the same fashion as 
other free amine species in peptide synthesis. Due to the solvent system requirements of 
the coupling procedure the metal complexes were first converted to DMF soluble salts. 
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[Pt(terpy)(AET)]Cl was initially converted to the PF6 salt, but this was found to be 
insoluble in DMF. This problem was overcome by converting the complex back to the 
chloride salt, from which the perchlorate salt could be obtained. This yielded a product 
that was sufficiently soluble in DMF. [Pt(terpy)(MPA)]Cl was also converted to the PF6 
salt and found to be soluble in DMF. The mixed salt system was not predicted to have a 
negative impact on the progress of the coupling reaction. [Pt(terpy)(MPA)]PF6 was 
activated by the addition of HBTU and DIEA following previously described 
conditions, and combined with the solution of [Pt(terpy)(AET)]ClO4. Unlike coupling 
reactions involving purely organic compounds this reaction was very difficult to 
monitor by TLC, and as a result the reaction time was extended to 4 h to ensure 
completion. The crude product was precipitated from the DMF solution without any 
reduction in volume by the addition of a saturated tetrabutylammonium chloride/acetone 
solution. The dark purple solid was collected by filtration, washed with cold acetone 
and diethyl ether, and air dried. The solid was dissolved in a minimum amount of 
distilled water, filtered, and the counter ion exchanged with the addition of a saturated 
PF6 solution. The purple solid was collected by filtration, washed with cold distilled 
water and air-dried overnight. A portion of the PF6 salt was retained for NMR analysis 
in organic solvents. In non-exchangeable organic solvents it was possible to see that the 
carboxylic acid proton resonance of [Pt(terpy)(MPA)]+ had been replaced by an amide 
peak further upfield, strong evidence that the peptide coupling procedure had been 
successful. The 195Pt spectrum of the dimer displays two peaks at -3187.12 ppm and -
3221.24 ppm. This suggested that the coupling reaction had been successful, which was 
later confirmed by ESI-MS analysis. Some of the solid was dissolved in a minimum of 
acetone and precipitated with tetrabutylammonium chloride to obtain the water soluble 
chloride salt for DNA binding studies described in Chapter Four.  
 
3.4.2.1 1H NMR Characterisation of [{Pt(terpy)}2(DMECA)]Cl2 
The proton labelling scheme for [{Pt(terpy)}2(DMECA)]Cl2 is provided in Figure 3.23. 
Unlike the 2D NOESY spectra of the mononuclear species, no connectivity was 
observed between the aliphatic H7 and H11 protons of the peptide bridging ligand and 
the aromatic H6 and H12 resonances, making it impossible to unambiguously assign the 
protons of the intercalating ligand. This was thought to be a function of the size and 
unfavourable tumbling rate of the molecule. To overcome this a 2D ROESY experiment 
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was performed from which the connectivity of these protons could be observed 






























Figure 3.23: The proton labelling scheme for [{Pt(terpy)}2(DMECA)]Cl2. Equivalent protons are not 
labelled. 
 
The four triplets in the 1H spectrum of [{Pt(terpy)}2(DMECA)]Cl2 at 3.2, 2.55, 2.5 and 
2.25 ppm each intergrate for 2 protons and correspond to the CH2 components of the 
peptide bridging ligand (Figure 3.24). The peak at 3.2 ppm can be assigned as H8, as it 
would be expected to appear the furthest downfield due to its proximity to the nitrogen 
atom of the peptide linkage. It is also consistent with the chemical shift observed for the 
same proton in the 1H NMR spectrum of [Pt(terpy)(AET)]Cl. H7 can be assigned as the 
peak at 2.55 ppm due to connectivity with H8 in the ROESY spectrum. The peak at 2.5 
ppm can therefore be assigned as H11, as it is in a similar chemical environment to H7, 
which is also adjacent to both a sulfur and a carbon atom in the molecular structure. 
This peak also shows connectivity to the resonance at 2.25 ppm in the ROESY 
spectrum, which can be assigned as H10. This is consistent with the chemical 
environment of the H10 proton, which would be expected to appear the furthest upfield 







Figure 3.24: An expansion of the aliphatic region of the 1H spectrum of [{Pt(terpy)}2(DMECA)]Cl2 
showing the assignment of the peptide bridging ligand protons. 
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The aliphatic proton resonances appeared broad in all of the spectra obtained, in contrast 
to the sharpness of the aromatic proton peaks, regardless of changes to the experimental 
conditions and parameters.  
 
The two doublets at 9.14 and 8.97 ppm are due to the aromatic H6 and H12 protons 
(Figure 3.25). The chemical shifts of these resonances are similar to those previously 
observed in the mononuclear species and they both display platinum coupling. 
Connectivity is observed between these resonances and the linker H7 and H11 protons 
allowing them to be unambiguously assigned. The peak furthest downfield at 9.14 ppm 
shows connectivity to H7, and long range connectivity to H8, and thus is assigned as 
H6. Similarly, the peak at 8.97 ppm shows connectivity to H11 and long range coupling 
to H10 in the ROESY spectrum, and can be assigned as H12. The triplet peaks that 
appear the furthest upfield in the aromatic section of the spectrum correspond to the H5 
and H13 protons. The resonance at 7.78 ppm displays connectivity with H6, so can be 
assigned as H5, similarly the H12 resonance shows connectivity with the peak at 7.67 
ppm, which is assigned as H13. From these assignments the chemical shifts of the 
remaining aromatic protons could be predicted, though significant overlap of the peaks 
and complexity of the spectrum did not allow exact assignments. The multiplet between 
8 and 7.85 ppm, which represents the H3, H3′ and H15, H15′ resonances. The multiplet 




H6 H12 H5 H13
H4, H4', H14, H14'
H3, H3', H15, H15'
 
Figure 3.25: An expansion of the aromatic region of the 1H spectrum of [{Pt(terpy)}2(DMECA)]Cl2 
showing the assignment of the intercalating ligand protons. 
 
The amido proton H9 was only visible in spectra obtained in organic solvents with non-
exchangeable protons, such as CD3CN, and appeared further upfield than the aromatic 
resonances at ~ 6.6 ppm (Figure 3.26). 
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Figure 3.26: An expansion of the 1H spectrum of [{Pt(terpy)}2(DMECA)]Cl2 in CD3CN showing the 
assignment of the intercalating ligand protons and the amido H9 proton. 
 
3.5 CONCLUSIONS  
The difficulties encountered in the attempts to coordinate the platinum DNA binding 
group terpyridineplatinum(II) through the free amine of various species was overcome 
by exchanging the nitrogen donor ligands for more reactive sulphur compounds. This 
led to the synthesis of two thiolato terpyridineplatinum(II) synthons that are ideal for 
incorporation into sequence selective polyamides by the formation of peptide bonds by 
standard coupling procedures, [Pt(terpy)(AET)]Cl and the novel [Pt(terpy)(MPA)]Cl.  
 
Crystals of the compound [Pt(terpy)(MPA)]Cl were successfully obtained by the vapour 
diffusion method and analysed by x-ray crystallography, revealing a novel stacking 
mode induced by the presence of silver nitrate. The crystal structure of 
[Pt(terpy)(MPA)]Cl was complicated by the presence of AgCl molecules, which 
induced the formation of a quasi-dinuclear species. The bond parameters provided a 
detailed description of the coordination geometry of the metal complex, which was 
comparable with previously studies of structurally related terpyridineplatinum(II) 
complexes. The chloride counter ions, which are required to balance the charge of the 
metal complex, were not well described in the crystal structure. The study of additional 
crystals will be required to identify the exact nature of this anomaly. It would also be of 
interest to study the crystal structure of this metal complex without the presence of 
AgCl, which appears to stabilise the molecules in the column like packing formation. 
Without AgCl the complex would be expected to have a stacking interaction and 
packing structure closely comparable to that of the analogue [Pt(terpy)(HET)]+. 
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As a proof of concept the two mononuclear species were successfully coupled together 
utilising standard organic based techniques. This proved that the carboxylic acid 
component of the [Pt(terpy)(MPA)]+ species can be activated by standard procedures, in 
this case utilising the coupling agent HBTU and the hindered base DIEA. It also 
demonstrated the ability of the amine component of [Pt(terpy)(AET)]+ to attack the 
activated ester of another compound. This paves the way for the incorporation of both 
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CHAPTER FOUR: DNA BINDING STUDIES 
 
4.1 INTRODUCTION 
CD and 1H NMR studies were undertaken to investigate the DNA binding mechanism, 
affinity and specificity of [Pt(terpy)(MPA)]Cl and [{Pt(terpy)}2(DMECA)]Cl2. Both 
methods are well established in the literature and give valuable insights into the possible 
pharmacological properties of a compound prior to biological testing. See Appendix I, J 
and K for related data. 
 
4.1.1 CD DNA Binding Studies 
A CD spectrum is characterised by a measure of the difference in absorption of left and 
right handed circularly polarised light. DNA is a chiral molecule, with each 
conformation absorbing plane polarised light in different ways and giving rise to a 
characteristic CD spectrum. For example, since the DNA CD from 200 to 300 nm is 
representative of the skewed orientation of the bases, any untwisting of the helix or 
change in the base orientation which is characteristic of the different DNA 
conformations will be readily apparent in the CD spectrum.274 The characteristic CD 
spectrum of B-DNA (Figure 4.1) 
generally contains a positive peak at 
275 nm, a negative peak at 240 nm 
with a zero point registered at around 
258 nm. The two positive bands are 
superimposed results of all the 
couplings of the transitions present in 
all the bases. At 220 nm the CD signal 
typically becomes positive (though under some conditions it will register as a reduction 
in the previous negative band), followed by a massive positive peak from 180 to 190 
nm. Stretching of B-DNA from 10.2 to 10.4 bases per turn, which can be induced by 
treatment with methanol or by interaction with histone cores to form nucleosomes, 
causes the positive peak at 275 nm to disappear. Conversely, if B-DNA is compacted 
causing the bases to tilt and be displaced from the centre of the helix it converts to A-
DNA. A-DNA is characterised by a positive CD band at 260 nm that is substantially 
more intense than the corresponding B-DNA equivalent, an intense negative band at 
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210 nm and another very intense positive band at 190 nm. The region between 250 and 
230 nm is typically flat, though not necessarily at zero absorbtion. Z-DNA is 
particularly important in the field of anticancer drug design because it can be induced by 
the binding of various compounds that display cytotoxicity.107-111 It is characterised by a 
negative CD band at 290 nm and a positive band at 270 nm,275 followed by an intense 
negative CD band in the 195-200 nm region, whereas B-DNA is near zero or positive at 
equivalent wavelengths. Additionally, the transition between positive and negative 
signals crosses the zero absorbance axis between 180 and 185 nm, whereas B-DNA 
crosses at 258 nm. Variation in the characteristic CD spectra of the DNA forms is 
possible and typically depends on the sequence and composition of the base-pairs 
present, especially in the case of custom synthesised oligonucleotides.274 It should also 
be noted that Z-DNA will not readily form for all sequences.  
 
CD is useful for probing the global conformational changes of DNA induced by the 
binding of drug molecules, which can then give valuable information about the 
host/drug stoichiometry, thermodynamics, binding size and affinity. When a non-chiral 
molecule or drug binds to DNA, it acquires a CD spectrum that is characteristic of the 
interaction, and frequently very different to that of native DNA. Such experiments are 
usually performed in a series whereby a single variable is altered, such as temperature, 
incubation time, ionic strength or mixing ratio (drug:DNA ratio). If the intensity of the 
peaks change, but the overall shape of the spectrum remains the same throughout the 
titration series, it can be hypothesised that the ligand binding mode has remained the 
same despite any increase in the amount of bound ligand. This can represent a single 
binding mode or the presence of a number of binding sites whose relative proportion is 
independent of the drug:DNA ratio. 
 
For experiments where the DNA concentration is very high, the total ligand 
concentration is assumed to be approximately equal to the bound ligand concentration, 
which allows the binding size and constant to be determined.274 If there is a change in 
the shape of the spectrum due to changes in the experimental variable, which is often 
the case when DNA binding agents are being analysed, it implies that an alteration in 
the interaction has occurred as a function of the experimental variable. This change can 
be due to the occupancy of more than one binding site as the drug concentration 
increases, especially in cases where a drug may have a preferential base sequence or 
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type, changes in the DNA conformation or ligand-ligand interactions such as stacking 
and dimerisation. The methods for determining binding strength and other 
pharmacologically relevant values are outlined in the publications of Rodgers and 
Nordén,274 and are shown here as they were utilised heavily in this work. This method is 
only valid where there is no ligand-ligand interactions, where uniform binding occurs 
(i.e. no change in the appearance of the CD spectra apart from magnitude of the peaks), 
and where there is only one binding mode. Where ligands stack externally on DNA, or 
their CD signal comes from ligand-ligand exciton coupling that increases in a non-linear 
fashion based on the number of molecules in the stack, an alternative method must be 
used. The method described here is valid for experimental CD spectra obtained by 
titrating a ligand into a fixed concentration of DNA. Subtraction of the native CD 
spectrum of DNA from the spectra obtained with increasing ligand concentration 
reveals the change in spectra induced by the binding of the drug alone (known as the 
ICD spectrum). From this data a binding curve can be generated at any wavelength; 
usually where the greatest change in ICD was observed over the course of the titration. 
The data points in the binding curve are used to determine the binding strength of 




Where Lb is the bound metal complex concentration, Lf is the free metal complex 
concentration and Sf is the concentration of free binding sites. The total binding site 




Where CM is the total macromolecular concentration, usually provided in terms of base 
concentration, in which case n is the number of bases in the binding site. The starting 
point for the experimental determination of these values and the equilibrium binding 
constant is the solving of the following Equation: 
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Where Ltot is the total metal complex concentration, ρ  is the measured ICD signal at a 
chosen wavelength, usually a peak of maximum positive or negative magnitude. The 
value of α is constant over the entire range of binding ratios being analysed (and is also 
a function of wavelength). The value α is derived from experimental data using the 
Intrinsic method, which is described in the following section. 
 
4.1.2 The Intrinsic Method 
The Intrinsic method is used to process experimental CD data to obtain a value for α, 
which can later be incorporated into a Scatchard plot to determine the binding constant 
(K). It is a flexible method that is valid across a broad range of experimental conditions 
that would cause difficulties in other methods. The method described here is used for 
processing data obtained from titrations where the macromolecular concentration is kept 
constant and the concentration of metal complex is changed throughout the course of 









Thus, for any two different total metal complex concentrations, i.e. atotL  and 
b
totL , at a 








Thus a plot of y = Equation 7 and x = Equation 8 (which are both components of 
Equation 6) for each experimental data point over the entire range of the titration should 
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The value derived for α can then be used in Equation 6 to determine Lf and Lb, from 
which a Scatchard plot can be created that gives the best value for K using all of the 
data points.  
 
4.1.3 The Scatchard Plot 








Since Sf = Stot - Lb, a plot of r/Lf versus r has a slope of K and y-intercept K/n. The x-
intercept occurs where r = n × Lb. 
 
4.1.4 Alternative Methods 
The intrinsic method can be altered to process data from experiments where the 
macromolecular concentration alters during the course of the assay while the metal 
complex concentration remains constant. There are other methods for the processing of 
data which were specifically developed for determining K when the plot of Equation 7 
versus Equation 8 is not a straight line. For example, if an exponential curve is obtained 
the data can be processed using a McGee von Hippel plot.276 Care must therefore be 
taken in interpreting the shape of the line in the Scatchard plot, especially where 
experimental error or variation provides ambiguity, to ensure that the most suitable 
method is used to process each data set. Recently, Stootman et al. have reported a novel 
method for determining the binding constant of achiral intercalators to DNA which 
utilises a “least squares” fitting program.277 Experimental CD spectra are obtained using 
the standard method described in Section 4.1.1. From this data a binding curve can be 
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program incorporates the experimental data into a non-linear least squares fit of a 
simple equilibrium model (Equation 11; derived from the previously described 
equations), and the binding constant and binding site size are automatically generated 





























ε   (11) 
Where ε is the molar extinction coefficient. 
 
4.1.5 1H NMR DNA Binding Studies 
NMR spectroscopy is a powerful tool for obtaining a detailed picture of DNA 
intercalation. It can provide information about DNA-drug interactions under 
physiological relevant conditions, as well as other information pertaining to binding 
affinity and strength. Additionally, whilst other methods such as X-ray diffraction may 
only provide a snap-shot of DNA/drug interactions as they are performed in the solid 
phase, NMR provides a dynamic model of binding. 1H NMR experiments are 
extensively used due to the large number of protons in both intercalating species and 
DNA, and the high natural abundance of 1H nuclei (99.985%).278 Most experiments 
probe the interaction between intercalating species and short sections of duplex DNA; 
generally oligonucleotides between six and twelve bases long. The minimum length of 
an oligonucleotide displaying a normal B-DNA helix conformation with well defined 
minor and major grooves is six base pairs,279-282 whereas oligonucleotides larger than 
twelve base pairs are generally too complicated to analyse without the use of more 
modern high field NMR spectrometers (800-900 MHz). Typical one-dimensional (1D) 
DNA binding experiments reveal large and selective upfield shifts of the resonances of 
both DNA and the compound upon intercalation. The largest alterations in chemical 
shifts are exhibited by resonances related to bases at the exact site of intercalation, thus 
revealing the DNA binding site and possible base preferences of the intercalating 
molecule. Additional information can be obtained through the application of two-
dimensional (2D) nuclear overhauser enhancement spectroscopy (NOESY) and double 
quantum filtered correlated spectroscopy (DQFCOSY) experiments. NOESY 
experiments reveal through-space interactions between protons. If the distance between 
two protons is less than 5Å an NOE cross-peak will be observed with an intencity 
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related to r-6 allowing exact proton-proton distances to be determined.283 NOESY 
experiments can therefore be used to determine the exact binding site and orientation of 
an intercalating species in the helix by observing NOE cross-peaks between the 
compound and DNA resonances. For example, NOEs from the intercalator resonances 
to thymine C5-methyl, guanosine/adenosine H8-protons or the cytosine C5-proton 
resonances indicate interactions with the DNA major groove, whereas NOEs to any of 
the H1′, H4′, H5′ or H5′′ proton resonances indicate interactions and binding in the 
minor groove. DQFCOSY experiments probe through-bond interactions between 
protons separated by three-four bonds, providing information on conformational 
changes to the DNA helix. In normal B-DNA the J-coupling of the H1′ proton to the 
H2′′ proton is 10 Hz. Intercalation can thus be observed through changes in the coupling 
constants due to conformational change. For example, the coupling constant of the 3′-
endo sugar H1′ to H2′′ changes to 2 Hz when the Z-DNA conformation is assumed. If 
the binding of an intercalator to DNA is in fast exchange on the NMR timescale and 
stoichiometric (1:1 binding intercalator and oligonucleotide) then a minimum binding 
constant can be estimated, or calculated if the binding is performed at less than 
stoichiometric molalities.284,285 The binding constant (K) can be expressed as shown in 
Equation 12.  
 
K = [I-DNA]                  (12) 
                    [I][DNA] 
 
Where [I-DNA] is the concentration of intercalator/DNA adduct and [DNA] and [I] are 
the concentrations of free oligonucleotide and intercalator respectively. These 
concentrations are estimated from the population weighted chemical shift, derived in 
Equation 13 
 
δobs = Pfδf + Pbδb       (13) 
 
Where δobs is the observed chemical shift of any given intercalator proton resonance, Pf 
and Pb are the mole fractions of the free and bound intercalator respectively and δf and 
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4.2 MATERIALS AND METHODS 
 
4.2.1 Reagents 
The d(GATGCGCATC)2 was synthesised by Geneworks. Samples were prepared in 
99.8% D2O obtained from Sigma Chemical Company. The oligo was dissolved in 0.6 
mL of 10 mM phosphate buffer (pH 7.0) containing 100 mM NaCl and 1 mM EDTA. 
The sample was lyophilised to dryness then redissolved in 99.8% D2O. 
 
4.2.2 CD Spectroscopy 
All CD measurements were recorded on a Jasco J-810 CD spectropolarimeter at room 
temperature using a cell length of 1 cm. Titrations were performed by incrementally 
adding aliquots of each complex to a 2600 μL solution of 28 μM ct-DNA as prescribed 
in the experimental section. After each addition, an average CD spectrum from 200 to 
350 nm (20 accumulations) was recorded. The concentration of each complex ranged 
from 0 to 17 μM in each of the experiments and was obtained from a 7.28 mM stock 
solution of [Pt(terpy)(MPA)]Cl and 1.82 mM stock solution of the dimer. Solutions 
were made in sodium phosphate buffer (10 mM), containing EDTA (1 mM) and NaCl 
(40 mM) adjusted to pH 7.0.  
 
4.2.3 NMR Spectroscopy 
Two dimensional 1H NMR NOESY spectra were obtained using a Varian Unityplus-
400 spectrometer by the method of States et al.,286 using 2048 data points in t2 for 256 t1 
values with a pulse repetition delay of 1.7 s. 
 
4.2.4 UV-vis Characterisation 
The UV-vis absorption of the metal complexes was recorded at concentrations of 1 mM 
(in distilled water), in the region of 200-400 nm. Spectra were obtained using a Cary 
300 Bio Spectrophotometer. Spectra were recorded at room temperature, using a 10 mm 
quartz cell. The concentration of ct-DNA or oligonucleotide in each experiment was 
determined using the Beer-Lambert equation: 
 
A = εCl            (14) 
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Where C is the oligonucleotide concentration, A is the measured absorbance at 260 nm, 
ε is the molar extinction coefficient and l is the cell path length (typically 1 cm). The 
molar extinction coefficient at 260 nm per nucleotide of ct-DNA is 6600 M-1cm-1.287 
 
4.2.5 Oligonucleotide Purification for NMR Analysis 
In preparation for the 1D and 2D 1H NMR binding experiments the oligonucleoptide 
d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10) was passed through a 2 g Waters C-18 sep-pak 
reverse phase column cartridge to remove any impurities from the manufacturing 
process. The column was activated by an initial wash with methanol, followed by 
distilled water. The oligonucleotide was dissolved in water and loaded onto the column, 
washed with water to remove any water soluble impurities, then eluted with a 1:1 
ACN/H2O solution. The fractions containing the oligonucleotide were detected by their 
absorbance at 260 nm. The relevant fractions were combined and concentrated under 
vacuum by lyophilisation. The oligonucleotide was then converted to the sodium salt by 
passing it through a CM-Sephadex cation exchange column. Preparation of the 
Sephadex column involved a thorough wash with water, followed by 1 M NaCl. The 
column was then washed again with water to elute any excess sodium ions. The 
oligonucleotide was then loaded onto the column, eluted with water and collected as 2 
mL fractions. The UV absorbance of the fractions was again monitored at 260 nm in 
order to locate the relevant fractions. 
 
4.2.6 Oligonucleotide Preparation for NMR Analysis 
The first step in the preparation of the oligonucleotide for NMR analysis was the 
addition of buffer components. This was achieved by lyophilising the purified 
oligonucleotide from 700 μL of pH 7 phosphate buffer (10 mM phosphate buffer, 1 mM 
EDTA, 20 mM NaCl). The oligonucleotide was then lyophilised twice from 99.9% D2O 
before being redissolved in 700 μL of 99.96% D2O. 
 
4.2.7 Addition of Intercalating Metal Complexes to DNA 
The metal complexes were dissolved in D2O (~ 15 mM) and added in 16 μL increments 
until an oligonucleotide:complex ratio of 1:1 was reached. This was determined by the 
integration of a selected oligonucleotide and metal complex resonance, with long d1 
times to allow for slow relaxation. 
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4.2.8 Cytotoxicity Assay 
The novel complexes [Pt(terpy)(MPA)Cl and [{Pt(terpy)}2(DMECA)]Cl2 were sent to 
the Peter McCallum Cancer Institute for biological testing using a standard method.288 
The platinum complexes were dissolved in distilled water and then diluted to the 
required concentrations. Growth inhibition results for L1210 murine leukaemia cells are 
reported after 48 h continous exposure to the metal complex. Cells were counted by 
Coulter counting. 
 
4.3 RESULTS AND DISCUSSION 
 
4.3.1 CD Binding Studies 
CD spectropolarimetry was used to determine the equilibrium constant and binding 
strength of the platinum complexes. CD titrations were carried out by incremental 
addition of complexes [Pt(terpy)(MPA)]Cl and [{Pt(terpy)}2(DMECA)]Cl2 into a fixed 
concentration of DNA, resulting in changes to the DNA spectra. The DNA studied in 
this work displayed the characteristic positive and negative bands of B-DNA at 260 nm 
and 245 nm, respectively. Binding curves at various wavelengths were produced from 
the ICD spectra, the data from which was then used to determine the equilibrium 
binding constants (K). Determination of K was obtained directly from the experimental 
data using a combination of the Intrinsic and Scatchard methods. Alternatively, some 
binding curves were analysed using the program designed by Stootman et al.277 for 
comparative purposes.  
 
4.3.1.1 The CD Binding Studies of [Pt(terpy)(MPA)]Cl 
The CD of the ct-DNA used in this study, as well as the spectral series of the compound 
[Pt(terpy)(MPA)]Cl binding to it at various ligand:DNA ratios, is provided below 
(Figure 4.2). It is clear from the ICD spectrum of the compound [Pt(terpy)(MPA)]Cl 
binding to ct-DNA that there is only a minor change in the CD of ct-DNA induced by 
the addition of the metal complex. The spectrum at each concentration is also highly 
irregular, making it difficult to choose a wavelength at which to attempt the 
determination of the equilibrium binding constant. 























Figure 4.2: The CD spectra of the compound [Pt(terpy)(MPA)]Cl binding to ct-DNA at ligand:DNA 
ratios between 0.1 and 1:1. Data was obtained from the average of three experiments. 
 
The native CD spectrum is subtracted from the other spectra in the series, allowing the 
changes in CD due to the interactions between the metal complex and DNA to be 
























Figure 4.3: The ICD spectra of the compound [Pt(terpy)(MPA)]Cl binding to ct-DNA at ligand:DNA 
ratios between 0.1:1 and 1:1. Data was obtained from the average of three experiments. 
A binding curve was obtained from the ICD values at 216 nm (Figure 4.4), the 
wavelength at which the greatest change was observed. This binding curve was used to 
determine the equilibrium binding constant using the Intrinsic method in conjunction 
with a Scatchard plot (see Appendix I). 
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Figure 4.4: The DNA binding curve of [Pt(terpy)(MPA)]Cl at 216 nm. The data points shown were 
obtained from the average of three experiments, from which the standard deviation was also calculated. 
 
The value for α calculated using the Intrinsic method was 7.0 × 10-6, allowing values for 
Lf and Lb to be determined (see Appendix I) at every ligand/DNA ratio. A Scatchard 
plot was created giving a value for K of 4.3 × 105. Due to the quality of spectra 
collected however, despite all efforts to optimise the experimental conditions, it is 
suggested that these values be seen as approximations of the true value and would 
require further experimentation by alternative methods to confirm. The size of the 
binding site determined by the Intrinsic method (2.23 bp) agrees closely with the value 
obtained using the Scatchard method (2.00 bp). The binding site size is consistent with 
the expected binding mode (intercalation), which is governed by the nearest neighbour 
exclusion principle. The appearance of the spectra suggests that the molecule may not 
be fully intercalating DNA. Full intercalation has been shown to cause significant 
changes in the CD spectrum of the ligand bound to DNA at ~ 215 nm,219,289 whereas the 
changes observed in this titration series were notably smaller than those reported in 
other studies. This is probably due in some way to the influence that the carboxylic acid 
component of [Pt(terpy)(MPA)]Cl has on the binding of the molecule. Regardless of the 
nature and strength of the binding mechanism, it clearly does not cause a significant 
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4.3.1.2 The CD Binding Studies of [{Pt(terpy)}2(DMECA)]Cl2 
The CD of the ct-DNA used in this study, as well as the spectral series of the compound 
[{Pt(terpy)}2(DMECA)]Cl2 binding to it at various ligand:DNA ratios, is provided 








































Figure 4.5: The CD spectra of the compound [{Pt(terpy)}2(DMECA)]Cl2 binding to ct-DNA at 
ligand:DNA ratios between 0.025:1 and 0.8:1. Data was obtained from the average of three experiments. 
 
The native CD spectrum is subtracted from the other spectra in the series, allowing the 
changes in CD due to the interactions between the metal complex and DNA to be 
observed more clearly, as illustrated in the ICD spectral series below (Figure 4.6). 






































Figure 4.6: The ICD spectra of the compound [{Pt(terpy)}2(DMECA)]Cl2 binding to ct-DNA at 
ligand/host ratios between 0.025:1 and 0.8:1. Data was obtained from the average of three experiments. 
 
In the ICD spectra of the compound [{Pt(terpy)}2(DMECA)]Cl2 binding to ct-DNA very 
strong interactions are observed between the drug and host molecules; as indicated by 
the major changes in the CD induced by the addition of the metal complex. The shape 
of the spectrum changes significantly during the course of the titration, suggesting that 
either two binding modes are present, the DNA provides two potential binding sites, or 
that a change in the DNA conformation has occurred. Alternatively a combination of 
these phenomena is possible, especially considering the predicted bis-intercalating mode 
of binding and the effects on DNA conformation that such a large adduct may induce. 
Similar concentration dependent DNA binding has been observed in anthracene phen 
and terpy based intercalators.219,290,291 The fact that the binding mode may not be 
uniform, given that the binding strength and DNA conformation appears to be 
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dependant on the concentration of metal complex, suggests that K will not be a true 
constant across the entire range of wavelengths monitored. Therefore, only an apparent 
equilibrium binding constant at a given wavelength can be determined. Three major 
regions of change in the ICD spectrum can be identified, at approximately 220, 245 and 
275 nm. Binding curves at 214.6 (Figure 4.7) and 247.4 nm (see Appendix J) were 
obtained from the ICD spectra, as at these wavelengths the change appears to be 
uniform in nature, whereas two distinct changes are observed in the peak at 275 nm (a 
slight increase followed by a decrease in the observed ICD). Values obtained for the 
curve at 214.6 nm were used to determine the equilibrium binding constant using both 
the Intrinsic Method in conjunction with a Scatchard plot (see Appendix J), and the 
method outlined by Stootman et al.277 Additionally, the values obtained from the 
binding curve at 247.4 nm were also analysed by the methods of Stootman et al.277 as 
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Figure 4.7: The DNA binding curve of [{Pt(terpy)}2(DMECA)]Cl2 at 214.6 nm. The data points shown 




The value for α calculated using the Intrinsic method was 1.0 × 10-6, allowing values for 
Lf and Lb to be determined (see Appendix J) at every ligand/DNA ratio. A Scatchard 
plot was created giving a value for K of 9.7 × 105, which is more than double the K 
value calculated for [Pt(terpy)(MPA)]Cl. This value is consistent with the degree of 
change observed in the CD spectra at comparably lower concentrations when compared 
to the monomer. The size of the binding site determined by the Intrinsic method (4.65 
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bp) agrees closely with the value obtained using the Scatchard method (3.89 bp). The 
size of the binding site is between four and five base pairs which is consistent with both 
the nearest neighbour exclusion principle and bis-intercalation. The binding of this 
compound causes significant perturbations to the conformation of DNA in a non-
uniform matter. The change in the CD spectra is similar to that observed in the binding 
of [Pt(terpy)(MPA)]Cl up to a ligand/DNA ratio of ~ 0.25, after which the shape of the 
spectra changes, with the peak at 275 nm reducing in magnitude. This may be indicative 
of the second intercalating moiety of each molecule achieving bis-intercalation, 
intercalation of a secondary binding site after the saturation of a preferred binding site, 
the interconversion to Z-DNA or a combination of one or more of these phenomena. 
The magnitude of the changes observed in the CD spectra during the course of the 
titration indicate that the compound interacts with DNA to a far greater extent than the 
monomeric parent molecule [Pt(terpy)(MPA)]Cl. The process of obtaining binding 
curves and equilibrium constants were repeated using the automated methods described 
by Stootman et al.277 The flexibility of the technique allows for the rapid calculation of 
values for K and n at any wavelength of interest. Below is the average binding curve at 
214.6 nm, incorporating the results of three experiments, generated using the program 
developed by Stootman et al.277(Figure 4.8). 
 
Figure 4.8: The DNA binding curve of [{Pt(terpy)}2(DMECA)]Cl2 at 214.6 nm. 
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The equilibrium constant obtained using this method, 1.15 × 107, is approximately an 
order of magnitude higher than the one obtained using the Intrinsic and Scatchard 
method. It is also much higher than the value obtained for the monomer. The binding 
site size, ~ 4, is consistent with values obtained using the previous combination of 
methods, particularly that of the Scatchard plot. Due to the apparent higher degree of 
suitability in processing the data from this titration series, an attempt was made to 
obtain an equilibrium binding constant at 247.6 nm, which had proven problematic 
using the Intrinsic/Scatchard method (see Appendix J). Below is the binding curve 
obtained at 247.4 nm, again displaying the results of three experiments (Figure 4.9). 
 
Figure 4.9: The DNA binding curve of [{Pt(terpy)}2(DMECA)]Cl2 at 247.4 nm. 
  
The apparent equilibrium constant at this wavelength is 5.61 × 108, which is 
approximately an order of magnitude higher than the one obtained at 214.6 nm using the 
same method. To further highlight the flexibility of this method, a third binding curve 
was obtained at ~ 275 nm (Figure 4.10). This is the wavelength at which the effects of 
the non-uniform binding interaction are most obvious. The values obtained for K and n 
at 275.6 nm are not accurate representations of the binding strength and site size of the 
molecule, though this binding curve clearly demonstrates the abilities of the program 
and the complexity of the binding interaction being analysed. 
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Figure 4.10: The DNA binding curve of [{Pt(terpy)}2(DMECA)]Cl2 at 275.6 nm. 
 
A summary of the K and n values obtained using this method is provided in Table 4.1. 
 
Table 4.1: A summary of the K and n values obtained for the compound [{Pt(terpy)}2(DMECA)]Cl2 
using the method described by Stootman et al.277 
Wavelength (nm) K n 
214.6 1.15×107 3.89 
247.4 5.61×108 2.28 
275.6 1.21 8.66×10-2 
 
4.3.2 1H NMR Binding Studies 
NMR spectroscopy has been utilised to study the interactions of anticancer drugs such 
as daunomycin to DNA.292,293,294 Advances in two dimensional NMR have promoted the 
complete assignment of the proton resonances from small nucleotides. Analysis of the 
magnitude of NOE cross-peaks between the various protons on a nucleotide yields 
qualitative interproton distance information, which can be used to the secondary 
structure of the oligonucleotide in solution. The oligonucleotide d(GATGCGCATC)2 
was synthesised as a model DNA segment in order to carry out 1H NMR studies of the 
DNA binding mechanisms of [Pt(terpy)(MPA)Cl and [{Pt(terpy)}2(DMECA)]Cl2. It 
was predicted that these molecules would bind via intercalation of their planar ring 
systems between the stacked bases of the DNA duplex. Any biological activity might 
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thus be attributed to the effect this interaction has on DNA replication and RNA 
transcription processes. The oligonucleotide d(GATGCGCATC)2 was predicted to 
provide a preferred binding site for both compounds in the GCGC stretch, as well as 
flanking AT sequences to cover any alternative binding modes/preferences.  
 
4.3.2.1 Assignment of the Oligonucleotide Resonances 
Assignment of the proton resonances of the free oligonucleotide was carried out using 
data obtained primarily from NOESY experiments. 2D NOESY experiments provide 
information about the proximity of protons through space. Protons that are within 5 Å of 
each other will generally give NOE cross-peaks which intensify as the distance between 
them is reduced. The solution conformation of the nucleotide was also determined by 
analysis of NOESY spectra. Figure 4.11 shows the 1H NMR spectrum of the 
palindromic oligonucleotide d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10)2. The assignment of 
the well resolved aromatic base resonances to adenosine, guanosine, cytidine or 
thymidine was straight forward.  
Base










Figure 4.11: The 1H NMR spectrum of the oligonucleotide d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10)2. 
 
The adenosine H8 proton resonances are found furthest down field due to experiencing 
only small ring current shifts from neighbouring bases.295 Guanosine H8 protons 
resonate further upfield in the 8.0 to 7.7 ppm range,296-298 along with the adenosine H2 
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protons which can be assigned from spin-lattice relaxation time (T1) measurements. 










Figure 4.12: An expansion of the 1H NMR spectrum used to assign chemical shifts of the adenosine H2 
protons. The AH2 peaks are negative due to their comparatively long T1 times. 
 
The adenosine H2 protons have significantly longer T1 than any of the other base 
protons.299 The cytidine and thymidine H6 proton resonances are found even further 
upfield between 7.65 and 7.1 ppm, with the cytidine H6 resonances being spin coupled 













Figure 4.13: An expansion of the aromatic proton resonance region of the 1H NMR spectrum of the 
palindromic oligonucleotide d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10)2. The resonances have been assigned to 
specific base types using well established methods and assigned unambiguously by their NOESY 
connectivity. 
 
Once the assignment of the base resonances to a specific base type has been made, the 
assignment of each resonance to a specific base in the decamer can be established 
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utilising well documented procedures. For a right handed duplex, each aromatic H8 and 
H6 should exhibit an NOE to its own H1′ and H2′/H2′′ protons and on the sugar of the 


























Figure 4.14: A diagrammatical representation of the connectivity observed between the H8 of adenosine 
and its own H1′ and H2′/H2′′ protons, and on the sugar of the nucleotide in the 5′ direction (in this case 
thymidine). 
 
By following the line of connectivity (starting from G1) it was possible to establish the 
exact assignment for each base H8/H6 and sugar H1′ proton in the DNA sequence. The 
assignments were made without the assumption of a right handed duplex because the 
base sequence was already known. For example, the H8 of A8 had two cross-peaks in 
the H1′ region (see Figure 4.15). One was shared by the H6 of a T base, the other by the 
H6 of a C base. Theoretically the sequence could have been 5′-CAT-3′ or 5′-TAC-3′, 
but only the 5′-CAT-3′ base sequence exists in the decamer and can thus be correctly 
assigned as such. Several other significant cross-peaks can be observed in Figure 4.14. 
These include small NOE cross-peaks between the A2 and A8 H2 protons to the H1′ 
protons of the nearest base in the 3′ direction (T3 and T9 respectively). Large NOE 
cross-peaks were also observed between the cytidene H6 and H5 protons (labelled as 
C5*, C7* and C10* in the spectrum) and weaker peaks between the cytidine H5 protons 
and the nearest base proton in the 5′ direction (circled in red). This NOE connectivity 
between protons on opposite nucleotide strands has been previously observed297,298 and 
can be used to help confirm the conformation of the DNA helix. Figure 4.15 shows an 
expanded plot of the NOESY spectrum relating the NOE connectivities between the 
base H8/H6 protons and the H1′ sugar protons. The sequential assignment pathway of 
the strand is displayed clearly, starting at the cross-peak between the G1H8 and G1H1′ 
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resonances (where F1 = 5.66 ppm, F2 = 7.92 ppm), and terminating at the cross-peak 
between C10H6 and C10H1′ (where F1 = 6.28 ppm, F2 = 7.64 ppm). 
 
Figure 4.15: An expansion of the 1H NOESY displaying the connectivity between the base H6/H8 
protons (F2 axis) and H1′ protons (F1 axis). Cross-peaks between the adenosine H2 protons and 
thymidine H1′ protons, and cytidine base and H5 protons are also labelled. Additional cross-peaks 
discussed in the text are circled in red. 
 
An extension of the sequential assignment strategy can be utilised for the assignment of 
the H2′ and H2″ sugar protons once the base and H1′ sugar proton resonances have been 
assigned. Figure 4.16 is an expansion of the NOESY spectrum displaying NOE cross-
peaks between base H8/H6 protons and sugar H2′/H2″ protons. Analysis of this region 
of the spectra is more complicated as each base proton displays connectivity to its own 
H2′ and H2″ protons as well as to the H2′ and H2″ protons of the sugar in the 5′ 
direction. Once the solution conformation has been determined it is generally a simple 
matter to assign which cross-peaks are due to the H2′/H2″ protons on the 5′ flanking 
sugar to their lower intensity (which is a function of the greater interproton distance 
when compared to the H2/H2 protons of the actual base). Additionally, cross-peaks 
were observed between the H8/H6 protons of the 5′ flanking base (A2 and A8 
respectively) and the thymidine CH3 protons of the T3 and T9 bases. The H2′/H2″ cross-
peaks of C10 are poorly resolved, appearing as a single broad peak at ~ 2.26 ppm, but 
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sequential assignment pathway of the first five H8/H6 and H2′/H2″ protons in the strand 
is displayed clearly, starting at the broad cross-peak between the C10H6 and C10H2′ and 
C10H2″ resonances (where F1 = 2.26 ppm, F2 = 7.64 ppm), and terminating at the cross-




Figure 4.16: An expansion of the 1H NOESY displaying the connectivity between the base H6/H8 
protons (F2 axis) and H2′/H2″ protons (F1 axis). Cross-peaks between thymidine base and CH3 protons 
are also labelled. Additional cross-peaks discussed in the text are circled in red. Only the first five sets of 
H2′/H2″ proton assignments are presented here, for the purposes of clarity. 
 
Analysis of the region displaying NOE connectivity between base H8/H6 protons to the 
H3′ sugar protons in the NOESY spectrum allows the assignment of the H3′ resonances 
to be made (Figure 4.17). The H4′ protons cannot be unambiguously assigned from the 
NOESY spectrum, though predictions can be made by analysis of their connectivity 
with the base H8/H6 proton resonances. The H5′ and H5″ protons generally cannot be 
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Figure 4.17: An expansion of the 1H NOESY displaying the connectivity between the base H6/H8 
protons (F2 axis) and H3′ protons (F1 axis). Cross-peaks between the thymidine base proton and the 
adenosine H3′ proton in 5′ direction are also visible. The cross-peak between the C10H6 and H3 proton is 
further upfield at 4.55 ppm on the F1 axis, and not shown here. 
 
The chemical shift assignments of the base and sugar protons of the decamer are 
summarised in Table 4.2, and are given in ppm. 
 
Table 4.2: A summary of chemical shift assignments for the base and sugar protons of the decamer d(G1-
A2-T3-G4-C5-G6-C7-A8-T9-C10)2 in ppm. 
                                 Base Protons                                          Sugar Protons 
 H8 H2 H6 H5 CH3 H1′ H2′ H2″ H3′ H4′ 
G1 7.92     5.66 2.56 2.74 4.85 3.7 
A2 8.33 7.97    6.32 2.76 2.98 5.05 4.2 
T3   7.12  1.39 5.76 2.05 2.44 4.87 4.2 
G4 7.82     5.85 2.58 2.68 4.97 4.15 
C5   7.26 5.27  5.67 1.98 2.38 4.98 4.15 
G6 7.86     5.86 2.60 2.72 4.96 4.15 
C7   7.33 5.37  5.61 2.10 2.42 4.97 4.15 
A8 8.29 7.70    6.25 2.66 2.92 4.92 4.15 
T9   7.24  1.46 6.02 2.06 2.46 4.84 4.55 














Chapter Four: DNA Binding Studies  116
4.3.2.2 NMR Binding Study of [Pt(terpy)(MPA)Cl] 
Figure 4.18 shows an expansion of the 1H NMR spectra of d(G1-A2-T3-G4-C5-G6-C7-A8-
T9-C10)2 upon addition of [Pt(terpy)(MPA)Cl] in a titration series, as well as the 









Figure 4.18: An expansion of the 1H NMR spectra of d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10)2 upon addition 
of [Pt(terpy)(MPA)Cl] in a titration series where; a, free decamer; b, 0.25:1; c, 0.50:1; d, 0.75:1 and e, 1:1 
metal complex/DNA base pair ratio.  
 
The apparent selective broadening of the G4, G6, C5, and C7 base resonances was 
immediately observed. The metal complex peaks also displayed a high degree of 
broadening, with the majority of peaks rendered unrecognisable. For example, the H6 
proton of the aromatic ligand, which was expected to give a resonance at ~ 9 ppm with 
distinctive platinum coupling, appears now as a broad peak between 8.85 and 8.75 ppm. 
Whilst this would complicate further analysis by 2D techniques, it is indicative of DNA 
intercalation with fast/intermediate exchange kinetics within the NMR timescale. An 
additional series of 1H experiments were performed to determine the optimum 
temperature for further 2D NOESY analysis, with the aim of increasing the resolution of 
the peaks. One dimensional proton NMR experiments were performed at temperatures 
between 2 oC and 60 oC, with the greatest resolution judged to be obtained at 35 oC 
(Figure 4.19), at which temperature the binding interaction appeared to still be occurring 
at a fast/intermediate rate of exchange.  




Figure 4.19: An expansion of the 1H NMR spectra of the monomer binding to d(G1-A2-T3-G4-C5-G6-C7-
A8-T9-C10)2 at a 1:1 ratio (metal complex/DNA base pair) at 35 oC. 
 
Several significant changes were observed in the 1D proton and NOESY spectrum of 
the oligonucleotide at the highest metal complex concentration. The metal complex 
peaks were subject to severe peak broadening indicating that intercalation is the primary 
binding interaction. Only the H6 and H5 resonances of [Pt(terpy)(MPA)Cl] were 
identifiable, as many of the metal complex peaks were no longer resolved and 
overlapped the broadened oligonucleotide resonances. Figure 4.20 displays an 
expansion of the NOESY spectrum displaying intramolecular NOE cross-peaks between 
protons on the intercalating ligand of the metal complex and the base H6/H8 and 
adenosine H2 protons. The cross-peak arising from the metal complex H6 resonance is 
assigned as the broad but well resolved at ~ 8.9 ppm, due to the expected chemical shift 
of this resonance. The peak displays connectivity to the broad peak at ~ 7.55 ppm which 
is assigned as H5. The H5 resonance displays shares a poorly resolved NOE cross-peak 
with a resonance at ~ 8.05 ppm which is assigned as H4. The cross-peaks between the 
multiple H4/H4′ and H3/H3′ resonances would be expected to appear in the boxed area 
of the spectrum in Figure 4.20. Clearly no further assignments can be made due to poor 
resolution, preventing the identification of other cross-peaks (circled in Figure 4.20) that 
may be due to the intramolecular connectivity of metal complex protons that have 
shifted upfield due to the DNA intercalation interaction, or intermolecular connectivity 
between metal complex and base proton resonances (and sugar protons in other regions 
of the spectrum) due to their proximity at the binding site. The sequential assignment 
pathway of the aromatic metal complex protons is displayed, starting at the broad cross-
peak between the metal complex H6 resonances (where F1 = 8.85 ppm, F2 = 8.85 ppm), 
continuing on to the H6/H5 cross-peaks as labelled in the figure, and terminating in the 
large mass of cross-peaks within the area boxed in red. 
 


















Figure 4.20: An expansion of the 1H NOESY displaying the connectivity between the base H6/H8 
protons and those of [Pt(terpy)(MPA)Cl after the addition of the metal complex in a 1:1 ratio (metal 
complex/DNA base pair) at 35 oC. The proton numbering scheme for [Pt(terpy)(MPA)Cl is provided 
above the spectrum. Equivalent protons are not numbered. 
 
There was also an apparent shift of the A8 H8 resonance so that it coalesced with the 
neighbouring A2 H8 peak, and a reduction in the intensity of the A2 and A8 H2 
resonances. The NOE cross-peaks between the base and H1 protons of A2 and A8 were 
no longer resolved in the NOESY spectrum, which in light of the 1H NMR data, was to 
be expected. The chemical shifts of the H1 protons of these bases were predicted using 
the position of cross-peaks belonging to the A2 and A8 H2 resonances, which were 
assigned through connectivity to the better resolved T3 and T9 base proton and H1 
resonances. In every case the intensity of the thymidine CH3 protons had increased 
considerably, suggesting that the interproton distance had reduced due to the binding 
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proton/H1 NOE cross-peaks was also observed (boxed in black in the Figure 4.21), 
coupled with a loss of resolution which may also be due to overlapping metal 
complex/H1′ cross-peaks, though this could not be confirmed. This is consistant with 
the preferred binding site predicitions made earlier, suggesting that the metal complex is 
intercalating between these base pairs preferentially. Assignment of the cytidine H6 
base proton and H1 resonances was achieved with the aid of connectivity to the cytidine 
H5 resonances, which were clearly resolved. Interestingly, it appeared that the the 
intensity of the cross-peak shared by C5H5 and G4H8, which is the nearest base proton 
in the 5′ direction (boxed in red in the Figure 4.21), cross-peak had been reduced. 
Whilst the sequential assignment pathway has been omitted in Figure 4.21 for the 
purposes of clarity, the resonances were assigned using methods identical to those 
depicted in Figure 4.15. 
 
 
Figure 4.21: An expansion of the 1H NOESY displaying the connectivity between the base H8/H6 
protons (F2 axis) and H1′ protons (F1 axis), and those of [Pt(terpy)(MPA)Cl after the addition of the 
metal complex in a 1:1 ratio (metal complex/DNA base pair) at 35 oC.  
 
There also appeared to be some NOE cross-peaks from the metal complex (possibly H4) 
resonances to the oligonucleotide H1′ resonances in the region dominated by G4, G6, C5 
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interacting within this region. No further intermolecular cross-peaks were observed. 
This apparent lack of NOE’s between the metal complex and DNA base pair resonances 
is probably a function of the molecules being in fast exchange with only a weak binding 
preference; they are not binding in any one place long enough for NOE cross-peaks to 
be observed. The selective broadening of the G4, G6, C5 and C7 peaks is evidence 
however that the molecules display some binding preferrance towards G and C base 
pairs. The loss of connectivity between some resonances also indicates that a minor 
change in the conformation of DNA had occurred due to the binding interaction, though 
the retention of the connectivity between base protons and their own H1 resonances, as 
well as the cross-strand connectivity of the A2H2 and A8H2 resonances, suggests that 
the B-DNA helical structure has been retained. Analysis of the changes in chemical 
shifts of the base and sugar proton resonances after the addition of the metal complex 
reveals the most significant changes occurring in the G4, G6, C5 and C7 components of 
the oligo, which is consistent with prior observations. The changes in chemical shift 
displaying the highest changes due to metal complex binding are the G4, G6 and C5 H1′ 
resonances, and the significant upfield shift of C5 andC7 H3′ resonances. The chemical 
shift assignments of the decamer, and the calculated changes in chemical shift, are 
summarised in Table 4.3 and Table 4.4 below. Assignment of the H4′ resonances was 
not possible due to poor resolution as a result of peak broadening. 
 
Table 4.3: A summary of chemical shift assignments for the base protons of the decamer d(G1-A2-T3-G4-
C5-G6-C7-A8-T9-C10)2 after addition of the metal complex in a 1:1 molar ratio. Values are given in ppm. 
Base Protons 
 H8 ∆ H2 ∆ H6 ∆ H5 ∆ CH3 ∆ 
G1 7.84 -0.08         
A2 8.28 -0.05 7.90 -0.07       
T3     7.08 -0.04   1.37 -0.02 
G4 7.78 -0.04         
C5     7.24 -0.02 5.22 -0.05   
G6 7.76 -0.10         
C7     7.32 -0.01 5.32 -0.05   
A8 8.32 +0.03 7.67 -0.03       
T9     7.20 -0.04   1.45 -0.01 
C10     7.65 +0.01 5.77 -0.01   
 
 
Chapter Four: DNA Binding Studies  121
Table 4.4: A summary of chemical shift assignments for the sugar protons of the decamer d(G1-A2-T3-
G4-C5-G6-C7-A8-T9-C10)2 after addition of the metal complex in a 1:1 molar ratio. Values are given in 
ppm. 
 Sugar Protons 
 H1′ ∆ H2′ ∆ H2″ ∆ H3′ ∆ 
G1 5.60 -0.06 2.47 -0.09 2.66 -0.08 4.85  
A2 6.26 -0.06 2.74 -0.02 2.94 -0.04 5.05  
T3 5.76  2.04 -0.01 2.40 -0.04 4.90 +0.03 
G4 5.78 -0.07 * * * * 4.95 -0.02 
C5 5.79 +0.12 2.02 +0.04 2.38  4.70 -0.28 
G6 5.78 -0.08 * * * * 4.95 -0.01 
C7 5.62 +0.01 2.04 -0.06 2.39 -0.03 4.70 -0.28 
A8 6.27 +0.02 2.69 +0.03 2.9 -0.02 5.05 +0.13 
T9 6.02  2.04 -0.02 2.43 -0.03 4.85 +0.01 
C10 6.28 -0.03 2.28 +0.02 2.28 +0.02 4.60 -0.05 
 
*The chemical shifts of these peaks could not be assigned due to peak broadness and poor resolution. 
 
The chemical shifts of the H2′ and H2″ resonances belonging to the G bases could not 
be determined due to the broadness of peaks and poor resolution, which indicates that 
the major binding interaction is occurring within close proximity to these protons. It was 
also of interest that the metal complex H6 protons displayed intramolecular connectivity 
to the thioalkyl linker protons in the NOESY spectrum whilst bound to DNA, but not in 
the NOESY experiment performed of the metal complex alone during its initial 
characterisation. This is probably due to the effect the binding interaction has on the 
tumbling rate and rigidity of the metal complex when bound, as compared to when it is 
free in solution, providing favourable conditions for this interaction to be observed. 
 
4.3.2.3 NMR Binding Study of [{Pt(terpy)}2(DMECA)]Cl2 
In a second titration series the oligonucleotide was titrated with the dinuclear species 
[{Pt(terpy)}2(DMECA)]Cl2. The apparent selective broadening of the C7, C5, G6 and 
G4 base resonances was observed at low metal complex concentrations, followed by the 
complete loss of resolution of all resonances due to peak broadening. The metal 
complex peaks also displayed a high degree of broadening. Whilst this would again 
complicate analysis by 2D techniques, it was indicative of strong DNA intercalation 
with fast/intermediate exchange kinetics within the NMR time scale. Figure 4.22 shows 
the 1H NMR spectra of d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10)2 upon addition of 
[{Pt(terpy)}2(DMECA)]Cl2 in a titration series, as well as the spectrum of the free 
decamer. 









Figure 4.22: An expansion of the 1H NMR spectra of d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10)2 upon addition 
of [{Pt(terpy)}2(DMECA)]Cl2 in a titration series where; a, free decamer; b, 0.25:1; c, 0.50:1; d, 0.75:1 
and e, 1:1 metal complex/DNA base pair ratio.  
 
An additional series of 1H experiments was performed to determine the optimum 
temperature for further 2D NOESY analysis, with the aim of increasing the resolution of 
the peaks. Higher resolution of the metal complex resonances was achieved at 
temperatures approaching 60 oC, but at these temperatures the structure of the duplex 
can revert to a base destacked single state (typically referred to as the DNA melting 
temperature), in which case the increase in resolution of the metal complex peaks may 
be due to its inability to interact by intercalating DNA in this form. The highest 
resolution at lower temperatures was judged to be obtained in reactions performed at 2 
oC (Figure 4.23). At this temperature the binding interaction appeared to occur at a slow 
rate of exchange (on the NMR timescale), with the appearance of multiple sets of 
sharper hexanucleotide and metal complex resonances and NOE cross-peaks. Even at 





Figure 4.23: An expansion of the 1H NMR spectrum of the dimer binding to d(G1-A2-T3-G4-C5-G6-C7-
A8-T9-C10)2 at a 1:1 ratio (metal complex/DNA base pair) at 2 oC. 
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Several significant changes were observed in the NOESY spectrum of the 
oligonucleotide at the highest metal complex concentration. The metal complex peaks 
were subject to severe peak broadening, indicating that intercalation is the primary 
binding interaction. Multiple intramolecular cross-peaks were observed between non-
equivalent H6/H12 resonances of the metal complex and H5/H13 resonances. Their also 
appeared to be a cross-peak to another metal complex resonance at ~ 8.5 ppm (this 
region is boxed in red in Figure 4.24), which at first was tentatively assigned as one or 
two H4/H14 protons. Connectivity between this resonance and the other metal complex 
resonances is not clear, precluding the empirical study of the DNA binding geometry of 
this compound. Another set of cross-peaks, which are likely to arise from intramolecular 
connectivity between unidentifiable metal complex peaks, are visible at ~ 6.9 ppm 







Figure 4.24: An expansion of the 1H NOESY displaying the connectivity between the base H8/H6 
protons and those of [{Pt(terpy)}2(DMECA)]Cl2 after the addition of the metal complex in a 1:1 ratio 
(metal complex/DNA base pair) at 2 oC. The proton numbering scheme for [Pt(terpy)(MPA)Cl is 
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The cross-peaks shared by the thymidine and adenosine base and H1′ protons appeared 
to coalesce, preventing the unambiguous assignment of these peaks. There appeared to 
be multiple sets of cross-peaks related to the connectivities of the H6, H8 and H1′ 
protons of G4, G6, C5 and C7. Additionally, the connectivity between the H1′ of G4, G6, 
C5 and C7 and the H8/H6 protons of the neighbouring 5′ base was no longer clear, 
preventing them from being assigned with any degree of confidence. For example the 
A8H8 base proton does not share a well resolved cross-peak with any of the protons of 
C7. This also precluded the accurate assignment of the G4, G6, C5 and C7 base protons, 
which was previously based on this connectivity. A prediction of the connectivity 
between these resonances based on weak and poorly resolved NOE cross-peaks is 
presented in Figure 4.25, with the correlation between the cross-peaks provided in red. 
An NOE for the base proton predicted to be C5 and its H5 resonance was observed, 
though no NOE was observed for the equivalent C7 protons, suggesting that the 
interproton distance between the C7H8 and C7H5 had increased due to the binding 
interaction of the metal complex. Conversely, the NOE for the C10 base proton and 
C10H5 appeared to be more intense, suggesting that the interproton distance had 
decreased. There was also no connectivity between the CH5 resonances and the next 
guanodine base proton in the 5′ direction (circled in red in Figure 4.25). These changes 
in the connectivity of the resonance peaks suggests a significant change in the 
conformation of the DNA helix at the binding site of the metal complex, though the 
consistant connectivity between the other base protons and their own H1 resonances 
suggests that the B-DNA conformation of the helix is retained. Interestingly, there also 
appeared to be an intermolecular NOE cross-peak between the metal complex H4 
resonance at ~ 8.5 ppm to the T9H1′ resonance (with the connectivity represented as a 
black line in Figure 4.25), though considering the uncertainty in the assignment of the 
metal complex peaks this cannot be confirmed. As mentioned previously, the predicted 
sequential assignment pathway of the strand is provided in Figure 4.25 in red, starting at 
the cross-peak between the A8H8 and C7H1′ resonances (where F1 = 5.55 ppm, F2 = 
8.30 ppm), and terminating at the cross-peak between T3H6 and T3H1′ (where F1 = 5.64 
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Figure 4.25: An expansion of the 1H NOESY displaying the connectivity between the base H6/H8 
protons (F2 axis) and H1′ protons (F1 axis), and those of [{Pt(terpy)}2(DMECA)]Cl2 after the addition of 
the metal complex in a 1:1 ratio (metal complex/DNA base pair) at 2 oC.  
 
Multiple NOE cross-peaks between the bridging linker and H6 protons of the metal 
complex were observed, but not in the NOESY experiment performed of the metal 
complex alone during its initial characterisation. This again is probably due to the effect 
the binding interaction has on the tumbling rate and rigidity of the metal complex when 
bound, as compared to when it is free in solution, providing favourable conditions for 
this interaction to be observed. Interestingly, the metal complex resonance at ~ 8.5 ppm, 
which had initially been assigned as one or more of the H4/H14 protons of the 
intercalating ligand, also shared intense cross-peaks with the protons of the bridging 
ligand (with the connectivity represented as a black line in Figure 4.26). This suggested 
that these aromatic peaks may in fact be a second set of H6/H12 resonances that have 
shifted upfield by 0.7 ppm, possibly due to the shielding effects caused by DNA 
intercalation. The metal complex peak at ~ 8.5 ppm displayed connectivity with the 
thymidine CH3 resonances (with the connectivity represented as a black line in Figure 
4.26), which is consistant with the apparent connectivity between this peak and the 
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uncertainty remains due to the extremely poor resolution observed throughout the 
binding study of this molecule. 
 
Figure 4.26: An expansion of the 1H NOESY displaying the connectivity between the base H8/H6 
protons and H2′/H2″ protons (in red), and intramolecular proton connectivity of the metal complex (in 
black). Only the first four sets of H2′/H2″ proton assignments are presented here, for the purposes of 
clarity. 
 
The chemical shift assignments of the decamer and the calculated changes in chemical 
shift are summarised in Table 4.5 and Table 4.6 below.  
 
Table 4.5: A summary of chemical shift assignments for the base protons of the decamer d(G1-A2-T3-G4-
C5-G6-C7-A8-T9-C10)2 after addition of the metal complex in a 1:1 molar ratio. Values are given in ppm. 
Base Protons 
 H8 ∆ H2 ∆ H6 ∆ H5 ∆ CH3 ∆ 
G1 7.86 -0.06         
A2 8.30 -0.03 7.90 -0.07       
T3     7.24 +0.12   1.36 -0.03 
G4 7.66* -0.16         
C5     7.42* +0.16 5.26* -0.01   
G6 7.74* -0.08         
C7     7.38* +0.05 *    
A8 8.30 +0.01 7.62 -0.08       
T9     7.24    1.42 -0.04 
C10     7.59 -0.05 5.78 -0.12   
*The chemical shifts of these peaks could not be assigned, or were made difficult, due to peak broadness, 
poor resolution and reduced connectivity. 
Metal complex cross peaks 
between H6/H12 and bridging linker 
(H7, H8, H10, H11) resonances 
Alternate H6/H12  
cross peaks 
Cross peaks between 
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Table 4.6: A summary of chemical shift assignments for the sugar protons of the decamer d(G1-A2-T3-
G4-C5-G6-C7-A8-T9-C10)2 after addition of the metal complex in a 1:1 molar ratio. Values are given in 
ppm. 
Sugar Protons 
 H1′ ∆ H2′ ∆ H2″ ∆ 
G1 5.65 -0.01 * * * * 
A2 6.23* -0.09 * * * * 
T3 5.64 -0.12 2.02 -0.03 2.43 -0.01 
G4 6.02* +0.17 * * * * 
C5 5.52* -0.15 * * * * 
G6 5.80* -0.06 2.56* -0.04 2.62* -0.10 
C7 5.55* -0.06 2.18* +0.08 2.41* -0.01 
A8 6.23* -0.02 2.62 -0.04 2.88 -0.04 
T9 5.97 -0.05 2.02 -0.04 2.43 -0.03 
C10 6.22 -0.04 2.22 -0.04 2.26 -0.04 
*The chemical shifts of these peaks could not be assigned, or were made difficult, due to peak broadness, 
poor resolution, and reduced connectivity. 
 
Analysis of the changes in chemical shifts of the base and sugar proton resonances, after 
the addition of the metal complex, reveals that significant changes have occurred in 
most of the oligo resonances. The chemical shifts of the H2′ and H2″ resonances 
belonging to the G1, G4, A2 and C5 bases could not be determined due to the existence 
of multiple sets of peaks, the broadness of those peaks and overall poor resolution. This 
is probably due to several phenomena including; the slow rate of exchange, the 
existence of multiple bound and unbound species and weak base pair selectivity of the 
metal complex. Some of the resonances and cross-peaks may again be due to a covalent 
interaction between metal complex degradation products that had formed during the 
course of the NMR experiments. The sum of all these interactions and conditions 
produces a very complex 2D spectrum that is exceedingly difficult to interpret. 
 
4.3.3 Cytotoxicity 
The influence of dimerisation to form a bisfunctional metallointercalator on cytotoxicity 
was examined against L1210 murine leukemia cells (Table 4.7).  
Table 4.7: The cytoxicity of the novel complexes [Pt(terpy)(MPA)]Cl and dimer against the L1210 
murine leukemia cell line. 





As expected, the dimer [{Pt(terpy)}2(DMECA)]Cl2 was more active against the cell line 
than the monomeric [Pt(terpy)(MPA)]Cl species. 
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4.4 CONCLUSIONS  
A careful study was made on the effects of experimental technique on the results 
obtained in the DNA binding study of [Pt(terpy)(MPA)]Cl by CD, due to the irregular 
nature of the spectra obtained. Variation of results due to pipetting and mixing 
technique was found to be insignificant across the series of experiments attempted in 
this study, eliminating experimental error as a major variable. Several different cuvettes 
deemed suitable for use in CD work were utilised and found to have little impact on the 
results of the experiment. The concentration of both the ligand and the DNA were 
increased to reduce the noise/signal ratio, though this caused other problems due to the 
limitations of the detector; there is an upper limit of absorbtion after which the CD 
spectrum obtained may no longer yield accurate data. The titration samples were left to 
equalibriate for between two and ten minutes, again causing no appreciable differences 
in the CD spectra obtained. The final spectral series used in this study was obtained by 
averaging the results of three experiments performed on consecutive days with the same 
cuvette and mixing technique.  
 
The DNA binding interactions of [Pt(terpy)(MPA)]Cl are most likely to involve partial 
intercalation and hydrogen bonding through the carboxylic acid component, which may 
also prevent complete intercalation. The perturbations in the DNA conformation due to 
this binding interaction appear minor, though an increase in the ICD spectrum was 
observed at 220 nm. A binding curve was obtained at this wavelength and analysis of 
the binding strength using the Intrinsic and Scatchard methods revealed an equilibrium 
binding constant of 4.3 × 105. The binding site size was consistent with the predicted 
size based on the assumed binding mode and the nearest neighbour exclusion principle.  
 
In comparison, the compound [{Pt(terpy)}2(DMECA)]Cl2 appeared to have a very 
strong interaction with DNA, causing significant changes in the CD spectrum of ct-
DNA in a non-uniform manner. This is probably a function of the bis-intercalating 
mode of binding, though it may also be related to a change in the DNA conformation or 
the intercalation of a secondary binding site. Significant changes in the ICD spectrum 
were observed at ~ 214.6, 247.4 and 275.6 nm. The increase of the peak at 214.6 nm 
over the course of the titration series was the most uniform in nature and judged to be 
the most suitable for further analysis. Analysis of the DNA binding strength of the 
dimer [{Pt(terpy)}2(DMECA)]Cl2 at 214.6 nm by the Intrinsic and Scatchard methods 
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revealed an equilibrium binding constant of 9.7 × 105, more than double that of the 
monomeric species. The binding site size was consistent with the predicted size based 
on the assumed binding mode and the nearest neighbour exclusion principle. A 
summary of relevant values obtained from this process is presented below in Table 4.8.  
Table 4.8: The values obtained for α (a function of wavelength), K (the equilibrium binding constant), nI 
(size of the binding site determined using the Intrinsic method) and nS (size of the binding site determined 
using the Scatchard method) 
 
Compound α K nI nS 
[Pt(terpy)(MPA)]Cl 7.0×10-6 4.3×105 2.23 2.00 
[{Pt(terpy)}2(DMECA)]Cl2 1.0×10-6 9.7×105 4.65 3.89 
 
The equilibrium binding constant obtained for these molecules was higher than the 
compounds described by Lowe and co-workers, which achieved K values between 0.23 
and 2 × 105.219 
 
Analysis of the titration data pertaining to [{Pt(terpy)}2(DMECA)]Cl2 was also 
performed using the methods and software described by Stootman et al.277 This allowed 
the apparent binding strength at various wavelengths to be obtained rapidly. Whilst the 
binding site size determined using this method (at 214.6 nm) was consistent with the 
previously determined values, the apparent K value was approximately an order of 
magnitude higher (1.15 × 107). This is a function of the way the different methods fit 
the data to their governing mathematical model. 
 
The compound [Pt(terpy)(MPA)]Cl was tested for cytotoxicity against the L1210 
murine leukaemia cell line and found to be inactive, with an IC50 >50. The dinuclear 
complex formed by the coupling of the two mononuclear species, 
[{Pt(terpy)}2(DMECA)]Cl2, was tested for cytotoxicity against the L1210 murine 
leukaemia cell line and found to be moderately active, with an IC50 of 10. As predicted 
by the results of the prior DNA binding studies by both CD and NMR, the dimer species 
displayed much higher cytotoxicity than its mononuclear parent species. This can be 
attributed to several characteristics, including its higher charge leading to increased 
DNA binding affinity. The significant perturbations to the native CD spectra of DNA 
caused by the addition of the dimer is also indicative of the formation of a more 
damaging adduct when compared to the monomer. 
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An attempt was made to characterise the binding mechanism of both 
[Pt(terpy)(MPA)]Cl and [{Pt(terpy)}2(DMECA)]Cl2 by performing a 1H NMR binding 
study with the custom synthesised oligonucleotide d(G1-A2-T3-G4-C5-G6-C7-A8-T9-
C10)2. The proton resonances for the base and sugar protons of the decamer were 
unambiguously assigned using well established methods. The analysis of 2D spectra 
depicting the through-space connectivity of protons on the oligo and the metal complex 
at a molar ratio of 1:1 was hampered by peak broadening and a general loss of 
resolution. The data obtained suggests that both compounds have some base pair 
binding preference to C and G binding sites, but will bind other sites readily at higher 
concentrations. Whilst significant broadening and shifting of the metal complex peaks is 
consistant with intercalation being the major binding interaction involved; shifts to the 
G base and sugar protons and the existence of multiple sets of resonances may be due to 
a covalent interaction caused by the binding of metal complex degradation products. 
Additionally, the apparent NOE cross-peaks between the metal complexes and the 
oligonucleotide resonances are not reliable enough for the establishment of accurate 
binding geometry data.  
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CHAPTER FIVE: SOLID PHASE SYNTHESIS 
 
5.1 INTRODUCTION 
The synthesis of organic molecules by solid phase was first conceived by Merrifield in 
1959.301 He proposed that if a peptide was bound to an insoluble support then excess 
reagents could be used in any subsequent reaction, driving it towards completion, with 
any unreacted material removed in a simple washing procedure. This would allow for 
faster synthetic preparations and a revolutionary degree of automation. This method 
required each individual step to be quantitative in yield to avoid racemisation, resulting 
in the development and strenuous testing of a limited set of synthetic techniques. Two 
reliable methods emerged which encompassed the same basic concepts, the use of a 
resin support, excess reagents and synthesis in the C → N terminal direction. They 
differed in the nature of the amine protecting group used to limit racemisation. The resin 
supports were designed to swell in the reaction solvent, providing an environment akin 
to a solvated gel, as opposed to a rigid particle, affording the reagents easy access to the 
growing polypeptide. Excesses of reagents were used during the elongation process in 
order to assure near quantitative yields and to reduce reaction times. By synthesising in 
the C → N terminal direction racemisation could be limited by the use of protecting 
groups, which suppress the reactivity of the amine group on the incoming activated 
peptide unit. Ideal protecting groups would display electron withdrawing capability, or 
introduce sufficient steric hindrance to the immediate reaction environment to prevent 
further activity. Two general methods were therefore developed, differing in the nature 
of the amine protecting group used, and therefore the mode of deprotection and resin 
cleavage. Both solid phase methods were found to be useful for the routine preparation 
of polypeptides with molecular weights up to five thousand, including functional 
proteins,302-304 and are equally valid for either the addition of one residue at a time 
(stepwise synthesis) or the coupling of larger peptide sequences (fragment 
condensation). 
 
5.1.1 Merrifield Synthesis 
Of the two predominant methodologies, “Merrifield Synthesis” was characterised by the 
use of tert-butyl (Boc) as temporary amino protecting groups for the N-terminus, 
combined with the orthogonal benzyl and substituted benzyl protection of side chains. 
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The Boc protecting group is obtained from tert-butoxycarbonyl anhydride, which reacts 
in high yields and can be stored and routinely handled safely, unlike the corresponding 
azide alternative which had been utilised previously. Boc removal is achieved by 
treatment with TFA (either neat or in a DCM solution) at room temperature. The tert-
butyl group decomposes under these conditions to form isobutene and CO2, both of 
which are easily removed under vacuum. A scheme for the protection of an amine with 
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Figure 5.1: A general model of Boc protection. The amino acid (2) is treated with the Boc anhydride (1) 
to provide the Boc protected derivative (3). Subsequent deprotection by treatment with TFA yields the 
original amino acid as a protonated trifluoro salt (4), liberating isobutene (5) and CO2. 
 
As a result of this sensitivity the use of mineral acids are avoided during acidification 
and acid wash procedures, in favour of citric or formic acid. The solid supports typically 
utilised in this method was a chloromethylphenyl substituted resin, with the first amino 
acid attached through substitution of the chloride by the caesium salt of the Boc-
protected amino acid. Other resins used for Boc based solid-phase synthetic procedures 
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Figure 5.2: Typical resins used for Boc based machine assisted procedures; 1, 4-
methylbenzylhydrylamine resin (MBHA);305 2, p-nitrobenzophenone oxime resin;306-308 3, 
hydroxymethylphenylacetamidomethyl resin (Pam);309,310 4, 3-nitro-4-hydroxymethylbenzoyl resin; 5, (4-
bromocrotonyl)aminomethyl resin.311 
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A typical procedure would involve the deprotection of the first amino acid by treatment 
with a 20-50% solution of trifluoroacetic acid (TFA) in dichloromethane, followed by 
neutralisiation of the resulting ammonium salt with a hindered tertiary base. The next 
amino acid could then be coupled to the growing peptide with the aid of additives and 
coupling agents, and the cycle repeated. Upon completion of the reaction scheme, the 
final product could be obtained from the resin using strong acids, usually hydrogen 
fluoride,312 trifluoromethane sulphonic acid313-315 or trimethylsilyl 
trifluoromethanesulfonate.316,317 This also served to remove any benzyl based side chain 
protecting groups. This method requires the use of specialised apparatus and techniques 
due to the highly acidic conditions employed. There are other resins, both available and 
under development, that require alternative cleavage conditions that are still compatible 
with Boc based procedures.  
 
5.1.2 Fmoc Based Polyamide Synthesis 
The repetitive use of TFA during the peptide chain elongation cycles and the use of 
strong hazardous acids during the final cleavage step of Boc based solid phase synthesis 
led to the development of a milder technique, based on the Nα-9-
fluorenylmethoxycarbonyl (Fmoc) protecting group.318-320 The Fmoc protecting group is 
obtained from the stable chloroformate or succinamide ester. Unlike Boc, Fmoc is stable 
under acidic conditions, but can be swiftly cleaved under certain basic conditions, such 
as 20% piperidine in DMF. Cleavage occurs via the production of 
dibenzocyclopentadienide anion, with the dibenzofulvine produced reacting with 


















Figure 5.3: A general model for cleavage of the Fmoc protecting group. The Fmoc protected amino (1) 
acid is treated with 20% piperidine (2), yielding the unprotected amino acid (3), carbon dioxide and 
dibenzofulvene (4). 
 
Fortunately, the terminal amines of the substrates used during the elongation process are 
unable to induce cleavage or react with dibenzofulvene to a significant extent. Therefore 
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the utilisation of the Fmoc protecting group in this synthetic strategy allows the use of 
far milder deprotection and cleavage conditions without decreasing the yield of the 
reaction by increased side reactions or racemisation. Side chains of the peptide are 
generally orthogonally protected with tert-butyl based groups, which are cleaved in a 
single step along with the resin linkage by TFA in the presence of scavengers. These 
reactions are often performed under continuous flow conditions, whereby the reagents 
are allowed to pass through the reaction chamber containing the resin supported 
polypeptide. The reagents can then be recirculated back through the chamber again or 
removed as waste. This procedure allows the resin to be washed clean of excess 
reagents and non resin bound side products. This in turn drives each reaction step 
towards completion in accordance with Le Chatelier’s principle. In addition to this the 
reaction solution can be passed through a UV detector during deprotection to monitor 
the release of the Fmoc chromophore. The most common resins for Fmoc solid phase 










Figure 5.4: Some commonly used resins in Fmoc based machine assisted protocols; 1, 
hydroxymethylphenoxymethyl resin (Wang resin); 2, 2-chlorotrityl chloride resin (Trt(2-Cl); 3, 4-(α-
amino-2′,4′-dimethoxybenzyl)phenoxymethyl resin. 
 
Hydroxymethylphenoxymethyl resin (Wang resin)321,322 and 2-chlorotrityl chloride resin 
(Trt(2-Cl) are used for the preparation of peptide C-terminal acids and 4-(α-amino-2′,4′-
dimethoxybenzyl)phenoxymethyl resin323 is used to produce peptide C-terminal amides. 
Peptides that are synthesised on Wang or Trt(2-Cl) resin are obtained in the final 
cleavage step by treatment with a solution containing TFA with additional cation 
scavengers. In the case of Trt(2-Cl), the resin utilised in this project, the polypeptide can 
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be released by treatment with a solution of acetic acid, trifluorethanol (TFE) and 
dichloromethane (DCM),324-326 or reagent containing 0.5% TFA or 
hexafluoroisopropanol solution. As with Boc based solid phase synthesis, various 
polymers consisting of a wide variety of matrixes, linkers, and spacers displaying 
different reactivity profiles are available. 
 
5.1.3 The Synthesis of Sequence Selective Polyamides on Solid Phase 
The development of solid phase peptide synthesis provided a great opportunity for 
researchers investigating the properties of sequence selective polyamides. Whilst the 
DNA base pair affinity and optimal 2:1 motif had been determined from the study of 
simple molecules, the actual implementation of the base pairing rules and design 
principles were hampered by the difficulties in synthesising the more complex 
molecules. Even the solution phase synthesis of the polyamide distamycin and its 
analogues was considered difficult.327-330 The multiple heterocycles were linked by 
peptide bonds that were formed from the coupling of aromatic carboxylic acids with 
aromatic amines. The limitations of this scheme were manifold. Primarily, the aromatic 
acid is prone to decarboxylation, and the aromatic amines are air and light sensitive.331 
The reactive intermediates involved (acid chlorides and trichloro ketones) and the long 
reaction times necessary for sufficient coupling only served to exacerbate the problems 
caused by these instabilities.332,333 In order to fully explore the capabilities of these 
molecules to bind to large designated target sites with pharmacologically relevant 
selectivity, researchers required a far more efficient method for synthesising these large 
and complex molecules. Early attempts to synthesise sequence selective polyamides by 
machine assisted protocols focused on Boc based synthetic schemes.157 For this 
purpose, two monomeric building blocks were developed; Boc-Py-OBt activated 
ester334 and Boc-Im-acid,335 with synthetic optimisation focusing on the elimination of 
chromatography steps that had proven to be low yielding and time consuming in 
previous studies.163,334-338 The reactions typically utilised Boc-β-alanine-PAM resin as 
the solid support media, after a study that examined the influence of resin structure on 
the success of the reaction. It was found that the incorporation of the short aliphatic 
amino acid β-alanine maximised the degree of substitution, and provided sufficient 
yields of the target molecule upon completion of the standard cleavage procedure 
involving aminolysis of the resin ester linkage.157 Attempts to isolate the polyamide by 
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direct aminolysis of heterocycles coupled directly to the solid support (not via a β-
alanine component) were unsuccessful.157 The methods pertaining to resin linkage, 
heterocyclic ring coupling, and cleavage required a high degree of optimisation, as well 
as the development of a rapid and accurate method for monitoring the success of these 
reactions whilst still on the solid support. The individual reaction times for the coupling 
procedures where found to be longer than the equivalent solution phase procedure using 
the same reagents and protocols, which can be attributed to a reduced level of access to 
reaction sites caused by the solid support gel environment when compared to a fully 
solvated system. The overall reaction time was much shorter, however, due to the 
elimination of the multiple collection and purification steps. Machine assisted protocols 
have also been developed for the synthesis of sequence selective polyamides utilising 
Fmoc based schemes.158 The milder conditions employed in such schemes are far more 
compatible for use in conjunction with automated peptide synthesisers, which are 
expensive to maintain. Development of these methods required new schemes for the 
production of suitably protected monomers Im and Py,158,339,340 which were then used to 
synthesise a large library of sequence selective polyamides displaying various 
functionalities and motifs. The first was ImPyPyPy-γ-PyPyPyPy-β-Dp, and the 
analogue ImPyPyPy-γ-ImPyPyPy-β-Dp (Figure 5.5), which were obtained with superior 









































Figure 5.5: The general structure of two concept molecules, ImPyPyPy-γ-PyPyPyPy-β-Dp (where Z = 
CH) and ImPyPyPy-γ-ImPyPyPy-β-Dp (where Z = N) used in the initial Fmoc based solid phase 
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The reactions were performed on Fmoc-β-alanine-WANG resin, utilising a previously 
successful HBTU/DIEA ring activation system.157 Reaction times were either shorter or 
equal to the equivalent Boc based reaction, typically 180 min per residue. Interestingly, 
it was observed that the deprotected imidazole did not react sufficiently with the Fmoc-
Py-OBT activated ester, requiring the use of a different activation system involving 
DCC and DMAP in DCM. After this modification each coupling step achieved >99% 
yield, followed by 79% recovery from the aminolysis based resin cleavage procedure. 
The relatively facile synthesis of complex hairpin polyamides afforded by these new 
methods greatly expanded the scope of functionality in this family of compounds. It also 
increased the rate at which new designs could be implemented and tested for structure 
activity relationships, which led to the proposal of alternative motifs that improved upon 
the benchmark set by hairpin polyamides. These motifs provided new synthetic 
challenges for the solid phase chemists, and would have been nearly impossible to 
obtain using traditional solution phase techniques. For example, development began on 
a new family of sequence selective polyamides that, unlike the γ-turn linear chain 
hairpins, were connected by flexible polymethylene chains across central ring pairs in 



















































Where n = 4, 5, 6, 7 or 8
n
 
Figure 5.6: The general structure for a family of H-pin sequence selective polyamides. 
 
The branched nature of these H-pin molecules made synthesis on solid phase 
problematic. The difficulties encountered in the development of these new methods 
were eventually overcome by the use of an appropriate catalyst for the formation of the 
cross-chain linkage by alkene metathesis, and careful manipulation of the inert support 
reaction environment. This scheme also involved the synthesis of several novel 
monomeric building blocks (Figure 5.7), each of which incorporated alkene components 
Chapter Five: Solid Phase Synthesis  138
suitable for metathesis of various lengths. An 
incremental study of the relationship between linker 
length and binding affinity revealed that the optimal 
space between the two chains was six methylene 
units, displaying the highest affinity for its target 
DNA sequence.345-347 Solid phase synthesis of these 
molecules begins as described previously, with the 
first heterocycle being coupled to the resin bound 
amine, followed by the stepwise additions of 
activated esters to the deprotected resin bound amine 
at the end of the elongating chain. This is followed, at 
some point, by the addition of the cross-link capable monomers, which are then linked 
via olefin based metathesis using a ruthenium benzylidene catalyst,348,349 a method that 
had already been proven in the solution phase synthesis of dimeric molecules,350,351 and 
the solid phase synthesis of complex natural products.352-356 Unintentional cross-linking 
reactions on solid support systems have been demonstrated, and have caused 
complications in the synthesis of large peptide fragments. To circumvent this, resins 
with lower substitution rates (0.05-0.2 mmol/g) and a high degree of cross-linking 
divinylbenzene (10-20%) were employed to minimise the possibilities of interactions 
between the individual peptide chains. The strategy employed in the synthesis of H-pin 
polyamides maximises these interactions, utilising PAM resins with low degrees of 
cross-linking divinylbenzene (~ 1%) and high loading (0.88-1.2 mmol) with a 
dichloromethane solvent system to promote maximum swelling of the resin.357 After the 
cross-linking procedure the elongation of the now linked peptide chains continues as it 
had previously, through the standard deprotection and coupling cycles. Final cleavage is 
achieved by treatment with N,N-[(dimethylamino)propyl]amine (DP).357 The sequence 
selectivity these H-pin polyamides was found to be competitive with equivalent hairpin 
polyamides, without resorting to the incorporation of a γ-turn to formalise the head-to-
tail motif.357 This is important as the γ-turn in hairpin polyamides is inherently specific 
to A/T binding sites, which negatively impacts on the targeting of GC rich binding sites. 
Future development of this family of compounds is focused on the replacement of DP as 








Where n: 1, 2 or 3
Figure 5.7: The general structure for a 
family of novel monomeric building 
blocks, developed specifically for the 
synthesis of H-pin polyamides by 
machine assisted protocols. 
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5.1.4 Metal Complex Incorporation on Solid Phase 
Recent efforts in our lab have focused on the synthesis of trans-DDP based 
metallopolyamides partially or completely by solid phase.171 In the case of the latter 
reactions, the trans-DDP species is introduced whilst the polyamide is still attached to 
the inert support; greatly improving the yield of the reaction due to the higher molar 
equivalents of reagent employed and simplified purification. A small family of 


























































































Figure 5.8: The novel trans-DDP based polyamides HLSP-6 (1) and HLWC-8 (2).171 
 
The formation of HLWC-8 was achieved by the condensation of two tetra-peptide 
segments which were synthesised rapidly using machine assisted protocols. The free 
amine was obtained by OH-anion exchange followed by coordination to trans-DDP. 
Activation of trans-DDP by AgNO3 was also employed in this work, as a result of the 
difficulties encountered during the experiments described in this thesis. A more 
ambitious scheme was used for the synthesis of HLSP-6, whereby the product was 
achieved in high yield by coordination of the platinum complex on solid phase. 
Unfortunately these compounds displayed very poor water solubility. Both HLWC-8 
and HLSP-6 are only soluble in DMF and DMSO, and degrade rapidly in the latter.171 
This has complicated the study of the biological activity and binding studies of these 
molecules. 
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5.1.5 Chapter Five Objectives 
Considering the significant difficulties encountered in the solution phase synthesis of 
the polyamide, and subsequent coordination to [Pt(terpy)Cl]Cl, in this work, a novel 
strategy was conceived whereby the entire target molecule could be assembled rapidly 
on solid phase using standard peptide coupling techniques. A new 
terpyrideneplatinum(II) based complex, [Pt(terpy)(MPA)]Cl, was synthesised 
specifically for this purpose, along with an Fmoc protected Py monomer suitable for 
machine assisted procedures. The components were successfully combined in a step-
wise fashion on solid phase, producing the first in a new family of 
terpyridineplatinum(II) based polyamides. 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Reagents 
1-Methylimidazole-2-carboxylic acid (99.5%) was purchased from Bachem. N-
Methylpyrrole (99%), sodium tert-butoxide (97%), anhydrous tert-butyl alcohol 
(99.9%) were purchased from Alfa Aesar. Ninhydrin was purchased from Ajax. 10% 
Palladium on charcoal, piperidene (99.5%) and N,N-diisopropylethylamine (99.5%) 
were purchased from Sigma-Aldrich Chemical Company. (9H- 
Fluoren-9-yl)methyl chloroformate (Fmoc.Cl) and Fmoc-β-alanine (99+%) were 
purchased from Fluka. 2-Chloro-chlorotrityl resin (100-200 mesh) and 2-(1H-
benzotriazole-1-YL)-1,1,3,3-tetramethyluroniumhexaflourophosphate (HBTU) was 
purchased from Auspep. 2,2,2-Triflouroethanol, 99+% was purchased from Reagent 
Plus. All other reagents and solvents were used as received unless otherwise stated. 
Dimethylsulfoxide (d6-, 99.9%), dimethylformamide (d7-, 99.9%) and deuterium oxide 
(d2-, 99.9%) were purchased from Cambridge Isotope Laboratories.        
 
5.2.2 General Methods 
Reactions were monitored by TLC using 0.25 mm thick pre-coated UV sensitive silica 
gel plates. Compounds were visualised with short-wave ultraviolet light at 254 nm. 
Flash chromatography was carried out using Kieselgel 60 (230-400) mesh. Routine 1H 
NMR spectra were recorded on a 300 MHz Varian Unity plus. 2D NOESY spectra were 
recorded on a Bruker Avance 400 MHz NMR spectrometer. The probe was matched, 
tuned, and the 90o pulse measured before all experiments. 2D NOESY spectra were 
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acquired with 2048 data points in F2, 512 increments and 16 scans, with a 10 ppm 
spectral width. Commercially available deuterated solvents were used and referenced to 
the residual solvent peak. The following abbreviations apply to spin multiplicity: s 
(singlet), bs (broad singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Mass 
spectra were obtained at the Mass Spectrometry Laboratory at the University of 
Wollongong, NSW, Australia. tert-Butyl-4-nitro-N-methyl-pyrrole-2-carboxylate (16) 
was synthesised using an adaptation of the method described by Wurtz et al.158 See 
Appendix A, B and H for related data. 
 
5.2.3 Machine Assisted Synthesis 
Machine assisted synthesis was performed on a Protein Technologies Symphony Quartet 
peptide synthesiser, using custom deprotection and coupling programs. Manual addition 
involved setting the solvent column as “none” within the program, setting the volume as 
“7 units” (the program does not give the option of “0 units”), pausing the operation at 




5.3.1 Preparation of Fmoc-β-Ala-Chlorotrityl Resin 
2-Chloro-chlorotrityl resin (0.5 g, 0.5 mmol) was suspended in anhydrous DCM (5 mL). 
Seperately, Fmoc-β-alanine (0.156 g, 0.5 mmol) in anhydrous DCM (4 mL) and DIEA 
(0.348 mL, 2 mmol) was stirred for 5 min. The Fmoc-β-Ala-COOH solution was added 
to the resin suspension and shaken for 5 h. Methanol (2.5 mL) was added and the 
mixture was shaken for 30 min. The resin was collected by filtration, washed with DCM 
and dried under vacuum overnight. The resin (0.56 g, 44% yield, 0.44 mmol/g loading) 
was used without further characterisation. 
 
5.3.2 Preparation of the Pyrrole Monomer 
 
5.3.2.1 tert-Butyl 4-nitro-N-methyl-pyrrole-2-carboxylate (16) 
To a suspension of compound 3 (19.71 g, 0.07 mol) in tert-butyl alcohol (210 mL) was 
added sodium tert-butoxide (9.85 g, 0.11 mol) over 1 h. The reaction was heated at 
reflux under nitrogen for 5 h, quenched with water (200 mL) and extracted with 
chloroform (3 × 200 mL). The solvent was removed to obtain compound 16 (14.98 g, 
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92% yield) as yellow crystals. 1H NMR 300 MHz (d6-DMSO): δ 8.19 (d, 1H, J = 1.8 




To a solution of compound 16 (9.50 g, 0.04 mol) in DMF (50 mL) was added 10% Pd/C 
(1 g) in DMF (10 mL). The mixture was vigorously stirred overnight under hydrogen 
(36 psi) and then filtered through celite and rinsed with DMF (80 mL). Fmoc.Cl (11.90 
g, 0.05 mol) and DIEA (16.60 mL, 0.10 mol) were added and the solution stirred 
overnight under nitrogen. The DMF was evaporated under reduced pressure and water 
(125 mL) added. The mixture was extracted with diethyl ether (2 × 200 mL), dried 
using anhydrous magnesium sulphate and the diethyl ether concentrated to ~ 150 mL 
under reduced pressure. Hexane (200 mL) was added and the solution left in the fridge 
for 3 h. The resultant brown precipitate was filtered and washed with cold 
methanol/water (1:1) to yield the product as a white solid (4.61 g, 26% yield). 1H NMR 
300 MHz (d6-DMSO): δ 9.38 (bs, 1H), 7.89 (d, 2H, J = 7.4 Hz), 7.69 (d, 2H, J = 7.6 
Hz), 7.41 (t, 2H, J = 7.0 Hz), 7.32 (t, 2H, J = 7.5 Hz), 6.90 (s, 1H), 6.60 (s, 1H), 4.41 (d, 
2H, J = 6.9 Hz), 4.28 (t, 1H , J = 6.9 Hz), 3.74 (s, 3H), 1.43 (s, 9H). 
 
5.3.2.3 4-[(9-Fluorenylmethoxycarbonyl)amino]-N-methylpyrrole -2-carboxylic 
acid (Fmoc-Py-COOH, 18) 
Compound 17 (5.00 g, 0.01 mol) was dissolved in DCM (100 mL) and cooled to 0 oC. 
TiCl4 (25 mL, 1 M in DCM) was added dropwise and the mixture stirred for 30 min at 0 
oC under nitrogen. Cold HCl (250 mL) was added dropwise and the precipitate was 
collected by vacuum filtration and washed with cold water to yield the product as a 
white solid (3.80 g, 88% yield). 1H NMR 300 MHz (d6-DMSO): δ 9.38 (bs, 1H), 7.89 
(d, 2H, J = 7.4 Hz), 7.71 (d, 2H, J = 7.6 Hz), 7.41 (t, 2H, J = 7.0 Hz), 7.32 (t, 2H, J = 
7.5 Hz), 7.02 (s, 1H), 6.61 (s, 1H), 4.41 (d, 2H, J = 6.9 Hz), 4.28 (t, 1H, J = 6.9 Hz), 
3.74 (s, 3H). Anal. Calc’d for C21H18N2O4: C, 69.60; H, 5.01; N, 7.73; found: C, 69.60; 
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5.3.3 Synthesis of [Pt(terpy)S(CH2)2NH-β-Ala-Py-Py-Py-β-Ala-COOH]Cl (19) 
  
5.3.3.1 Washing and Deprotection of Fmoc-β-Ala-Chlorotrityl Resin 
Fmoc-β-ala-chlorotrityl resin was washed and prepared for coupling to the first pyrrole 
ring using the following step-wise program on a solid phase synthesiser (Table 5.1).   
 
Table 5.1: The resin washing and deprotection program. 
Step Solvent Volume (Units)* Time** Drain Repetitions 
1 DCM 7 00:00:30 Yes 1 
2 DMF 7 00:00:30 Yes 1 
3 20 % Piperidine 7 00:03:00 Yes 1 
4 20% Piperidine 7 00:17:00 Yes 1 
5 DMF 7 00:00:30 Yes 1 
6 DCM 7 00:00:30 Yes 1 
7 DMF 7 00:01:00 Yes 2 
*The term “unit” is provided by the manufacturer of the solid phase apparatus, and equates to 
approximately 1 mL. **Time is given in the general form of HH:MM:SS 
 
5.3.3.2 Activation and Coupling of the First Pyrrole Component  
Fmoc-Py-COOH (0.18 g, 0.50 mmol) and HBTU (0.18 g (0.48 mmol) were dissolved in 
DMF (5 mL). DIEA was added (0.26 mL, 1.5 mmol) and the mixture shaken for 5 min. 
The solution was added to the drained and deprotected resin by manual addition and 
mixed under nitrogen for 3.5 h. The resin was drained in preparation for further 
elongation through deprotection of the new amino terminus.  
 
5.3.3.3 Deprotection of the Fmoc-Py-β-Ala-Chlorotrityl Resin 
Fmoc-Py-β-ala-chlorotrityl resin was washed and deprotected for coupling to the second 
pyrrole ring using the following stepwise program on a solid phase synthesiser (Table 
5.2). 
 
Table 5.2: The deprotection program for Fmoc-py-β-ala-chlorotrityl resin. 
Step Solvent Volume (Units) Time Drain Repetitions 
1 DCM 7 00:00:30 Yes 1 
2 DMF 7 00:00:30 Yes 1 
3 20 % Piperidine 7 00:03:00 Yes 1 
4 DMF 7 00:00:30 Yes 1 
5 20% Piperidine 7 00:03:00 Yes 1 
6 DMF 7 00:00:30 Yes 1 
7 DCM 7 00:00:30 Yes 1 
8 DMF 7 00:01:00 Yes 2 
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5.3.3.4 Activation and Coupling of the Second Pyrrole Component  
Fmoc-Py-COOH (0.18 g, 0.50 mmol) and HBTU (0.18 g, 0.48 mmol) were dissolved in 
DMF (5 mL). DIEA was added (0.26 mL, 1.5 mmol) and the mixture shaken for 5 min. 
The solution was added to the drained and deprotected resin by manual addition and 
mixed under nitrogen for 3.5 h. The resin was drained in preparation for further 
elongation through deprotection of the new amino terminus.  
 
5.3.3.5 Deprotection of the Fmoc-Py-Py-β-Ala-Chlorotrityl Resin  
This was achieved using the procedure described in Section 5.3.3.3. 
 
5.3.3.6 Activation and Coupling of the Third Pyrrole Component  
Fmoc-Py-COOH (0.18 g, 0.50 mmol) and HBTU (0.18 g (0.48 mmol) were dissolved in 
DMF (5 mL). DIEA was added (0.26 mL, 1.5 mmol) and the mixture shaken for 5 min. 
The solution was added to the drained and deprotected resin by manual addition and 
mixed under nitrogen for 3.5 h. The resin was drained in preparation for further 
elongation through deprotection of the new amino terminus.  
 
5.3.3.7 Deprotection of the Fmoc-Py-Py-Py-β-Ala-Chlorotrityl Resin  
This was achieved using the procedure described in Section 5.3.3.3. 
 
5.3.3.8 Activation and Coupling of the Fmoc-β–Ala Spacer 
Fmoc-β-alanine (0.31 g, 1 mmol) and HBTU (0.36, 0.96 mmol) were dissolved in DMF 
(5 mL). DIEA (0.52 g, (3 mmol) was added and the mixture shaken for 5 min. The 
solution was added to the drained and deprotected resin by manual addition and mixed 
under nitrogen for 3.5 h. The resin was drained in preparation for deprotection and the 
addition of the platinum species. 
 
5.3.3.9 Deprotection of the Fmoc- β –Ala-Py-Py-Py-β-Ala-Chlorotrityl Resin 
This was achieved using the procedure described in Section 5.3.3.3. 
 
5.3.3.10 Activation and Coupling of [Pt(terpy)(MPA)]PF6 
[Pt(terpy)(MPA)]PF6 (0.34 g, 0.5 mmol) was dissolved in DMF (5 mL) as a PF6 salt. 
HBTU (0.18 g, 0.48 mmol) and DIEA (0.26 mL, 1.5 mmol) were added and the mixture 
shaken for 5 min. The solution was added to the drained and deprotected resin by 
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manual addition and mixed under nitrogen for 5 h. The final compound was washed 
thoroughly on the resin using the regime outlined in Table 5.3. 
 
Table 5.3: The final washing program for compound 19, in preparation for resin cleavage. 
Step Solvent Volume(Units) Time Drain Repetitions 
1 DMF 7 00:00:30 Yes 10 
2 DCM 7 00:00:30 Yes 5 
3 Brine* 7 00:03:00 Yes 3 
4 H2O** 7 00:00:30 Yes 5 
5 DCM 7 00:03:00 Yes 1 
6 H2O** 7 00:00:30 Yes 5 
7 DCM 7 00:00:30 Yes 5 
*Brine was added by manual addition. This was achieved by setting the solvent column as “none” within 
the program, setting the volume as “7 units” (the program does not give the option of “0 units”), pausing 
the operation at the start of 3 and manually adding 7 mL of brine. The automated program was then 
resumed. **H2O was added by manual addition in steps 4 and 5, using the method described for brine. In 
addition to this the H2O was heated to between 50 oC and 60 oC, prior to the addition, to aid in dissolving 
NaCl left over from the brine wash.  
 
5.3.3.11 Cleavage of the Final Product 
A solution of DCM (4.2 mL), trifluoroethanol (TFE, 1.2 mL) and acetic acid (0.6 mL) 
was added to the resin and the mixture shaken gently for 1.5. The resin was filtered and 
washed with TFE:DCM (1:4, 6 mL). The purple filtrate was collected and the solvent 
was evaporated under reduced pressure to provide a dark purple solid. Yield: (0.205 g, 
87%). Anal. Calc’d for C42H50Cl3N11Na2O10PtS: C, 40.41; H, 4.04; N, 12.34; found: C, 
40.36; H, 4.06; N, 12.09. 
 
5.4 RESULTS AND DISCUSSION 
Whilst synthesis via solution phase techniques involves elongation through the 
carboxylic acid terminal of the growing peptide chain, and catalytic hydrogenation of 
each successive monomer as it is added, the solid phase procedure requires elongation 
through the amine terminal. This is achieved by hydrogenation prior to the coupling 
procedure, and temporary protection of the newly formed amine group. The Fmoc 
protecting group was used in this study, as the mild deprotection conditions are more 
suitable for machine assisted synthesis. Subsequent hydrolysis to form the carboxylic 
acid terminal produces a heterocyclic monomer suitable for incorporation in a peptide 
elongated by solid phase techniques. The entire reaction scheme, including the solid 
phase synthesis steps, is provided in Figure 5.9. 
 
















h) 18, HBTU, DIEA
i) 20% Piperidene
j) 18, HBTU, DIEA
k) 20% Piperidene
l) 18, HBTU, DIEA
q) TFE, acetic acid, DCM
m) 20% Piperidene
n) Fmoc- B -Ala-COOH, 
HBTU, DIEA
o) 20% Piperidene




a) tert-butyl alcohol 
b) sodium tert-butoxide
c) 10% Pd/C, DMF, H2(g)
d) Fmoc.Cl, DIEA



















































































































Figure 5.9: The reaction scheme for the synthesis of the terpyridineplatinum(II) based polyamide 19. 
Steps a-f involve the conversion of the previously synthesised heterocycle 3 to the Fmoc protected 
carboxylic acid 18 in a three part procedure. Each cycle of monomer addition involves an automated 
Fmoc removal step, achieved by treatment with 20% piperidine in DMF. This is followed by the manual 
addition of the next heterocycle or amino acid component, which has been activated with HBTU and 
DIEA in preparation for coupling. Steps g-p are performed under a nitrogen atmosphere. The resin is 
washed thoroughly with DCM and DMF using an automated program, before a manual wash with brine 
and water prior to the final cleaving procedure (q). 
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5.4.1 Preparation of the Fmoc Protected Pyrrole Monomer 
 









Figure 5.10: Conversion of compound 3 to a tert-butyl ester. 
 
Compound 3 was rapidly converted to a tert-butyl ester in tert-butyl alcohol, without the 
aid of an acid catalyst, due to the strong reactivity of the trichloroacetyl group (Figure 
5.10). Sodium tert-butoxide was added to the reaction mixture to neutralise the 
subsequent HCl formed during the conversion. The yield of the reaction was 
considerably higher in reactions where the sodium tert-butoxide was first dried in an 
oven at 100 oC overnight before use. 
 












Figure 5.11: Catalytic hydrogenation and Fmoc protection of compound (16). 
 
The hydrogenation of compound 16 was performed in DMF, with the addition of 10% 
Pd/C, instead of methanol which is more commonly used for this type of reaction 
(Figure 5.11). The aim of this was to reduce the handling time required for the 
subsequent Fmoc protection step, which also utilises a DMF solvent system. The 
mixture was vigorously stirred overnight under hydrogen (36 psi) using an automated 
hydrogenation apparatus. This reduced the reaction time, which can be long due to the 
inefficiency of hydrogenation in DMF at atmospheric pressure compared to the 
traditional methanolic solvent system under the same conditions. The reaction mixture 
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was filtered through celite and rinsed with DMF. Fmoc.Cl and DIEA were added and 
the solution stirred overnight under nitrogen. The solvent was evaporated under reduced 
pressure and the product extracted from water with diethyl ether. The product was dried 
over anhydrous magnesium sulphate and the diethyl ether concentrated under reduced 
pressure. Precipitation of the pure product was achieved by the addition of hexane, 
which was collected by filtration and washed with copious amounts of a cold 
MeOH/H2O solution (1:1). The product was obtained as a white solid in relatively low 
yield (26%). 
 












Figure 5.12: Lewis acid catalysed hydrolysis of the tert-butyl ester. 
 
The Lewis acid catalysed hydrolysis of compound 17 was achieved in high yield using 
the reagent TiCl4 in a 1 M solution with DCM (Figure 5.12). The hazardous nature of 
the vigourous reaction was minimised by performing the dropwise addition of the TiCl4 
solution cautiously and at 0 oC under nitrogen. Acidification with cold HCl yielded the 
product as a white precipitate, which was collected by vacuum filtration and washed 
with cold water to yield the pure product. The proton labelling scheme for compound 18 


















Figure 5.13: The proton labelling scheme of compound 18. Equivalent protons are not numbered. 
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The protons in the 1H NMR spectrum of the product (Figure 5.14) were assigned with 
the aid of 2D NOESY experiments. The singlet furthest upfield (3.74 ppm) in the 1H 
spectrum of compound 18 integrates for three protons, and was immediately assigned as 
H10. The triplet at 4.28 ppm integrates for one proton and can be assigned as H5. 
Similarly the doublet at 4.41 ppm integrating for can be assigned as H6. As expected by 
the molecular structure both H5 and H6 display connectivity to each other in the 
NOESY spectrum, with a coupling constant of 6.9 Hz observed for both resonances. 
Both H5 and H6 display connectivity with the doublet at 7.71 ppm which integrates for 
two protons, which is assigned as H4. From the assignment of H4 the rest of the protons 
on the Fmoc protecting group can be assigned sequentially. The peak assigned as H4 
displays connectivity to the triplet peak at 7.32 ppm, which integrates for two protons, 
and is assigned as H3. H3 displays connectivity to the adjacent triplet at 7.41 ppm, 
which also integrates for two protons, and is assigned as H2. The remaining doublet that 
integrates for two protons at 7.89 ppm is therefore assigned as H1, and displays 
connectivity with the peak assigned as H2 as expected. The two remaining peaks in the 
1H spectrum integrate for only one proton each, and are due to the protons of the 
heterocycle labelled H8 and H9. The peak at 7.02 ppm displays connectivity with the 
methyl resonance H10, and is assigned as H9 due to the proximity of these two protons 
in the molecular structure of compound 18. The remaining peak is thus assigned as H8. 
The peak at 9.38 ppm displays connectivity with the aromatic protons H4, H8 and H9, 
and can therefore be assigned as the amido proton H7. The final broad peak, the furthest 










Figure 5.14: An expansion of the 1H spectrum of compound 18 in d6-DMSO at 35 oC showing the proton 
assignments. 
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Figure 5.15: Preparation of the Fmoc-β-ala-chlorotrityl resin. 
 
Fmoc-β-ala-chlorotrityl resin was prepared from the commercially available 2-chloro-
chlorotrityl resin, for use as a solid support in further machine assisted synthetic 
processes (Figure 5.15). Chlorotrityl chloride resin was chosen due to the superior 
results described in the literature, in preference to the more traditional WANG resin. 
Taleb et al. have hypothesised that nitrogen containing heterocycles react with WANG 
resin to form a diketopiperizine that prevents further substitution or elongation.171 The 
resin was left to swell in anhydrous DCM whilst Fmoc-β-Ala-OH was activated in 
anhydrous DCM by the base DIEA. The Fmoc-β-Ala-OH solution was added to the 
resin suspension and shaken using a mechanical agitator for 5 h. Methanol was added 
and the reaction mixture shaken for a further 30 min to cap any unreacted positions on 
the resin. The reaction length in this last step was found to be critical to the success of 
the preparation, as after a period of 30 min the yields of substituted resin dropped 
dramatically. The resin was collected by filtration, washed with DCM and dried under 
vacuum overnight. The new resin loading amount was determined using the method 
outlined in Appendix L. 
 


























Figure 5.16: The chemical structure of 19, a terpyridineplatinum(II) based polyamide synthesised using 
machine assisted protocols. 
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Following the failure of solution phase methods to yield the target metallopolyamides, 
an attempt was made to incorporate the novel molecule [Pt(terpy)(MPA)]PF6 (15) into a 
polyamide via purely solid phase techniques (Figure 5.16). The reaction was performed 
on a 0.22 mmol scale, with coupling of the heterocyclic rings, β-alanine units and 
[Pt(terpy)(MPA)]PF6 achieved by standard peptide coupling procedures utilising a 
HBTU/DIEA activation system. The final product was washed thoroughly with DMF 
and DCM whilst still on the solid support, until the reaction vessel consistently drained 
as a colourless solution. The resin was then washed manually with copious amounts of 
brine to convert the complex to a chloride salt. Cleavage of the final product was 
achieved using TFE and acetic acid, yielding a dark purple coloured solution. The 
solvent was removed under reduced pressure and the product dried under vacuum. 
Attempts to dissolve the resulting solid in deuterated solvents (D2O, d4-MeOH, d3-
ACN, d7-DMF and d6-DMSO) for characterisation by 1H and 195Pt NMR were 
unsuccessful. Attempts were made to dissolve the compound in D2O with the addition 
of deuterated hydrochloric acid (DCl), to ensure that the product was a positively 
charged molecule and not a neutral deprotonated species, without any success. The 
application of heat and sonication had no positive effect on this process. Elemental 
analysis of the solid suggests that the target metallopolyamide had been successfully 
synthesised in high yield with residual NaCl from the brine washes and waters of 
crystallisation, though its lack of solubility in even the strongest organic solvents (such 
as DMSO) prevented any further biological or DNA binding assays being performed.  
 
5.5 CONCLUSIONS 
In this work the use of solid phase techniques was shown to simplify the coupling and 
purification processes, though preparation of the monomeric starting materials required 
more elaborate schemes. Synthesis of the Fmoc protected pyrrole monomer required 5 
synthetic steps, as opposed to the 3 step reaction scheme of the monomer used in 
solution phase synthesis (Chapter 2), though the methods for both synthetic schemes are 
now well established and high yielding. The coupling procedure itself is far more 
efficient using the solid phase technique, with the elimination of all chromatographic 
purification steps in favour of a simple automated resin wash, which can be repeated as 
required prior to cleavage of the final product. As purification of the polyamide 
intermediates constituted a significant stumbling block in the schemes described in this 
work, complete synthesis by solid phase was determined to be the most effective 
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method for the synthesis of metallopolyamides. Additionally, the novel method in 
which the platinum(II) centre was incorporated by standard peptide coupling techniques 
appears to have been successful, where traditional platinum coordination methods had 
failed. 
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CHAPTER SIX: CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
In this study an attempt was made to incorporate the novel terpyridineplatinum(II) based 
synthon [Pt(terpy)(MPA)]+ into a polyamide using solid phase peptide coupling 
techniques. The target molecule was designed to be a synergistic platinum(II) complex, 
which has the potential to display both DNA sequence selectivity and cytotoxicity 
afforded by a DNA intercalating moiety. After the development of robust methods for 
the synthesis of the monomeric starting materials, synthesis of the final compound (19) 
appeared to be achieved within 72 hours, compared to the many months of development 
required to produce a molecule of similar complexity by solution phase methods. 
Furthermore, the incorporation of the metal complex on solid phase avoided 
chromatography steps that had troubled earlier work. Unfortunately, the 
metallopolyamide developed in this work was found to be highly insoluble, precluding 
further structural and biological characterisation, apart from elemental analysis which 
suggested the success of the procedure. 
 
A number of solution phase methods for the synthesis of this type of molecule were 
explored in Chapter Two. The solution phase synthesis of a suitable polyamide ligand 
was successful, though extensive re-evaluation of the reaction conditions and 
purification methods were required at every step of the reaction scheme, as the 
solubility and reactivity of the compound changed as it elongated. Attempts to 
coordinate [Pt(terpy)Cl]Cl through the free amine of this ligand failed under a wide 
range of reaction conditions, requiring the development of an alternative method of 
platinum incorporation. 
 
In response to this, two sulfur containing terpyridineplatinum(II) complexes synthesised 
in Chapter Three, [Pt(terpy)(AET)]+ and the novel [Pt(terpy)(MPA)]+. These molecules 
were specifically chosen for use as peptide coupling synthons in both solution and solid 
phase reaction schemes. As a “proof of concept” the two mononuclear platinum(II) 
species were coupled together using standard peptide procedures, to give the novel 
complex [{Pt(terpy)}2(DMECA)]2+, the first in a new family of polyamido bis-
intercalators. Both [Pt(terpy)(MPA)]+ and [{Pt(terpy)}2(DMECA)]2+ were characterised 
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by a combination of 1H and 195Pt NMR, ESI-MS and elemental analysis. Crystals of 
[Pt(terpy)(MPA)]+ were also obtained and studied by x-ray crystallography, revealing 
an interesting stacking and packing arrangement induced by AgCl. This led to an 
improvement of the synthetic procedure which eliminated this impurity. 
 
The DNA binding properties of both [Pt(terpy)(MPA)]+ and [{Pt(terpy)}2(DMECA)]2+ 
were explored by CD and 2D 1H NMR techniques in Chapter Four. Both ct-DNA and a 
custom synthesised decamer oligonucleotide were utilised. [Pt(terpy)(MPA)]+ was 
found to cause minor conformational changes in DNA upon binding with a very weak 
preference for G and C base pairs. Additionally, [Pt(terpy)(MPA)]Cl displayed little 
cytotoxicity when tested against the L1210 murine leukemia cell line. In contrast, the 
dinuclear [{Pt(terpy)}2(DMECA)]2+ found to cause significant conformational changes 
in DNA upon binding with a very weak preference for G and C base pairs. It also 
displayed a five fold increase in cytotoxicity when tested against the L1210 murine 
leukemia cell line, when compared to parent complex [Pt(terpy)(MPA)]Cl. 
 
Finally, the metal complex [Pt(terpy)(MPA)]+ was successfully incorporated into an N-
methylpyrrole based polyamide using solid phase methods in Chapter Five. The 
addition of each heterocyclic ring was performed by established machine assisted in a 
rapid manner, and the product was successfully cleaved from the inert support using 
TFE and acetic acid. The poor water solubility of the product (19) is a major hurdle that 
must be addressed in second generation molecules, in order to explore the anticancer 
properties of this new family of agents. 
 
6.2 Recommendations 
Strategies for the further development of the incorporation of terpyridineplatinum(II) 
into sequence selective polyamides by solution phase techniques should focus on the re-
investigation of coordination by amino ligands. If successful, this would provide 
compounds with higher charges that may display greater solubility in water. 
Unfortunately, while the use of a sulphur donating ligand was necessary in this study, it 
reduced the overall charge of the resultant complexes which had a negative impact on 
their water solubility. Other novel methods should also be explored, such as the 
coordination of platinum using π-organometallic chemistry, whereby [Pt(terpy)Cl]Cl is 
coordinated orthogonally to the plane of a suitably functionalised arene ring. This 
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method has been demonstrated in other studies, and may provide a novel method of 
metal complex incorporation into sequence selective polyamides. Additionally, whilst it 
was not possible during the time frame of this study, the complexes [Pt(terpy)(AET)]+  
and [Pt(terpy)(MPA)]+ can be incorporated into polyamides using standard solution 
phase peptide coupling procedures. Several of the intermediates synthesised in Chapter 
Two would be suitable for such a procedure (Figure 6.1), though purification of the final 





























































































Figure 6.1: Two possible synthetic schemes for the synthesis of terpyridineplatinum(II) based sequence 
selective polyamides using compounds explored in Chapter Two and Three of this study. 
 
In order to address solubility issues, the polyamide component of the final compound 19 
can be modified by the incorporation of more water soluble components. Further 
substitution of the terpyridene ligand in various positions may also increase solubility. 
Additionally, the positive charge can be spread across the compound by the strategic 
addition of more platinum centres. A current investigation within our research group is 
focusing on the productions of trans-DDP based synthons (Figure 6.3) designed 
specifically for incorporation on solid phase that would make this achievable.  










Figure 6.2: A trans-DDP based Fmoc protected complex under investigation as a synthon for solution 
and solid phase chemistry. 
 
Further development of this family of compounds should also focus on the synthesis of 
hairpin polyamides, which can be achieved by the addition of an aminobutyric acid 
linker (γ) to the design of the molecules. The γ turn linker formalises the register of the 
ring pairings, preventing the formation of “slipped dimers” which alter the recognition 
of the molecule away from its intended target.  
 
Once a water soluble terpyridineplatinum(II) based polyamide has been synthesised 
binding properties of these interacalators can be studied again by CD, though it may be 
even more difficult to obtain empirical data. With both an intercalating and groove 
binding component, and the ability to form informal dimers in solution, it can be 
predicted that at least two, and possibly four, different binding mechanisms will be 
observed during such an experiment. Binding of the polyamide ligand to the minor 
groove of DNA would cause the appearance of DNA-induced ligand CD bands at about 
300-360 nm. More specifically, positive induction at ~ 320 nm is due to the UV 
absorption π to π* transition of the polyamide binding in the minor groove of the 
platinum-DNA complex.358-360 Quantifying the binding affinity and strength of such 
molecules will require far more elaborate mathematical techniques than were employed 
in this study.  
 
An increase in the DNA base pair affinity, afforded by the incorporation of a sequence 
selective polyamide component, would be expected to improve the results of two 
dimensional 1H DNA binding experiments. The 1H NOESY experiments of the 
intercalating species in this study showed that the terpyridineplatinum(II) intercalating 
moiety has very little base pair selectivity, so would not be expected to compete with 
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the sequence selectivity of the polyamide component. Assuming that the 
oligonucleotide contains a suitable target sequence, the complex would be expected to 
bind with high selectivity and affinity as an informal bis-interacalating species. The 
improvement in selectivity afforded by the polyamide component should allow the 
exact binding geometry of the complex to be determined, and as it has been shown in 
this study, the bis-intercalating mode of binding should provide the complex with 
greater cytotoxicity profiles. Additional experiments such as DNA footprinting would 
also help to characterise the DNA base sequence affinity of the complex. 
 
Future work should focus on confirming intercalation as the primary mode of binding 
for both [Pt(terpy)(MPA)]+ and [{Pt(terpy)}2(DMECA)]2+ by duplex melting 
experiments using the oligonucleotide d(G1-A2-T3-G4-C5-G6-C7-A8-T9-C10)2. The 
intercalation of DNA is typically characterised by an increase in the melting 
temperature of the helix,361 which can be monitored by UV-vis spectroscopy and 
analysed using well established methods. This phenomenon is due to the stabilising 
effect that intercalation has on the conformation of DNA,361 whereas covalent binding 
destabilises the helix causing the melting temperature to decrease.361  
 
NMR studies utilising pulse gradient spin echo (PGSE) techniques can also be used to 
further characterise the DNA binding and intermolecular stacking interactions of these 
compounds, as well as any metallopolyamides synthesised in future projects. PGSE 
(also referred to as diffusion-ordered spectroscopy, or DOSY) is a common method for 
measuring the diffusion of molecules in solution, and can provide information of the 
DNA binding interactions of drugs.362-365 The theory behind using diffusion 
measurements to analyse such interactions is based on the ability to separate different 
species based on their diffusion coefficient, which will change as molecules interact 
closely.364  
 
The binding preference of [Pt(terpy)(MPA)]+ and [{Pt(terpy)}2(DMECA)]2+ to 
quadruplex DNA, a commonly observed conformation adopted by telomeres, can also 
be analysed by ESI-MS techniques.366 Binding to such structures is thought to be 
governed by π-π interactions,367 and may provide a route for the inhibition of the 
telomerase enzyme. As previously mentioned in Chapter One, telomerase maintains the 
length of telomere sequences, and is expressed in 85% of cancer cells.368 
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Development of the dinuclear species [{Pt(terpy)}2(DMECA)]2+ has already begun, 
with an investigation into the affect of increasing the length between the two DNA 
binding platinum centres by the incorporation of one or more amino acids to the 
structure. This can be easily achieved on solid phase by the addition of amino acids to a 
suitable solid support, followed by the addition of the activated ester species of 
[Pt(terpy)(MPA)]+, cleavage from the resin, and the final solution phase addition of 
[Pt(terpy)(AET)]+ by standard coupling procedures. In this manner the length, and type, 
of connecting chain can be systematically varied using solid phase methods (Figure 
6.2). There is virtual no limit to the combination of amino acids that could be utilised to 
achieve this, each capable of effecting the solubility, binding strength, affinity, and 
cytotoxicity of the molecule. This would also serve to introduce various degrees of 
chirality to the compound, depending on the types of amino acids used. This would also 












































2) HBTU, DIEA, Fmoc-ß-alanine
5) TFE, acetic acid, DCM
6) HBTU, DIEA, [Pt(terpy)(AET)]ClO4 (13) 
in DMF under N2
3) 20% Piperidine/DCM
4) HBTU, DIEA, [Pt(terpy)(MPA)]PF6 (14) 
in DMF under N2
 
Figure 6.3: A proposed reaction scheme for the machine assisted synthesis of a 
[{Pt(terpy)}2(DMECA)]Cl2] analogue that has been increased in size by the addition of two central β-
alanine units. 
 
The development of the metal complex [Pt(terpy)(MPA)]+ and its use as a synthon in 
peptide synthesis provides an alternative strategy for the incorporation of DNA binding 
platinum moieties into sequence selective polyamides. Hopefully this will lead to the 
development of more active sequence selective drugs in the future which are suitable for 




APPENDIX A: CHEMICAL DATA 
 
Table A.1: The chemical formulas and molecular weights of the compounds synthesised in this study. 















































































































































































































Figure B.5: 1H NMR spectrum of the protonated form of 4-(1-methylimidazole-2-carboxyamido)-N-methylpyrrole-2-carboxylate (4), obtained at 35 oC in  
























Figure B.6: The 1H NMR spectrum of 4-(1-methylimidazole-2-carboxyamido)-N-methylpyrrole-2-carboxylate (5), obtained at 35 oC in d6-DMSO and 

















Figure B.7: The 1H NMR spectrum of 4-(1-methylimidazole-2-carboxyamido)-N-methylpyrrole-2-carboxylic acid (6), obtained at 35 oC in d6-DMSO and 
















Figure B.8: The 1H NMR spectrum of methyl-4-[4-(1-methylimidazole-2-carboxyamido)-N-methylpyrrole-2-carboxyamido]-N-methypyrrole-2-carboxylate (7), obtained at 



















Figure B.9: The 1H NMR spectrum of methyl-4-[methyl 4-(1-methylimidazole-2-carboxyamido)-N-methylpyrrole-2-carboxyamido]-N-methypyrrole-2-carboxylic  































Figure B.11: The 1H NMR spectrum of tert-butyl-6-{4-[4-(1-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxyamido]-N-methylpyrrole-2-

































Figure B.12: 1H NMR spectrum of  6-{4-[4-(1-methylimidazole-2-carboxamido)-N-methylpyrrole-2-carboxyamido]-N-methylpyrrole-2-carboxamdo}hexylamine (11), 

















































































































































Figure B.21: The 1H NMR spectrum tert-butyl 4-[(9-fluorenylmethoxycarbonyl)amino]-N-methylpyrrole-2-carboxylate (17), obtained at 35 oC in d6-DMSO  

























Figure B.22: The 1H NMR spectrum of 4-[(9-fluorenylmethoxycarbonyl)amino]-N-methylpyrrole-2-carboxylic acid (18), obtained at 35 oC in d6-DMSO and  




















Figure C.3: The 195Pt spectrum of [Pt(terpy)(MPA)]Cl obtained at 25 oC in D2O and refenced to a 




Figure C.4: The 195Pt spectrum of [{Pt(terpy)}2(DMECA)]Cl2 obtained at 25 oC in D2O and refenced to a 
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APPENDIX D: TITRATION DATA 
 
Titration Data for the Equilibrium Study of ImPyPy.HCl 
 
Table D.1: Titration Data 
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Equation 15 demonstrates how Ka of the protonated species was determined from the 





=aK   (15) 
Where [H3O+] = the concentration of hydronium ion 
           [A-] = the concentration of dissociated ImPyPy.HCl salt 
           [HA] = the original concentration of the ImPyPy.HCl salt 
 
It can be assumed that x== −+ ][A]OH[ 3 , due to the insignificant concentration of 
hydronium ions formed by the self hydrolisation of H2O. 
 







  (16) 
Where x = 10(-pH) = 10-1.55 = 0.028 M 
 
2106.1 −×=∴ aK  







x   (17) 
 
Thus the ionisation percentage is 37%.  Additionally, the pKa for this compound can 
also be easily calculated from the –log of Ka, giving a value for pKa of 1.78.
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APPENDIX E: SYNTHESIS OF COMPOUND 20  
 
E.1 Preparation of trans-chlorodiammine-N-[tert-butyl 6-aminohexylcarboxamide] 
platinum(II) chloride (20)  
Trans-DDP (0.20 g, 0.67 mmol) in DMF (9 ml) was added AgNO3 (0.10 g, 0.6 mmol) 
in DMF (1 mL) and the solution stirred in the dark overnight. The mixture was passed 
through a 0.45 um cartridge filter, and to the green solution was added tert-butyl 6-
aminohexylcarboxamide (10, 0.071 g, 0.33 mmol ) in DMF (5 mL). The solution was 
stirred in the dark overnight and the solvent removed under reduced pressure. Acetone 
was added and the mixture cooled at 4 oC overnight. The crude, pale yellow, solid was 
collected by filtration and recrystallised from methanol to yield the pure white 






















Figure E.1: A reaction scheme for the synthesis of compound (20).  
 
Trans-DDP was first activated with 0.95 molar equivalents of AgNO3, before reaction in 
excess with the Boc protected ligand (9) for 48 hours at room temperature in DMF 
(Figure E.1). After removal of the solvent under reduced pressure the product and 
excess trans-DDP was precipitated by the addition of acetone. The pure white product 
(20) could then be recrystallised from the crude pale yellow solid with methanol, in 
70% yield. The 1H NMR spectrum of the product displayed peaks that are consistent 
with the Boc protected linker in the aliphatic region, including a singlet integrating for 
nine protons arising from the tert-butyl group (Figure E.2). Three other peaks were also 
observed, and assigned as the ammine protons of trans-DDP, the amine group of the 
linker coordinated directly to the platinum atom (which displayed platinum coupling as 
expected), and the amide proton of the protected functional group at the terminal end of 













Figure E.2: The 1H NMR spectrum of compound 20 obtained at 35 oC in d6-DMSO and referenced to a 
residual solvent peak. 
 
The 195Pt NMR spectrum (Figure E.3) shows a single resonance at -2415 ppm indicating 
a change in the coordination sphere of the platinum metal which is consistent with the 
chemical shift observed in PtN3Cl complexes (where N = two trans-ammine ligands and 
one primary amine ligand). More specifically it is consistent with the substitution of one 
of the ligands of trans-DDP with the Boc protected diamino linker. 







Figure E.3: The 195Pt spectrum of compound 20 at 25 oC in d7-DMF referenced to K2PtCl4. 
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APPENDIX F: X-RAY CRYSTALLOGRAPHIC DATA 
 
The final positional, thermal and occupancy parameters, with their standard deviations 
derived from the inverse matrix of the final least squares refinement cycle, for the metal 
complex [Pt(terpy)(MPA)]2AgCl.5H2O are reported in Table F.1 and Table F.2. The 
interatomic distances and angles, with their standard deviations are reported in Table 
F.3 and Table F.4. An ORTEP drawing of the [Pt(terpy)(MPA)]2AgCl.5H2O molecule 
showing the atom labelling scheme is provided in Figure F.1. 
 
Figure F.1: ORTEP drawing of the [Pt(terpy)(MPA)]2AgCl.5H2O molecule showing the atom 
labelling scheme and 50% probability thermal ellipsoids. The positions for several disordered oxygen 
atoms (assumably from water molecules) and hydrogens on the complex are provided.
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Table F.4: Final positional, thermal and occupancy parameters of the atoms of [Pt(terpy)(MPA)]2AgCl.5H2O Atoms are labelled as indicated in Figure F.1. Standard 
deviations are provided in parentheses after each value. 
 
Atom x y z β11 β22 β33 β23 β13 β12 
Pt1 0.721918(18) 0.210951(18) 0.791395(9) 0.03333(10) 0.03769(11) 0.02433(9) -0.00561(7) -0.00346(7) -0.00168(7) 
Pt51 0.995419(18) -0.071890(17) 0.809553(8) 0.03488(10) 0.03015(10) 0.02479(9) -0.00184(7) -0.00172(7) -0.00312(7) 
Ag81 0.88361(4) 0.00013(4) 0.95061(2) 0.0402(2) 0.0337(2) 0.0496(2) -0.00436(17) -0.00221(17) -0.00277(16) 
Cl82 0.72454(14) -0.14506(12) 1.00948(7) 0.0471(7) 0.0351(7) 0.0469(7) 0.0003(5) 0.0039(5) -0.0092(5) 
Cl91 0.2901(3) 0.6390(3) 0.75030(14) 0.133(2) 0.150(3) 0.0818(16) -0.0003(16) -0.0076(15) -0.074(2) 
S20 0.76520(12) 0.20561(11) 0.90404(6) 0.0381(6) 0.0340(6) 0.0246(5) -0.0027(4) -0.0024(4) -0.0056(5) 
S70 1.08503(12) -0.12588(11) 0.91745(6) 0.0353(6) 0.0294(6) 0.0281(5) -0.0019(4) -0.0042(4) -0.0077(5) 
N2 0.5977(4) 0.0808(4) 0.7937(2) 0.037(2) 0.038(2) 0.039(2) -0.0119(18) -0.0041(17) -0.0018(18) 
N13 0.6783(4) 0.6783(4) 0.6942(2) 0.036(2) 0.061(3) 0.0235(19) -0.0124(19) -0.0061(16) -0.002(2) 
N19 0.8371(4) 0.3442(4) 0.7565(2) 0.040(2) 0.046(3) 0.029(2) -0.0005(18) -0.0006(17) -0.0067(19) 
N52 0.8612(4) -0.1916(4) 0.8014(2) 0.034(2) 0.040(2) 0.031(2) -0.0078(17) -0.0054(16) -0.0028(17) 
N63 0.9467(5)  -0.0213(4) 0.7131(2) 0.050(3) 0.039(2) 0.0234(19) 0.0030(17) -0.0058(17) 0.0018(19) 
N69 1.1066(4) 0.0691(4) 0.7853(2) 0.045(2) 0.032(2) 0.031(2) -0.0003(17) 0.0017(17) -0.0059(18) 
O24 0.4713(5) 0.3645(5) 0.8353(3) 0.062(3) 0.071(3) 0.082(4) -0.009(3) -0.023(3) -0.007(3) 
O25 0.4490(5) 0.5351(5) 0.8796(4) 0.068(3) 0.049(3) 0.126(5) -0.008(3) 0.027(3) -0.003(2) 
O74 1.1754(5) -0.5304(4) 1.0161(2) 0.084(3) 0.032(2) 0.040(2) 0.0031(16) -0.015(2) -0.0068(19) 
O75 1.1667(4) -0.5947(3) 0.91663(19) 0.068(3) 0.0318(19) 0.0365(19) -0.0070(15) 0.0039(17) 0.0007(17) 
O101 0.8285(12) 0.1809(11) 0.3648(6) - - - - - - 
O103 0.6793(9) 1.0158(9) 0.4385(5) - - - - - - 
O104 0.9316(9) 0.3113(8) 0.4597(5) - - - - - - 
O105 0.4526(15) 0.5163(14) 0.6597(8) - - - - - - 
O107 0.5681(18) 0.6992(17) 0.5871(10) - - - - - - 
C3 0.5663(6) -0.0018(5) 0.8467(3) 0.047(3) 0.042(3) 0.047(3) -0.012(2) -0.002(2) -0.005(2) 
C4 0.4815(7) -0.0873(6) 0.8406(4) 0.057(4) 0.045(3) 0.065(4) -0.004(3) 0.000(3) -0.010(3) 
C5 0.4293(7) -0.0905(7) 0.7774(4) 0.058(4) 0.053(4) 0.080(5) -0.025(4) -0.006(3) -0.011(3) 
C6 0.4612(6) -0.0065(6) 0.7224(4) 0.055(4) 0.055(4) 0.063(4) -0.027(3) -0.013(3) -0.004(3) 
C7 0.5448(6) 0.0775(6) 0.7307(3) 0.040(3) 0.056(4) 0.042(3) -0.022(3) -0.009(2) 0.004(2) 
C8 0.5867(6) 0.1688(6) 0.6747(3) 0.045(3) 0.061(4) 0.038(3) -0.016(3) -0.007(2) 0.001(3) 
C9 0.5457(7) 0.1949(8) 0.6077(3) 0.063(4) 0.086(5) 0.043(3) -0.022(3) -0.017(3) -0.003(4) 
C10 0.5996(8) 0.2845(9) 0.5639(3) 0.074(5) 0.107(7) 0.035(3) -0.009(4) -0.015(3) 0.002(4) 
C11 0.6918(7) 0.3516(8) 0.5857(3) 0.066(4) 0.090(5) 0.033(3) -0.001(3) -0.006(3) -0.008(4) 
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Atom x y z β11 β22 β33 β23 β13 β12 
C12 0.7297(6) 0.3267(6) 0.6529(3) 0.046(3) 0.062(4) 0.032(3) -0.002(3) 0.001(2) 0.003(3) 
C14 0.8249(6) 0.3842(6) 0.6879(3) 0.043(3) 0.055(3) 0.029(2) 0.001(2) 0.001(2) 0.002(2) 
C15 0.8984(7) 0.4734(7) 0.6553(3) 0.058(4) 0.067(4) 0.035(3) 0.008(3) 0.003(3) -0.007(3) 
C16 0.9885(7) 0.5196(7) 0.6923(3) 0.058(4) 0.061(4) 0.054(4) 0.007(3) 0.011(3) -0.014(3) 
C17 1.0021(6) 0.4778(6) 0.7607(3) 0.047(3) 0.056(4) 0.044(3) -0.008(3) 0.008(2) -0.013(3) 
C18 0.9242(6) 0.3911(6) 0.7914(3) 0.045(3) 0.050(3) 0.035(3) -0.005(2) -0.001(2) -0.013(2) 
C21 0.6091(6) 0.2200(6) 0.9499(3) 0.043(3) 0.057(4) 0.038(3) -0.010(3) 0.006(2) 0.002(3) 
C22 0.5481(6) 0.3510(6) 0.9509(4) 0.044(3) 0.060(4) 0.076(4) -0.038(4) -0.004(3) 0.002(3) 
C23 0.4856(6) 0.4169(6) 0.8820(5) 0.026(3) 0.047(4) 0.115(7) 0.012(4) 0.019(3) -0.002(2) 
C53 0.8132(5) -0.2720(5) 0.8497(3) 0.040(3) 0.041(3) 0.042(3) -0.006(2) -0.006(2) -0.007(2) 
C54 0.7222(6) -0.3485(6) 0.8363(3) 0.038(3) 0.053(4) 0.054(3) -0.007(3) -0.004(2) -0.014(2) 
C55 0.6783(6) -0.3416(7) 0.7718(3) 0.043(3) 0.064(4) 0.059(4) -0.018(3) -0.009(3) -0.012(3) 
C56 0.7236(6) -0.2566(6) 0.7214(3) 0.044(3) 0.062(4) 0.048(3) -0.017(3) -0.016(3) -0.001(3) 
C57 0.8139(5) -0.1799(5) 0.7352(3) 0.037(3) 0.047(3) 0.038(3) -0.012(2) -0.009(2) 0.001(2) 
C58 0.8631(6) -0.0847(6) 0.6861(3) 0.043(3) 0.055(3) 0.033(3) -0.011(2) -0.006(2) 0.000(2) 
C59 0.8319(8) -0.0504(7) 0.6178(3) 0.076(4) 0.073(5) 0.031(3) -0.009(3) -0.014(3) -0.003(4) 
C60 0.8895(8) 0.0414(8) 0.5798(3) 0.089(5) 0.086(5) 0.029(3) -0.008(3) -0.006(3) 0.001(4) 
C61 0.9790(8) 0.1052(7) 0.6090(3) 0.086(5) 0.058(4) 0.028(3) 0.011(3) 0.005(3) 0.002(3) 
C62 1.0064(6) 0.0709(5) 0.6772(3) 0.060(3) 0.037(3) 0.029(2) 0.004(2) 0.001(2) 0.003(2) 
C64 1.0971(6) 0.1228(5) 0.7179(3) 0.063(4) 0.033(3) 0.035(3) 0.002(2) 0.010(2) 0.000(2) 
C65 1.1685(7) 0.2174(6) 0.6929(3) 0.071(4) 0.043(3) 0.043(3) 0.006(3) 0.015(3) -0.007(3) 
C66 1.2486(7) 0.2616(6) 0.7364(3) 0.073(4) 0.033(3) 0.057(4) 0.000(3) 0.021(3) -0.014(3) 
C67 1.2549(6) 0.2106(6) 0.8037(3) 0.054(3) 0.040(3) 0.059(4) -0.012(3) 0.009(3) -0.012(3) 
C68 1.1833(6) 0.1129(5) 0.8267(3) 0.051(3) 0.038(3) 0.033(2) -0.006(2) 0.003(2) -0.011(2) 
C71 1.0729(5) -0.2856(4) 0.9576(2) 0.048(3) 0.025(2) 0.027(2) 0.0003(18) -0.0040(19) -0.006(2) 
C72 1.1306(6) -0.3784(5) 0.9152(3) 0.053(3) 0.036(3) 0.036(3) -0.002(2) -0.001(2) 0.000(2) 
C73 1.1596(5) -0.5072(4) 0.9553(3) 0.032(2) 0.026(2) 0.038(3) 0.0001(19) -0.0032(19) -0.0033(18) 
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Table F.2: Final positional parameters of the protons of [Pt(terpy)(MPA)Cl. The H atoms were all 
located in a difference map, but those attached to carbon atoms were repositioned geometrically. The H 
atoms were initially refined with soft restraints on the bond lengths and angles to regularise their 
geometry (C-H in the range 0.93-0.98, N-H in the range 0.86-0.89 and O-H = 0.82) after which the 
positions were refined with riding constraints. Standard deviations are not provided. 
 
Atom x y z 
H31 0.6042 -0.0018 0.8891 
H41 0.4587 -0.1410 0.8785 
H51 0.3736 0.1490 0.7719 
H61 0.4263 -0.0055 0.6800 
H91 0.4821 0.1518 0.5929 
H101 0.5741 0.3010 0.5189 
H111 0.7289 0.4107 0.5564 
H151 0.8874 0.5010 0.6098 
H161 1.0407 0.5783 0.6705 
H171 1.0636 0.5080 0.7862 
H181 0.9317 0.3649 0.8380 
H211 0.6293 0.1794 0.9960 
H212 0.5464 0.1776 0.9303 
H221 0.6165 0.3969 0.9644 
H222 0.4780 0.3484 0.9839 
H251 0.4139 0.5836 0.8464 
H531 0.8416 -0.2765 0.8934 
H541 0.6918 -0.4033 0.8713 
H551 0.6186 -0.3935 0.7621 
H561 0.6934 -0.2496 0.6770 
H591 0.7726 -0.0909 0.5980 
H601 0.8697 0.0628 0.5336 
H611 1.0186 0.1691 0.5827 
H651 1.1631 0.2511 0.6472 
H661 1.2962 0.3248 0.7199 
H671 1.3059 0.2410 0.8338 
H681 1.1878 0.0771 0.8722 
H711 1.1241 -0.3015 0.9994 
H712 0.9802 -0.2957 0.9671 
H721 1.2126 -0.3543 0.8948 
H722 1.0673 -0.3803 0.8790 































































































































Table F.4: Bond angles (deg.). 
Coordination Spheres 


























Mercaptopropionic Acid Ligands 




























































































































































APPENDIX G: MASS SPECTRA 
 
Figure G.1: The mass spectrum of N-(6-aminohexyl)-4-[4-(1-methylimidazole-2-carboxyamido)-N-methylpyrrole-2-carboxyamido]-N-methylpyrrole-2-carboxyamide (12), 
with the source block and cone voltage set at 100 oC and 40 V respectively. 
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Figure G.3: The mass spectrum of [{Pt(terpy)}2(DMECA)]Cl2 (15), with the source block and cone voltage set at 40 oC and 40 V respectively. 
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Figure H.1: An expansion of the 2D NOESY spectrum of 4-[(9-fluorenylmethoxycarbonyl)amino]-N-methylpyrrole-2-carboxylic acid (18),  







Figure H.2: An expansion of the 2D NOESY spectrum of [Pt(terpy)(MPA)]Cl (14), obtained at 25 oC in D2O and referenced to the residual solvent peak, 
showing cross peak correlations between proton resonances of the aromatic terpyridyl ligand and the aliphatic mercaptopropionic acid ligand. 
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Figure H.3: An expansion of the 2D ROESY spectrum of [{Pt(terpy)}2(DMECA)]Cl2 (15), obtained at 25 oC in D2O and referenced to the residual solvent peak, showing 
cross peak correlations between proton resonances of the aromatic terpyridyl ligands and the aliphatic bridging ligand. 
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Figure H.4: An expansion of the 2D ROESY spectrum of [{Pt(terpy)}2(DMECA)]Cl2 (15), obtained at 25 oC in D2O and referenced to the residual solvent peak, showing 





APPENDIX I: CD BINDING DATA 1 
 
This appendix contains the CD and ICD spectra for the binding of the metal complex 
[Pt(terpy)(MPA)]Cl (7.28 × 10-3 M) and ct-DNA (2.8 × 10-5 M/bp). All CD 
measurements were recorded on a Jasco J-810 CD spectropolarimeter at room 
temperature using a cell length of 1 cm. The titration was performed by incrementally 
adding 1 uL aliquots of [Pt(terpy)(MPA)]Cl to a 2600 μL solution of ct-DNA After 
each addition, an average CD spectrum from 200 to 320 nm (20 accumulations) was 
recorded. Solutions were made in sodium phosphate buffer (10 mM), containing EDTA 

























Figure I.1: The CD spectral series for the binding of [Pt(terpy)(MPA)]Cl to ct-DNA. Data was obtained 



























Figure I.2: The ICD spectral series for the binding of [Pt(terpy)(MPA)]Cl to ct-DNA. Data was obtained 
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Figure I.3: The binding curve obtained from the ICD spectral series at 216 nm. The data points shown 




Table I.1: The values obtained for α (a function of wavelength), K (the equilibrium binding constant), nI 
(size of the binding site determined using the Intrinsic method) and nS (size of the binding site determined 
using the Scatchard method) 
 
α K nI nS 
7.0 × 10-6 4.3 × 105 2.23 2.00 
 

















Figure I.4: A plot of the values obtained by using the Intrinsic method to process data from the binding 
curve obtained at 216 nm. 
 












Lb Lf r r/Lf 
0 0 0 0 N/A N/A N/A 
0.1 2.80E-6 0.330101 2.31E-06 4.88E-07 0.0826 169100.2 
0.2 5.60E-6 0.701905 4.91E-06 6.8E-07 0.1756 257358.5 
0.3 8.40E-6 0.885008 6.19E-06 2.19E-06 0.2215 100902.3 
0.4 1.12E-5 1.090418 7.63E-06 3.55E-06 0.2730 76911.0 
0.5 1.40E-5 1.318471 9.23E-06 4.74E-06 0.3303 69617.1 
0.6 1.68E-5 1.365901 9.56E-06 7.20E-06 0.3423 47536.5 
0.7 1.96E-5 1.637424 1.15E-05 8.10E-06 0.4105 50765.3 
0.8 2.24E-5 1.567684 1.09E-05 1.14E-05 0.3931 34613.9 
0.9 2.52E-5 1.581908 1.11E-05 1.40E-05 0.3968 28265.9 





















Figure I.5: The Scatchard plot of values obtained using the Intrinsic Method. Note that values from the 
table pertaining to 0.2 and 0.7 metal complex/DNA binding ratios have been omitted from the graph, as 





APPENDIX J: CD BINDING DATA 2 
 
This appendix contains the CD and ICD spectra for the binding of the metal complex 
[{Pt(terpy)}2(DMECA)]Cl2 (1.82 × 10-3 M) and ct-DNA (2.8 × 10-5 M/bp). All CD 
measurements were recorded on a Jasco J-810 CD spectropolarimeter at room 
temperature using a cell length of 1 cm. The titration was performed by incrementally 
adding 1 uL aliquots of [{Pt(terpy)}2(DMECA)]Cl2 to a 2600 μL solution of ct-DNA 
After each addition, an average CD spectrum from 200 to 320 nm (20 accumulations) 
was recorded. Solutions were made in sodium phosphate buffer (10 mM), containing 









































Figure J.1: The CD spectra of the compound [{Pt(terpy)}2(DMECA)]Cl2 binding to ct-DNA at 







































Figure J.2: The ICD spectra of the compound [{Pt(terpy)}2(DMECA)]Cl2 binding to ct-DNA at 
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Figure J.3: The DNA binding curve of [{Pt(terpy)}2(DMECA)]Cl2 at 214.6 nm. The data points shown 
were obtained from the average of three experiments, from which the standard deviation was also 
calculated. 
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Table J.1: The values obtained for α (a function of wavelength), K (the equilibrium binding constant), nI 
(size of the binding site determined using the Intrinsic method) and nS (size of the binding site determined 
using the Scatchard method) 
 
 
α K nI nS 
1.0 × 10-6 9.7 × 105 4.65 3.89 
 













Figure J.4: A plot of the values obtained by using the Intrinsic method to process data from the binding 



















Table J.2: A summary of values obtained from the ICD spectra, binding curve at 214.6 nm and the 











Lb Lf r r/Lf 
0 0 0 0 N/A N/A N/A 
0.025 7.00E-7 0.50163203 4.92E-07 2.08E-07 0.0176 84466.8 
0.050 1.40E-6 1.07167903 1.06E-06 3.37E-07 0.0379 112563.8 
0.075 2.10E-6 1.78056237 1.77E-06 3.27E-07 0.0633 193662.5 
0.100 2.80E-6 2.19621903 2.19E-06 6.09E-07 0.0782 128332.9 
0.125 3.50E-6 2.80211237 2.79E-06 7.01E-07 0.0999 142516.8 
0.150 4.20E-6 3.30192237 3.29E-06 8.98E-07 0.1178 131184.5 
0.175 4.90E-6 3.64074903 3.63E-06 1.26E-06 0.1300 103521.8 
0.200 5.60E-6 4.2307057 4.22E-06 1.36E-06 0.1512 111017.3 
0.225 6.30E-6 4.67242237 4.66E-06 1.62E-06 0.1671 103417.0 
0.250 7.00E-6 5.10878903 5.09E-06 1.87E-06 0.1828 97532.3 
0.275 7.70E-6 5.22353903 5.21E-06 2.45E-06 0.1870 76200.3 
0.300 8.40E-6 5.5104757 5.50E-06 2.86E-06 0.1974 68985.6 
0.325 9.10E-6 5.7374890 5.73E-06 3.33E-06 0.2056 61788.8 
0.350 9.70E-6 5.81148237 5.80E-06 3.95E-06 0.2083 52792.4 
0.375 1.04E-5 5.83050788 5.82E-06 4.62E-06 0.2091 45263.3 
0.400 1.11E-5 6.0309357 6.02E-06 5.11E-06 0.2164 42336.8 
0.425 118E-5 6.05481237 6.04E-06 5.78E-06 0.2173 37609.8 
0.450 1.25E-5 5.80147903 5.79E-06 6.72E-06 0.2083 30984.9 
0.475 1.33E-5 5.97313903 5.96E-06 7.24E-06 0.2145 29630.0 
0.500 1.40E-5 6.10875903 6.09E-06 7.79E-06 0.2195 28160.7 
0.600 1.66E-5 5.97453903 5.96E-06 1.07E-05 0.2150 20126.9 
 












Figure J.5: The Scatchard plot of values obtained using the Intrinsic method. Note that the first three 
values from the table pertaining to 0.025, 0.050 and 0.075 metal complex/DNA binding ratios have been 
omitted from the graph, as they do not fit the mathematical model. 
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Below is the binding curve obtained from the ICD values at 247.4 nm, a wavelength at 
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Figure J.6: The DNA binding curve of [{Pt(terpy)}2(DMECA)]Cl2 at 247.4 nm. The data points shown 
were obtained from the average of three experiments, from which the standard deviation was also 
calculated. 
 
Below is the Intrinsic Method plot and Scatchard plot obtained by using the binding 
curve at 247.4 nm. No further analysis was performed as the data does not fit the ideal 
Scatchard mathematical model. 
Intrinsic Plot Method












Figure J.7: A plot of the values obtained by using the Intrinsic method to process data from the binding 
curve obtained at 247.4 nm. 
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Figure J.8: The Scatchard plot of values obtained using the Intrinsic method. 
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APPENDIX K: 1H NOESY SPECTRA 
 
 
Figure K.1: The 1H NOESY spectrum of the oligonucleotide obtained in a buffered D2O solution, 
referenced to an internal residual solvent peak at 25 oC. 
 
Figure K.2 An expansion of the region in the 1H NOESY spectrum displaying the base proton to H1′ 
connectivity of the oligonucleotide. The spectrum was obtained in a buffered D2O solution at 25 oC and 




Figure K.3: An expansion of the region in the 1H NOESY spectrum displaying the base proton to H2′ 
and H2″ connectivity of the oligonucleotide. The spectrum was obtained in a buffered D2O solution at 25 
oC, and referenced to an internal residual solvent peak. 
 
 
Figure K.4: An expansion of the region in the 1H NOESY spectrum displaying the base proton to H3′ 
connectivity of the oligonucleotide. The spectrum was obtained in a buffered D2O solution at 25 oC, and 




Figure K.5: The 1H NOESY spectrum of the oligonucleotide after the addition of [Pt(terpy)(MPA)]Cl in 
a 1:1 molar ratio, obtained in a buffered D2O solution and referenced to an internal residual solvent peak 
at 25 oC. 
 
 
Figure K.6: An expansion of the region in the 1H NOESY spectrum displaying the base proton to H1′ 
connectivity of the oligonucleotide after the addition of [Pt(terpy)(MPA)]Cl in a 1:1 molar ratio. The 





Figure K.7: An expansion of the region in the 1H NOESY spectrum displaying the base proton to H2′ 
and H2″ connectivity of the oligonucleotide after the addition of [Pt(terpy)(MPA)]Cl in a 1:1 molar ratio. 




Figure K.8: An expansion of the region in the 1H NOESY spectrum displaying the aromatic metal 
complex and oligonuceotide base proton connectivity after the addition of [Pt(terpy)(MPA)]Cl in a 1:1 
molar ratio. The spectrum was obtained in a buffered D2O solution at 25 oC and referenced to an internal 




Figure K.9: The 1H NOESY spectrum of the oligonucleotide after the addition of 
[{Pt(terpy)}2(DMECA)]Cl2 in a 1:1 molar ratio, obtained in a buffered D2O solution and referenced to an 
internal residual solvent peak at 25 oC. 
 
 
Figure K.10: An expansion of the region in the 1H NOESY spectrum displaying the base proton to H1′ 
connectivity of the oligonucleotide after the addition of [{Pt(terpy)}2(DMECA)]Cl2 in a 1:1 molar ratio. 





Figure K.11: An expansion of the region in the 1H NOESY spectrum displaying the base proton to H2′ 
and H2″ connectivity of the oligonucleotide after the addition of [{Pt(terpy)}2(DMECA)]Cl2 in a 1:1 
molar ratio. The spectrum was obtained in a buffered D2O solution at 25 oC and referenced to an internal 
residual solvent peak. 
 
 
Figure K.12: An expansion of the region in the 1H NOESY spectrum displaying the aromatic metal 
complex and oligonuceotide base proton connectivity after the addition of [{Pt(terpy)}2(DMECA)]Cl2 in 
a 1:1 molar ratio. The spectrum was obtained in a buffered D2O solution at 25 oC and referenced to an 
internal residual solvent peak. 
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APPENDIX L: RESIN LOADING DETERMINATION 
 
The loading of the unsubstituted chlorotrityl resin, according to the manufacturer, is 1 
mmol/g of resin. As 0.5 g of resin was used in preparation of Fmoc-β-ala-chlorotrityl 
resin, a theoretical loading of 0.5 mmol is expected. This equates to a theoretical 
increase in weight of 0.1375 g (Equation 18), given that the change in molecular weight 
(274.87 g/mol) is equal to the weight of Fmoc-β-ala-COOH minus the molecular weight 












 311.33 g/mol 36.46 g/mol
Difference in weight = 311.33 - 36.46 = 274.87 g/mol  
Figure L.1: The reaction of chlorotrityl resin with Fmoc-β-ala-COOH. 
 
Fw
mN =  (18) 
Where N = the theoretical loading of the resin (0.5 × 10-3 mol/g) 
           Fw = the change in formula weight of the resin (274.87 g/mol) 
 
Therefore the theoretical weight increase (m) is 0.14 g. 
 
An increase of 0.06 g (44% yield) after the reaction was recorded, indicating that only 
0.22 mmol of Fmoc-β-ala-COOH had reacted with the resin. The new loading of the 
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